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1 Introduction 
 
1.1 Introductory Remarks 
 
This thesis deals predominantly with the structure-based design of inhibitors of blood 
coagulation factor XIII (FXIII) which appears to be an auspicious target for an anticoagulant 
with a lower bleeding risk compared to current anticoagulants. A more detailed elucidation 
about the relevance of FXIII as a target for novel anticoagulants is given in the introduction of 
Chapter 2 and Chapter 3. Information detailing the chemical environment of the active site, 
provided by the crystal structures of FXIII in complex with different inhibitors, was used in 
collaboration with the biotech company Zedira GmbH to improve the affinity and size of the 
lead compound (Chapter 2-4). 
Moreover, the crystal structures of FXIII in complex with different inhibitors reveal new 
detailed information about mechanistic features of FXIII and its isozymes (transglutaminases), 
especially, concerning the involvement of calcium in the activation process (Chapter 5). This 
in turn gives valuable information for the development of drugs addressing transglutaminases, 
as well. 
In Chapter 6, an academic collaboration projects dealing with a crystallographic fragment 
screening will be described. 
 
1.2 Transglutaminases 
 
Transglutaminases (TGs) represent an enzyme class catalyzing the covalent linkage of 
proteins/peptides by transamidation between the γ-carboxamide group of glutamine and the ε-
amino group of lysine (Fig. 1.1a).[1] As substrates also other amines and carboxamides can 
serve with an appropriate distance to the functional group. Thus, TGs also catalyze the 
incorporation of amines into proteins (Fig. 1.1b) and the acylation of proteins (Fig. 1.1c). 
Furthermore, TGs catalyze the esterification of carboxamides (Fig. 1.1d) and the hydrolysis of 
carboxamides (Fig. 1.1e) and isopetide bonds (Fig. 1.1f). 
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Fig. 1.1: Reactions catalyzed by transglutaminases. Image taken from Lorand and Graham.[1] 
 
In total, there are eight human catalytically active transglutaminases (TG1-TG7 and FXIII). 
The prevalent physiological function of TGs is to improve the stability of several components 
of the organism by protein cross-linking.[1] For example, TG2 is involved in the assembly and 
remodeling of the extracellular matrix[2], TG1, TG3 and TG5 are involved in the formation of 
the cornified cell envelope[3-5] and FXIII stabilizes blood clots.[6] Moreover, with their ability 
to modify proteins post-translationally (Fig. 1.1), TGs exhibit a regulative function as well[1, 7], 
whereas TG2 can even act as a G-protein[8] and kinase.[9, 10] Finally, TG2 and FXIII possess 
also protein disulfide isomerase activity.[11, 12] Owing to their versatile reactivity and ubiquity 
(intracellular and extracellular), particularly, TG2 is expressed in almost all cell types[7], the 
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activity of TGs is highly regulated. The most important regulator is calcium. In the absence of 
this ion, the enzyme is not active. Additionally, TG2 is allosterically regulated by 
GTP/GDP[13, 14] and the redox condition of the local environment (formation of a disulfide 
bond).[15, 16]  
In 1994, with blood coagulation factor XIII the first crystal structure of a transglutaminase was 
published by Yee and co-workers and gave firstly structural insights into the enzyme family.[17] 
Transglutaminases consist of a β-sandwich domain, a catalytic domain and two β-barrel 
domains (described in more detail in Chapter 2 and Chapter 5). The catalytic domain carries a 
catalytic triad comprising a cysteine, histidine and an aspartate residue. Approximately 10 years 
later, the crystal structure of transglutaminase 3, enzymatically cleaved between the catalytic 
domain and the β-barrel 1 domain, was published revealing three calcium binding sites.[18] 
However, the enzyme was crystallized in the absence of an inhibitor. Finally, in 2007 the crystal 
structure of transglutaminase 2 in complex with a substrate-derived inhibitor was published.[19] 
Bizarrely, despite of the calcium dependency of transglutaminases, the calcium binding sites 
were not established in contrast to transglutaminase 3. 
The detailed mechanism of transglutaminases is shown in Fig. 1.2.[20] The catalytic cycle starts 
with the entrance of the glutamine-bearing substrate (acyl-donor substrate or Q-substrate) into 
the active site (I), followed by a nucleophilic attack of the thiolate sulfur of Cys 277 (TG2 
nomenclature, FXIII: Cys 314) of the uncomplexed enzyme at the carbonyl carbon of the 
glutamine side chain of the Q-substrate (II). The tetrahedral intermediate (III) decomposes to 
the acyl-enzyme (IV) under release of NH3 whereas an imidazolium proton is abstracted from 
His 335 (TG2 nomenclature, FXIII: His 373). Subsequently, the lysine bearing co-substrate 
(acyl acceptor substrate or K-substrate) enter into the active site and the side chain amine 
nitrogen of the K-substrate attacks the carbonyl carbon of the thioester nucleophilicly (V). 
Decomposition of the tetrahedral intermediate releases the iso-peptide product and the 
regenerated enzyme (VI). Alternatively, the thioester (IV) can be hydrolyzed. Here, water acts 
as a nucleophile instead of the amine whereas the imidazole nitrogen of His 335 accepts a 
proton of the water molecule (VII). The tetrahedral intermediate decomposes to the deamidated 
glutamine (glutamate) and the regenerated catalytic site. 
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Fig. 1.2: Catalytic cycle of transglutaminases with involvement of Cys 277 (TG2 nomenclature, FXIII: 
Cys 314) and His 335 (TG2 nomenclature, FXIII: His 373) of the catalytic triad.[20] Image taken from 
Keillor (slightly modified). 
 
Due to a progressive knowledge concerning physiological functions of transglutaminases and 
their involvement in a variety of disease processes (Fig. 1.3), this enzyme class has increasingly 
evolved pharmacological interest in the last decades.[21] Blood coagulation factor XIII 
represents a promising target in thrombolytic therapy and for preventive treatment of 
thromboembolic events.[22-24] TG2 is traded as a promising target for treatment of auto-immune 
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diseases like celiac disease[7, 24, 25], neurodegenerative diseases like Alzheimer’s and 
Huntington’s Diseases[26-28] and fibrotic disorders such as diabetic nephropathy[29]. 
Additionally, TG2 is involved in inflammation and in the regulation of cell growth and 
apoptosis.[30] Thus, TG2 has also become of interest as a pharmacological target for anti-
inflammatory drugs[21, 31] and in cancer therapy.[32] Aside from FXIII and TG2, other human 
transglutaminases are also involved in several disease processes.[33-38] For example, TG4 plays 
a crucial role in the pathogenesis of prostate cancer.[39] 
 
                      
 
Fig. 1.3: Most important human diseases with involvement of transglutaminases.[40]  
 
 
1.3 Blood Coagulation Factor XIII 
 
Blood coagulation factor XIII, also designated as fibrin-stabilizing factor or after its discoverer 
Laki-Lorand factor[6], plays a crucial role in hemostasis and constitutes a promising target for 
safer anticoagulants (described in more detail in the upcoming chapters). 
Alzheimer’s Disease (TG2) 
Huntington’s Disease (TG2) 
Ischemic stroke (FXIII) 
Celiac disease (TG2) 
Thrombosis (FXIII) 
Pulmonary embolism (FXIII) 
Prostate cancer (TG4) 
Breast cancer (TG2) 
Myocardial infarction (FXIII) 
Diabetic nephropathy (TG2) 
 
Chapter 1 - Introduction 
 
15 
 
In the blood plasma, the enzyme exists in a tetrameric form (FXIII-A2B2) consisting of two 
identical catalytic active subunits (FXIII-A) and two identical regulatory subunits (FXIII-B).[41] 
The two A-subunits form a homodimer and the two B-subunits are attached to the latter 
(Fig. 1.4). Each A-subunit is furnished with an activation peptide on the N-terminus that 
extends into the other monomer and reinforce the interaction between both monomers.  
 
 
 
Fig. 1.4: Plasmatic form of blood coagulation factor XIII. In the blood plasma FXIII adopts a 
heterotetrameric structure (A2B2). 
 
The activation peptide is unique for FXIII within the transglutaminase family and is most likely 
an important regulatory element required to involve a transglutaminase into the coagulation 
cascade. Plasmatic FXIII (pFXIII; FXIII-A2B2) is activated by thrombin that cleaves the 
activation peptide weakening the interaction between both A-subunits.[42, 43] In the presence of 
calcium the B-subunit dissociates from the A-subunit and the enzyme becomes active.[44, 45] 
Moreover, the presence of polymerized fibrin accelerates the activation by two orders of 
magnitude.[45-47] Interestingly, pFXIII can be also activated by a high calcium concentration 
without prior proteolytic cleavage.  
FXIII is also present in the cytoplasm of certain cells, especially in platelets and 
monocytes/macrophages.[48, 49] In the cellular form (cFXIII), the enzyme exists as a homodimer 
(FXIII-A2)
[17, 41] and is activated by an elevation of the intracellular calcium level without prior 
cleavage of the activation peptide.[50, 51] 
A-subunits B-subunits 
Activation 
peptide 
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The main function of FXIII concerns the enhancement of the mechanical stiffness of fibrin.[52] 
Here, FXIII cross-links fibrin fibers by forming isopetide bonds between glutamine and lysine 
side chains. In addition to fibrin-cross-linking, FXIII attaches α2-antiplasmin to fibrin 
increasing the resistance towards fibrin degradation (fibrinolysis) by plasmin. Notably, aside 
from fibrin and α2-antiplasmin, 145 further substrates of FXIII in the blood plasma have been 
identified whereas 48 substrates are incorporated into the blood clot.[53] FXIII is also involved 
in additional biological processes like pregnancy[54], wound healing[55] and angiogenesis[56]. 
 
1.4 Structure-Based Drug Design 
 
The average human life time has been increased drastically in the last century by medical 
science. The development of therapeutic substances is an elaborate process and requires the 
entire knowledge of natural science and engineering.  
The common procedure to discover first leads for a drug development project in industry 
represents high-throughput screening (HTS). Here, the target protein is exposed to hundreds of 
thousands of molecules in a test assay system to detect functional modulation of the target 
protein. Substances with sufficient affinity serve as starting point for a subsequent drug design 
process where the lead molecule is improved in terms of affinity concerning the target protein 
by chemical modification. This procedure is costly in terms of time and financial resources 
because there is no information available about how the molecule has to be exactly modified. 
This issue was overcome with the development of X-ray crystallography for large protein 
systems as a routine tool in the 1990s providing information about the target protein on a 
molecular level. Ligands can be crystallized in complex with their target protein and knowledge 
of the chemical environment of the active site can be used for specific chemical modifications. 
Additionally, computer programs can be used to estimate how modified ligands can bind to the 
protein (docking). 
The common approach in industry to develop new drugs is to combine HTS for lead discovery 
and X-ray crystallography to optimize the lead molecule based on the crystal structure. 
However, a screening with hundreds of thousands of molecules can be costly. Thus, an in silico 
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search for potential lead structures based on the crystal structure of the protein (virtual ligand 
screening) is discussed as a powerful alternative to HTS.[57, 58]  
Nevertheless, a clear disadvantage of HTS is to start with large molecules that can only be 
optimized by a considerable synthetic effort, often by simultaneously reducing them in their 
original size. This issue can be overcome by using a fragment-based approach where a search 
is conducted based on small molecules (fragments) binding to different sub-pockets of the 
active site. Subsequently, potential fragments can be chemically connected obtaining high-
affinity inhibitors of the corresponding target. The fragment-based development of drugs has 
already turned out to be a powerful alternative to HTS.[59] Additionally, the computer-aided 
approach enables the adjustment of the compound library on the respective target. This 
flexibility is a clear advantage over HTS because the success of a screening campaign depends 
predominantly on the quality of the preselected substance library. 
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2 Structure of Active Coagulation Factor XIII Triggered by 
Calcium Binding: Basis for the Design of Next-Generation 
Anticoagulants 
 
2.1 Introductory Remarks 
 
The following chapter represents a slightly modified and supplemented version of an article 
published in Angewandte Chemie.[60] The inhibited protein for crystallization was provided by 
Zedira GmbH. The crystallization was performed by the author of this thesis and Zedira GmbH. 
The minimization of a co-substrate mimetic was done by Prof. Dr. Peter Kolb. The structure 
determination, functional analysis and draft of the paper was performed by the author of this 
thesis. 
 
2.2 Introduction 
 
Remarkable effort has been devoted to develop drugs that target coagulation factors or platelet 
activation to prevent and treat thrombosis, pulmonary embolism, and acute coronary 
syndromes, or for reducing the risk of stroke in patients with atrial fibrillation. For decades, 
vitamin K antagonists were the only available anticoagulants that could be administered orally. 
Only recently, a new generation of direct-acting oral anticoagulants that block thrombin directly 
or indirectly via upstream factor Xa has become available.[61] However, depending on its 
activation state, thrombin can either promote or prevent blood clotting. Interference with 
thrombin activity by the currently available anticoagulants is characterized by an enhanced 
bleeding risk, thus excluding many patients from beneficial treatment.[62] 
The currently targeted enzymes of the blood-clotting cascade, namely factor Xa and thrombin, 
belong to the family of serine proteases. Remarkably, the final enzyme in the blood clotting 
cascade, coagulation factor XIII, shows a markedly different mode-of-action (Fig. 2.1). 
 
 
Chapter 2 - Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-
Generation Anticoagulants 
19 
 
 
 
Fig. 2.1: In case of a blood vessel injury it comes to a cascade of zymogen activations that finally leads 
to the formation of thrombin (FIIa). Thrombin is the central key enzyme of the clotting cascade 
activating fibrinogen to fibrin that forms together with platelets and other blood cells a so called “soft” 
thrombus. Concomitantly, fibrin is stabilized by FXIIIa achieved by cross-linking fibrin chains via iso-
peptide bonds and furthermore decorating fibrin with α2-antiplasmin that prevents fibrinolysis catalyzed 
by plasmin. All current anticoagulants directly or indirectly inhibit thrombin leading to reduced blood 
coagulation. In any case, inhibition of FXIIIa will not interfere with the coagulation cascade nor affect 
fibrin formation providing a unique mode of action. 
 
FXIII is a member of the transglutaminase family, and catalyzes the covalent cross-linking of 
protein chains bearing susceptible glutamine and lysine residues through iso-peptide bonds 
(Fig. 2.2).[1, 41, 63, 64] In a blood clotting event, FXIII recognizes fibrin as the substrate and 
triggers clot maturation and accretion. In the case of congenital FXIII deficiency, delayed 
bleeding has been reported as a clinical manifestation. Taking these considerations into account, 
FXIII is regarded as a prospective target to achieve potentially safer and more efficient 
thrombolysis at a lower dosage of clot-dissolving agents.[23] In fact, a FXIII inhibitor may even 
prevent thrombus formation altogether.[22] 
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Fig. 2.2: General reaction and mechanism catalyzed by transglutaminases. The carboxamide group of 
a glutamine containing substrate (orange) is crosslinked with the amino group of a lysine containing 
substrate (cyan) by formation of a iso-peptide bond (a). The carboxamide side chain of a peptide- or 
protein-bound glutamine (orange) is activated leading to the acyl-enzyme intermediate while ammonia 
is released. Subsequently, the thioester reacts with the ε amino group of lysine in the co-substrate (cyan) 
yielding the stable and characteristic iso-peptide bond (b). The catalytic site exhibits a catalytic triad 
composed of Cys 314, His 373 and Asp 396 (light blue) and a catalytic His 342 (violet). Once the Gln-
substrate (orange) is accommodated, Cys 314 attacks nucleophilically its carboxamide group, His 373 
binds the proton of the sulfhydryl group and is electrostatically stabilized by the adjacent Asp 396. The 
formed tetrahedral intermediate interacts with the oxyanion hole formed by the indole NH of Trp 279 
and backbone NH of Cys 314 (not shown). Subsequently, the Lys-co-substrate (cyan) enters the catalytic 
center and attacks nucleophilically via its amino group the acyl-enzyme complex. Its nucleophilicity is 
enhanced by the neighboring His 342. 
 
FXIII acts downstream of thrombin, effectively determining the mechanical stability, half-life, 
and lysis rate of clots. Although discussed as a promising target to interfere with coagulation, 
no suitable drug candidates are available to explore the pharmacological potential of FXIII 
inhibition. This situation might also result from the fact that a protein structure representing a 
a) 
b) 
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relevant active state of FXIII was previously unknown, but is necessary to embark on structure-
based drug design. Only crystal structures of inactive, homodimeric FXIII have been reported 
so far, where the active site is completely buried and any access to the catalytic center is 
obscured. Such structures are unsuitable for drug design. In the structure described herein, three 
calcium ions recruit polar functional groups of the protein and establish local metal ion 
coordination sites, which induce the rearrangement of two domains along with local adaptations 
of the catalytic domain to expose the enzyme in an active state. The observed transformations 
establish the substrate and co-substrate binding sites for the formation of an iso-peptide bond 
and suggest involvement of a catalytic triad and a newly identified dyad in the enzyme 
mechanism which is considered valid for the entire transglutaminase family. 
Until now, very few FXIII inhibitors have been described. Finney et al.[65] reported that the 66 
amino acid peptide tridegin from the salivary gland of the giant Amazon leech Haementeria 
ghilianii is a potent inhibitor. In the late 1980s, a series of small molecules that irreversibly 
inhibit FXIII were explored in animal models of thrombosis. As a result of the lack of selectivity 
along with the short plasma half-life of only a few minutes, these inhibitors were solely 
considered as pharmacological tools to elucidate the physiological role of FXIII and not as 
prospective drug candidates.[66] For preclinical development of direct FXIII blockers it is 
important to have potent and selective compounds at hand to study the benefit-to-risk ratio 
relative to existing anticoagulants. 
Factor XIII is composed, as are all human transglutaminases, of a β-sandwich domain, a 
catalytic domain, and two β-barrel domains. In several features, however, FXIII differs 
remarkably from all other members of this enzyme family. The enzymatically inactive pro-
transglutaminase carries a unique 37-residue-long activation peptide which is excised by 
thrombin in the final phase of a coagulation event. Moreover, FXIII is the only dimeric 
transglutaminase composed of two zymogen A subunits (cellular FXIII-A2 found, for example, 
in platelets and megakaryocytes) or complexed in plasma with two B-carrier subunits, thereby 
forming a heterotetramer (plasma FXIII-A2B2). 
Recombinant human cellular factor XIII (FXIII-A2) was activated using a high concentration 
of calcium ions rather than by applying proteolytic activation with thrombin.[67] Activated 
FXIIIa° was subsequently inhibited by the irreversible peptide inhibitor ZED1301, which 
possesses a Michael acceptor warhead that mimics the substrate’s glutamine residue (Fig. 2.3).  
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Fig. 2.3: Inhibitor ZED1301 used for inhibition and subsequent crystallization of FXIIIa°. The inhibitor 
was derived based on a phage display screening[68] and bears instead of the substrate glutamine an α,β-
unsaturated methyl ester (blue) for covalent linkage to Cys 314.  
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2.3 Results & Discussion 
 
2.3.1 General Structural Features and Overall Structural Rearrangements 
 
Here we report the first high-resolution crystal structure (1.98 Å) of FXIII in an active state 
(termed FXIIIa°, as suggested by Muszbek et al.[69] for Ca2+ activation without proteolysis) in 
complex with an irreversibly bound inhibitor. The complex crystallized in the space group P1 
with two independent FXIIIa° molecules per asymmetric unit (Fig. 2.4). 
 
 
Fig. 2.4: Molecule 1 (blue) and molecule 2 (beige) in the asymmetric unit of FXIIIa° (PDB ID: 4KTY).  
 
A structural superposition of both molecules of the asymmetric unit shows that there are only 
minor structural differences (Fig. 2.5a). The rmsd of both molecules of the asymmetric unit 
amounts 0.816 Å. The most significant one concerns the β-barrel 2 domain whereby both 
domains are translocated to each other by around 4 Å and show an rmsd of 0.877 Å (Fig. 2.5b).  
 
Chapter 2 - Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-
Generation Anticoagulants 
 
24 
 
   
Fig. 2.5: a) Structural superposition of both molecules of the asymmetric unit of FXIIIa° (PDB ID: 
4KTY) on the β-sandwich and catalytic domain. b) Magnified representation of the β-barrel 2 domains 
of both molecules of the asymmetric unit.  
 
Regarding the crystal packing, an interaction between the three-stranded β-sheet of molecule 1 
and the C-terminus of molecule 2 occurs. In detail, the backbone oxygen of Glu 543 accepts a 
hydrogen bond of the hydroxyl group of Ser 730. However, comparing both three-stranded β-
sheet of molecule 1 and 2, the β-sheet of molecule 1 adopts the same conformation as the β-
sheet of molecule 2 that exhibits no interactions. 
 
 
a) b) 
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Fig. 2.6: a) Hydrogen bond between Glu 453 of the three-stranded β-sheet and Ser 730 of the C-
terminus between two symmetry-related molecules. b) Interaction has no effect on the conformation of 
the three-stranded β-sheet. 
 
The inhibitor ZED1301 binds at the surface of the catalytic domain of FXIIIa°. This region can 
be split into three main interaction sites, the catalytic site, the adjacent proximal “α-space”, and 
the more distant hydrophobic pocket (Fig. 2.7). 
 
 
Fig. 2.7: The ligand ZED1301 (orange, Fo-Fc difference electron density contoured at 3σ) binds 
covalently to Cys 314 in the catalytic site. Next to the latter site, the interaction region, called α-space, 
E453 
S730 
b) a) 
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is formed (green). At its far end, the ligand exposes an indole moiety to the hydrophobic pocket (yellow). 
The surface of FXIIIa° is depicted in gray. 
 
In the previously determined inactive state, the catalytic site is covered by β-barrel 1, where 
Tyr 560OH forms a hydrogen bond to Sγ of Cys 314. Here we show that binding of ZED1301 
in the presence of calcium ions induces a large conformational transition, whereby the two β-
barrel domains swing aside to expose the catalytic center (Fig. 2.8). 
 
 
Fig. 2.8: In the inactive state FXIII (PDB ID: 1GGU) exists as a dimer (one monomer colored by 
domain, second in gray). Upon substrate binding, FXIII dissociates and the positions of the β-sandwich 
(turquoise) and catalytic domain (blue) remain unchanged, whereas β-barrel 1 (green) and β-barrel 2 
(yellow) undergo a remarkably large movement (red arrow). The activation peptide (orange) stabilizes 
the dimer contact in the inactive state and is still bound to the protein and partly exposed to solvent. The 
active site is located in the upper left part of the catalytic domain, where the inhibitor ZED1301 (gray) 
is covalently attached to the sulfur atom of Cys 314. The catalytic domain of the active form (PDB ID: 
4KTY) contains three calcium ions (pink) instead of only one calcium ion in the case of the inactive 
form. The loop connecting the β-sandwich domain and β-barrel 1 (dashed line) is not defined by electron 
density. 
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The complex crystallizes as a monomer, in agreement with our biochemical data determined 
from size-exclusion chromatography (Tab. 2.1). The apparent molecular weight of the FXIII-
ZED1301 complex was determined using size exclusion chromatography. Beside standard 
globular calibration proteins FXIII-A2 (dimeric, calculated 166 kDa) and TG2-ZED1301 
complex (monomeric, calculated 79 kDa) were analyzed. The data revealed an apparent 
molecular weight of FXIIIa°-ZED1301 complex of 47.7 kDa matching to the monomeric tissue 
transglutaminase inhibitor complex (TG2-ZED1301; 41.1 kDa) while displaying about half the 
apparent molecular weight of dimeric FXIII-A2 (93.5 kDa). 
 
Tab. 2.1: Size exclusion chromatography (performed by Zedira GmbH). 
Protein/ Complex Ve [ml] Ve/V0 Apparent MW [kDa] 
FXIII-A2 8.77 1.589 93.5 
FXIII-ZED1301 9.26 1.678 47.7 
TG2-ZED1301 9.37 1.697 41.1 
 
We propose that the adopted conformation represents an active FXIII structure, relevant for 
drug design, as functionally important and previously hidden sites are exposed. These findings 
are in agreement with mass spectrometry data obtained for hydrogen/deuterium exchange in 
solution.[70, 71] Structural rearrangements upon activation occur only within the catalytic 
domain, while the β-sandwich and the two β-barrel domains conserve their overall fold. The 
electron density of the loop connecting the catalytic and β-barrel 1 domain (residues 502-515) 
is not visible, possibly because of the pronounced flexibility of this portion. This observation 
agrees with biochemical evidence[72] that the Lys 513-Ser 514 peptide bond is easily accessible 
in this flexible loop and can be cleaved by thrombin. Furthermore, in our structure, the 
uncleaved pro-peptide remains at the N terminus of the β-sandwich domain. We cannot fully 
exclude an effect of the flexible and distant pro-peptide on the conformation of the catalytic 
subunit; however, we presume its relevance for drug design should be negligible. Nonetheless, 
most of the contacts formed in the inactive state are lost due to rearrangements upon activation 
and dissociation of the dimer in the monomeric state. Twenty-three amino acids of the N-
terminal propeptide chain are visible in the electron density. 
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The active state of factor XIII contains two cis peptide bonds that are also present in the inactive 
form (Fig. 2.9). Weiss et al. suggested that a cis-trans isomerisation would parallel the transition 
from inactive to active form and would produce part of the energy required for such a 
tremendous conformational change.[73] However, their assumption is not confirmed by our 
structure. 
 
 
Fig. 2.9: Both inactive (grey) and active form (blue) of FXIII contains cis-peptide bonds. One is formed 
by the amino acids Gln 425 and Phe 426 (a). The other one is formed by Arg 310 and Tyr 311 (b). 
 
 
2.3.2 Structural Rearrangements Triggered by Calcium Binding 
 
There has been much speculation concerning the driving forces that induce rearrangement upon 
activation. Since the discovery of FXIII by Laki and Lorand in the 1940s, the importance of 
calcium ions for FXIII activation, as for all transglutaminases, has now become well 
established.[6] Thus, it was surprising that crystals grown with inactive FXIII at high calcium 
concentrations, or crystals of inactive FXIII exposed to solutions containing large amounts of 
calcium ions, indicated only a single calcium-binding site per monomer (Fig. 2.10b).[17, 74] In 
our FXIIIa° structure, we observe three calcium ion sites (Fig. 2.10a) that are essential for 
driving the enzyme into an active state. Presumably, this form can only be captured when a 
peptide inhibitor is bound simultaneously with the three calcium ions and stabilizes the protein 
in this state. 
 
a) b) 
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Fig. 2.10: a) In the active state, three calcium ions (pink) bind to the catalytic domain (blue). They 
induce structural changes from the inactive to the active form (gray, site 1: 1GGU; sites 2 and 3: 1F13). 
Dashed lines indicate coordinative, hydrogen bonds or salt bridges. ZED1301 is colored in orange. 
b) At site 1, Ca2+ binding results in a shift of an α-helix in the active state of FXIII enabling a strong 
interaction between Arg 491 and Asp 438. The inactive form also binds calcium (turquoise sphere), but 
only with one direct interaction to Ala 457CO. The remaining coordination sphere is completed by 
water molecules (gray spheres). c) At site 2, the calcium ion binding drags the loop containing Asp 367 
downwards and supports rotational movement of the three-stranded β-sheet by calcium coordination of 
Asp 351 (red arrow). Both interactions lead to the formation of the hydrophobic pocket next to the active 
site (gray-blue arrow), which is important for substrate accommodation. Site 2 is also involved in the 
b) a) 
c) d) 
Chapter 2 - Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-
Generation Anticoagulants 
 
30 
 
formation of the catalytic dyad. Coordination of Asp 343 to Ca2+ drags a loop downwards (turquoise 
arrow) and enables the spatial proximity of His 342 and Glu 401 required for activity. d) Population of 
site 3 results in a loop rearrangement that contains residues which are part of the K-substrate binding 
region such as Lys 269 and Tyr 407. 
 
From a comparison of the structures of active and inactive FXIII, the following activation 
mechanism can be proposed. Calcium binding site 1 is already populated in the inactive state. 
However, only Ala 457CO coordinates directly to the calcium ion and the remaining 
coordination sites are filled with water molecules. Upon activation, the calcium ion recruits, 
besides Ala 457CO, the side chains of Asn 436, Glu 485, and Glu 490 to accomplish its 
coordination polyhedron. Glu 490 belongs to the α-helix and is mainly responsible for a shift 
of this helix (Fig. 2.10b). This in turn facilitates Arg 491 to form a strong salt bridge with 
Asp 438 between the guanidinium moiety and the carboxy group, respectively. Importantly, 
both residues are highly conserved between the human transglutaminase family and Asp 438 
belongs to the three-stranded β-sheet. 
The development of the second calcium binding site translocates part of the catalytic domain 
into a geometry that enables formation of a hydrophobic pocket next to the catalytic center 
(Fig. 2.11b). This movement is initiated by the coordination of Asp 367 to Ca2+, and the 
adjacent β strand is dragged towards the central ion (Fig. 2.10c). Importantly, the pocket thus 
created accommodates, and is stabilized at the same time by, the C-terminal Trp residue of our 
inhibitor. Furthermore, the β strand comprises Trp 390, whose indole moiety is flipped by 
almost 90° to form a hydrophobic tunnel next to the catalytic site together with the side chain 
of Trp 279 (Fig. 2.11c). This tunnel can subsequently host the putative K-substrate to form an 
iso-peptide bond. Such a tunnel has similarly been observed for TG2 in the crystal structure 
assumed to correspond to an active state.[17, 19, 75] 
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Fig. 2.11: Comparison of the substrate binding site of FXIII adopted in the inactive (PDB ID: 1F13) 
and the active state (PDB ID: 4KTY). The shape of the surface of FXIIIa° (b), which hosts the inhibitor 
ZED1301 (red), differs significantly from the geometry adopted in the inactive state (a), particularly 
with respect to the hydrophobic pocket induced upon calcium binding and occupied by the indole ring 
of the ZED1301. The inhibitor of the superimposed FXIIIa° structure is also shown for simplifying the 
orientation. c) Superposition of the inactive state (grey sticks) and the active state (blue sticks) reveals 
that the main reorientation of both states occurs in the area of the hydrophobic pocket. At the α-space, 
only Arg 223 adopts a further conformation. At the catalytic site, the indole ring of Trp 370 rotates aside 
and thus enables the formation of the hydrophobic tunnel. 
 
 
a) b) 
c) 
R223 
W370 
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Moreover, population of the second Ca2+ site affects the orientation of a three-stranded 
antiparallel β-sheet in the upper part of the catalytic domain that is also involved in the 
formation of the above-mentioned hydrophobic pocket. The involvement of Asp 351 in Ca2+ 
coordination moves the adjacent β strand downwards. In addition, on the following loop, the 
side chain and the backbone carbonyl oxygen atom of Gln 349 together with Asn 347, Asp 345, 
and Asp 343 shape the second Ca2+ site by wrapping around the metal ion. This site has a 
significant impact on the structural establishment of a catalytic dyad formed by His 342 and 
Glu 401 needed for activation of the K-substrate (Fig. 2.10c, Fig. 2.12). In the inactive 
conformation, the Nε imidazole nitrogen atom of His 342 and the carboxylate oxygen atom of 
Glu 401 are too distant for any productive interaction (about 10 Å, Fig. 2.10c). The coordination 
of Asp 343 to Ca2+ drags the loop towards the calcium ion, thereby resulting in a shift of His 
342 into a position now capable of forming a hydrogen bond with Glu 401, which is located on 
a flexible loop and can therefore easily be shifted towards His 342. 
The third calcium binding site further affects the binding of the lysine-containing co-substrate 
that attacks the thioester intermediate from the opposite side of the above-mentioned 
hydrophobic tunnel. The interaction of Asp 271 with Ca2+ results in a reorientation of a loop 
near the protein surface (Fig. 2.10d). Moreover, Asn 267 and Asp 270 are part of this loop and 
interact with Tyr 407. The incorporated calcium ions act as a template and induce, through the 
involvement of polar side chain functions in Ca2+ coordination, structural changes essential for 
the enzyme to shift from its active-site-shielded, inactive state to a functionally active state. 
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Fig. 2.12: The structural rearrangement of the co-substrate binding site during transition from the 
inactive state (grey, PDB ID: 1F13) to the active state (blue, PDB ID: 4KTY) is even more extensive 
compared to the substrate binding site (as shown in Fig. 2.11). The surface is depicted of FXIIIa°. Both 
calcium binding site 2 and 3 affects the shape of the co-substrate binding site. The formation of the 
catalytic dyad (His 342, Glu 401) is induced by site 2. Calcium coordination at site 3 leads to loop 
rearrangements (Lys 269 and Tyr 407 are shown as surrogates for the structural change). 
 
 
2.3.3 Binding Mode of ZED1301 
 
In the α-space the inhibitor interacts via seven hydrogen bonds with the FXIIIa° (Fig. 2.13a). 
The acetyl oxygen of the ligand forms hydrogen bonds to the oxygen of Tyr 283 and 
carboxamide nitrogen of Gln 313. The backbone NH of the N-terminal aspartate of the ligand 
interacts via a hydrogen bond with the carboxamide oxygen of Gln 313 that forms a further 
hydrogen bond to the adjacent backbone nitrogen of the ligand. The backbone oxygen of the 
ligand’s N-terminal aspartate is hydrogen-bonded to the terminal nitrogen of Asn 371. 
Furthermore, the hydroxyl group of the N-terminal aspartate of the ligand forms H-bonds to 
both the hydroxyl oxygen of Tyr 372 and the guanidinium NH of Arg 223 that adopts two 
conformations. 
K269 
Y407 
H342 
E401 
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Within the active site of FXIIIa°, the catalytic triad most likely adopts a geometry similar to 
that required for substrate binding and subsequent transformation into the thioester form. The 
Michael acceptor β-carbon atom of ZED1301 forms a covalent bond with Cys 314 (Fig. 2.13b). 
Moreover, the carbonyl oxygen atom of the terminal methyl ester establishes hydrogen bonds 
to the oxyanion hole formed by the indole nitrogen atom of Trp 279 and the backbone NH group 
of Cys 314. The adjacent hydrophobic tunnel is formed by Trp 279 and Trp 370 and prevents 
hydrolysis of the intermediately formed thioester. 
The central bridging part of the ligand interacts via two H-bonds with the protein (Fig. 2.13c). 
The backbone nitrogen of the amino acid, that comprises the war head, forms a hydrogen bond 
to carboxamide oxygen of Asn 371. Asn 371 interacts with the backbone oxygen of the adjacent 
N-terminal norleucine of the ligand. The second H-bond is formed between the ligand’s 
backbone NH of valine and the backbone carbonyl oxygen of Val 369. 
The indole ring of the ligand’s tryptophan addresses the hydrophobic pocket of FXIIIa° that 
consists predominantly of apolar amino acids residues (Fig. 2.13d). 
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Fig. 2.13: a) Multiple hydrogen bonds formed between the ligand and FXIIIa° in the α-space. b) The 
ligand forms a covalent bond to Cys 314 in the catalytic site and interacts through its Michael acceptor 
carbonyl oxygen atom with the NH groups of Trp 279 and Cys 314, which comprise the oxyanion hole. 
A hydrophobic tunnel is formed, flanked by Trp 279 and Trp 370, preventing hydrolysis of the 
intermediately formed thioester. c) Two hydrogen bonds are formed between the peptidic backbone of 
the inhibitor and the region between the catalytic site and the hydrophobic pocket. d) Enlargement of 
the hydrophobic pocket which is predominantly comprised of hydrophobic residues. 
 
 
  
a) b) 
d) c) 
Chapter 2 - Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-
Generation Anticoagulants 
 
36 
 
2.3.4 Modeling of a Co-substrate Mimetic 
 
The tunnel adopts a shape similar to that in TG2,[19] but in the active state of FXIIIa° the 
terminal “exit” that serves as an entrance port for the side chain of the reacting lysine residue 
of the K-substrate is much better established. This helps to orient the K-substrate in the correct 
geometry required to react with the thioester intermediate. This assumption is corroborated by 
docking an artificial Ala-Lys-Ala tripeptide that mimics the orientation of the K-substrate in 
this site (Fig. 2.14). The lysine side chain fits perfectly into the hydrophobic tunnel and places 
the lone pair of electrons on its terminal ε-amino group at an appropriate distance to the thioester 
carbon atom. This location is compatible with the requirements of a nucleophilic attack of Lys 
on the thioester-enzyme intermediate. Furthermore, potential hydrogen bonds are readily 
identifiable between the tripeptide and protein, firmly fixing the co-substrate in position 
(Fig. 2.14). 
 
 
Fig. 2.14: The K-substrate modeled as an Ala-Lys-Ala tripeptide (cyan) fits perfectly into the back side 
of the hydrophobic pocket. Hydrogen bonds of the minimized tripeptide are shown as dashed lines. The 
original ligand was remodeled into a Q-substrate (Ala-Gln-Ala tripeptide, orange) to simulate the 
binding of the two substrates. 
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2.3.5 Catalytic Dyad 
 
In addition to the well-accepted catalytic triad, we propose the existence of a catalytic dyad also 
exposed to the catalytic center to facilitate nucleophilic attack of the K-substrate in FXIIIa° 
(Fig. 2.15). This dyad is composed of His 342 and Glu 401 and attains a productive arrangement 
upon calcium activation (Fig. 2.10c). Both His 342 and Glu 401 are conserved across all human 
transglutaminases except TG7, which contains Gln instead of Glu. About 20 years ago, Yee et 
al. attributed a catalytic function to His 342 and suggested assistance by Glu 434 and not 
Glu 401.[17] 
 
 
Fig. 2.15: The newly established catalytic dyad consisting of His 342 and Glu 401 is located next to the 
entrance of the hydrophobic tunnel at the binding site of the K-substrate and is only formed in the active 
state (blue sticks). 
 
Mutation of His 342 to Ala resulted in a strikingly reduced activity with respect to the formation 
of the iso-peptide bond, but only a minor change in the affinity of the K-substrate towards the 
enzyme.[76] In the recently determined TG2 structure, assumed to represent the active state, the 
corresponding His 305 residue is oriented towards the glutamine-containing substrate-binding 
region.[19] Thus, one could argue that the latter structure does not yet correspond to the fully 
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active state of TG2. Admittedly, our structure also represents only a different frozen situation 
in the solid state, reflecting a geometry the protein is, in principle, able to adopt. Nonetheless, 
we propose that this structure approaches the situation in the active state more closely as it can 
easily accommodate both substrates along with full population of all three calcium binding 
sites, establishment of the hydrophobic tunnel, and formation of the additional catalytic dyad. 
The change in the protonation states of the substrates during formation of the iso-peptide bond 
appears puzzling. Under physiological conditions, the lysine residue of the K-substrate should 
bear a charged ammonium group. Yet, entering the protein binding site could induce a 
substantial pKa shift towards lower basicity, thus resulting in an uncharged state of lysine. This 
effect might be supported by the adjacent His 373 of the catalytic triad, which could carry a 
positive charge. Upon formation of the amide bond, the catalytic dyad could operate reversibly, 
similar to the well-known mechanism of the catalytic triad in serine proteases, and pick up the 
second proton from the amino head group of the reacting lysine residue. Finally, the catalytic 
site of FXIII and also of other human transglutaminases can be extended by Glu 401 (Fig. 2.16). 
 
 
Fig. 2.16: General mechanism for FXIII and other human transglutaminases completed by Glu 401. 
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2.4 Summary & Conclusion 
 
Blood coagulation factor XIII represents a promising target for the development of 
anticoagulants with a lower bleeding risk compared to current anticoagulants. We were able to 
crystallize calcium activated FXIII in complex with a covalently attached inhibitor. The yielded 
crystal structure adopts an open conformation whereby the active site is not covered by the β-
barrel 1 domain anymore as in the inactive state.  
Aside the usage of the crystal structure for structure based development of a blood coagulation 
factor XIII blocker, the structure of FXIIIa° reveals the involvement of calcium in the activation 
process. Calcium binding affects both the shape of the substrate and co-substrate binding site. 
Furthermore, a catalytic dyad could be identified induced by calcium binding as well. 
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2.5 Experimental Part 
 
2.5.1 Methods Protein Expression, Purification and Inhibition 
 
The functional expression of recombinant FXIII-A2 (A-subunits) in insect cells, its respective 
purification and the synthesis of Michael acceptor (MA) transglutaminase blockers has recently 
been described[77] and will be shortly summarized below. Based on the results of phage display 
screening for preferred substrates[68] we designed the lead ZED1301 Ac-Asp-MA-Nle-Nle-Leu-
Pro-Trp-Pro-OH (Nle: norleucine) as a potent inhibitor. Activation of blood coagulation factor 
XIII was achieved by high calcium ion concentrations instead of exposure to thrombin.[78] A 
solution of purified recombinant FXIII-A2 (0.2 mg/mL) in 10 mM Tris-HCl, pH 8.0, 300 mM 
NaCl, 15% (v/v) glycerol containing 100 mM Ca2+ was mixed with the inhibitor at a molar ratio 
of 1:25. The mixture was stirred and incubated at room temperature for 1 h. The inhibited 
complex was concentrated and subsequently applied to a Superdex75pg HiLoad gel filtration 
column equilibrated with 10 mM Tris-HCl pH 8.0, 300 mM NaCl, 15% (v/v) glycerol 
containing 3 mM CaCl2. 
 
 
2.5.2 Crystallization, Data Collection and Structure Determination 
 
The eluted protein was concentrated to 9.7 mg/mL and protein crystals were grown at ambient 
temperature using the hanging drop vapor diffusion method. Crystallization was achieved by 
mixing 5 μL protein solutions with 5 μL precipitation solution (170 mM ammonium sulphate, 
85 mM sodium cacodylate pH 6.5, 25.5% (w/v) PEG 8,000, 15% (v/v) glycerol). A suitable 
single crystal was obtained after removal of small satellites from its surface. The crystal was 
flash-frozen in liquid nitrogen and a dataset of 400 images with 0.5 degree rotation at a 
wavelength of 0.91841 Å was collected at the BL14.2, BESSY II electron storage ring.[79] Data 
were processed to a resolution of 1.98 Å in space group P1 using the program HKL2000.[80] 
Higher C2 symmetry could be excluded by checking for alternative settings with XPREP.[81] 
The structure was determined by molecular replacement with the CCP4[82] program Phaser.[83] 
The molecular replacement model had to be split into the four subunits. The β-sandwich domain 
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and the two β-barrel domains were used as determined for the inactive form of FXIII (PDB ID: 
1F13). For the catalytic domain, a homology model based on the active form of TG2 (PDB ID: 
2Q3Z) was generated using Modeller.[84] The appropriate sequence alignment was performed 
taking into account secondary structural motifs with PROMALS.[85] Subsequently, significant 
improvement of the starting model could be achieved by automated improvement of a 
molecular replacement model using ARP/wARP.[86] The model was manually improved with 
Coot[87] and refined with Phenix.[88] At the beginning, a simulated annealing step was 
performed. The structure was refined with coordinates, individual B-factors, occupancies, TLS 
groups, optimized X-ray/stereochemistry weight and optimized X-ray/ADP weight. The ligand 
was optimized with the Tripos Force Field in Sybyl.[89] The ligand restraints were created with 
the Monomer Library Sketcher implemented in the CCP4 Program Suite. According to 
Procheck,[90] 1107 residues (90 %) are found in the most favored, 120 residues (9.8 %) in 
allowed, and 3 residues (0.2 %) occur in disallowed regions (Asp 270 of molecule 1 and 2 and 
Asp 139 of molecule 1). Asp 270 is located between two coordinating residues of Ca2+ at site 
3, enforcing a tight loop turn. Asp 139 of molecule 1 is located in a tight β-turn and is part of a 
three-stranded β-sheet in the β-sandwich domain. In the final difference electron density map 
residual density could be identified next to the amino acids Phe 60 and Lys 61. The peak is in 
H-bonding distance to the latter residues and approximates tetrahedral geometry. Several 
tetrahedral species were tested and a sulphate ion, possibly picked up from the crystallization 
buffer, gave the best fit. However, as some unexplained residual density remained after 
refinement we did not assigned any molecular species to this density. 
 
 
2.5.3 Molecular Modelling 
 
The K- and Q-substrates were modeled as tripeptides Ala-Xxx-Ala (Xxx: Lys, Gln) based on 
the coordinates of the inhibitor in the crystal structure and placed such that the ε-amino group 
of the lysine residue was within ~7 Å of Sγ of the catalytic cysteine. In the following HARMm22 
force field minimization,[91] the protein structure was kept rigid, while full flexibility was 
allowed for both substrates. No restraints were included, such that the final position represents 
an unbiased minimum of the potential energy. 
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2.5.4 Synthesis of ZED1301 
 
The peptidic blocker ZED1301 is a modified octapeptide derived from phage display 
screening[68] containing a Michael Acceptor as substrate glutamine mimetic. The C-terminal 
peptide sequence “NleNleLPWP” was synthesized by standard Fmoc solid-phase peptide 
chemistry (reactions in DMF, coupling with TBTU/HOBt/DIPEA, deprotection with 
piperidine) using H-Pro-2-ClTrt-resin as starting material. Coupling (in DMF, using HATU/ 
DIPEA) with the Boc-protected Michael Acceptor amino acid was followed by cleavage from 
the resin (using 95 % TFA / 2.5 % water / 2.5 % triisopropylsilane). The resulting peptide “MA-
NleNleLPWP-OH” was subsequently modified by coupling with Ac-Asp(OtBu)-OH (in DMF, 
using HATU/DIPEA). Finally, the tBu-protecting group was removed by TFA (in DCM) 
yielding Ac-Asp-MA-NleNleLPWP-OH. Purification was performed by reverse phase HPLC. 
Identity was confirmed by massspectrometry, purity was >97 %, as analyzed by HPLC at 214 
nm. 
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2.6 Appendix 
 
2.6.1 Alignment of the Catalytic Domain of Human Transglutaminases 
 
An alignment of the human transglutaminase family shows that the calcium ion binding sites 
(site 1: yellow, site 2: green, site 3: cyan) are well conserved with exception of these residues 
interacting by their amide oxygen with the calcium ion. Also Arg 491 and Asp 438 involved in 
the interacting between the shifted α-helix and the three-stranded β-sheet are highly conserved 
(grey). A high conservation is also presented in case of the catalytic site (red) consisting of a 
catalytic triad and a hydrophobic tunnel. The alignment indicates a fundamental function of the 
catalytic dyad (violet) within the entire transglutaminase family due to a high conservation of 
His 342 and Glu 401.  
 
  190 200 210 220 230   240  
  •   •   •   •   •   •  
F13A NPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRA....... 
TG1  NPWCPEDIVYVDHEDWRQEYVLNESGRIYYGTEAQIGERTWNYGQFDHGVLDACLYILDRR....... 
TG2  NAWCPADAVYLDSEEERQEYVLTQQGFIYQGSAKFIKNIPWNFGQFEDGILDICLILLDVNPKFLKNA 
TG3  NPWLNVDSVFMGNHAEREEYVQEDAGIIFVGSTNRIGMIGWNFGQFEEDILSICLSILDRSLNFRRDA 
TG4  NPWCKEDMVFMPDEDERKEYILNDTGCHYVGAARSIKCKPWNFGQFEKNVLDCCISLLTES....... 
TG5  NPWCPEDAVYLDSEPQRQEYVMNDYGFIYQGSKNWIRPCPWNYGQFEDKIIDICLKLLDKSLHFQTDP 
TG6  NPWCAEDDVFLASEEERQEYVLSDSGIIFRGVEKHIRAQGWNYGQFEEDILNICLSILDRSPGHQNNP 
TG7  NPWSPEDDVYLPSEILLQEYIMRDYGFVYKGHERFITSWPWNYGQFEEDIIDICFEILNKSLYHLKNP 
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 250 260 270 280 290 300 310 
   •   •  •   •   •   •   • 
F13A MDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSE.NPVRYGQ 
TG1  MPYGGRGDPVNVSRVISAMVNSLDDNGVLIGNWSGDYSRGTNPSAWVGSVEILLSYLRTG.YSVPYGQ 
TG2  RDCSRRSSPVYVGRVVSGMVNCNDDQGVLLGRWDNNYGDGVSPMSWIGSVDILRRWKNHGCQRVKYGQ 
TG3  TDVASRNDPKYVGRVLSAMINSNDDNGVLAGNWSGTYTGGRDPRSWNGSVEILKNWKKSGFSPVRYGQ 
TG4  LKPTDRRDPVLVCRAMCAMMSFEKGQGVLIGNWTGDYEGGTAPYKWTGSAPILQQYYNTK.QAVCFGQ 
TG5  TDCALRGSPVYVSRVVCAMINSNDDNGVLNGNWSENYTDGANPAEWTGSVAILKQWNATGCQPVRYGQ 
TG6  TDVSCRHNPIYVTRVISAMVNSNNDRGVVQGQWQGKYGGGTSPLHWRGSVAILQKWLKGRYKPVKYGQ 
TG7  KDCSQRNDVVYVCRVVSAMINSNDDNGVLQGNWGEDYSKGVSPLEWKGSVAILQQWSARGGQPVKYGQ 
 
 320 330 340 350 360 370 380 
   •   •   • •  •   •   • 
F13A CWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMT 
TG1  CWVFAGVTTTVLRCLGLATRTVTNFNSAHDTDTSLTMDIYFDENMKPLEHLNHDSVWNFHVWNDCWMK 
TG2  CWVFAAVACTVLRCLGIPTRVVTNYNSAHDQNSNLLIEYFRNEFGEIQGD.KSEMIWNFHCWVESWMT 
TG3  CWVFAGTLNTALRSLGIPSRVITNFNSAHDTDRNLSVDVYYDPMGNPLDK.GSDSVWNFHVWNEGWFV 
TG4  CWVFAGILTTVLRALGIPARSVTGFDSAHDTERNLTVDTYVNENGEKITSMTHDSVWNFHVWTDAWMK 
TG5  CWVFAAVMCTVMRCLGIPTRVITNFDSGHDTDGNLIIDEYYDNTGRILGNKKKDTIWNFHVWNECWMA 
TG6  CWVFAGVLCTVLRCLGIATRVVSNFNSAHDTDQNLSVDKYVDSFGRTLEDLTEDSMWNFHVWNESWFA 
TG7  CWVFASVMCTVMRCLGVPTRVVSNFRSAHNVDRNLTIDTYYDRNAEMLSTQKRDKIWNFHVWNECWMI 
 
 390 400 410 420 430 440  
   •   •   • •   •  •  
F13A RPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKD.. 
TG1  RPDLPSGFDGWQVVDATPQETSSGIFCCGPCSVESIKNGLVYMKYDTPFIFAEVNSDKVYWQRQDD.. 
TG2  RPDLQPGYEGWQALDPTPQEKSEGTYCCGPVPVRAIKEGDLSTKYDAPFVFAEVNADVVDWIQQDD.. 
TG3  RSDLGPSYGGWQVLDATPQERSQGVFQCGPASVIGVREGDVQLNFDMPFIFAEVNADRITWLYDNT.. 
TG4  RPDLPKGYDGWQAVDATPQERSQGVFCCGPSPLTAIRKGDIFIVYDTRFVFSEVNGDRLIWLVKMVNG 
TG5  RKDLPPAYGGWQVLDATPQEMSNGVYCCGPASVRAIKEGEVDLNYDTPFVFSMVNADCMSWLVQGG.. 
TG6  RQDLGPSYNGWQVLDATPQEESEGVFRCGPASVTAIREGDVHLAHDGPFVFAEVNADYITWLWHED.. 
TG7  RKDLPPGYNGWQVLDPTPQQTSSGLFCCGPASVKAIREGDVHLAYDTPFVYAEVNADEVIWLLGDG.. 
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 450 460 470 480 490 500 
   •   •   •   •   •   • 
F13A ..GTHVV.ENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTE... 
TG1  ..GSFKI.VYVEEKAIGTLIVTKAISSNMREDITYLYKHPEGSDAERKAVETAAAHGSKPNVYA.... 
TG2  ..GSVHK.SINRSLIVGLKISTKSVGRDEREDITHTYKYPEGSSEEREAFTRANHLNKL......... 
TG3  ..TGKQWKNSVNSHTIGRYISTKAVGSNARMDVTDKYKYPEGSDQERQVFQKALGKLKPNTPFAAT.. 
TG4  GQEELHV.ISMETTSIGKNISTKAVGQDRRRDITYEYKYPEGSSEERQVMDHAFLLLSSEREHRR... 
TG5  ..KEQK..LHQDTSSVGNFISTKSIQSDERDDITENYKYEEGSLQERQVFLKALQKLKARSFHGSQRG 
TG6  ..ESRER.VYSNTKKIGRCISTKAVGSDSRVDITDLYKYPEGSRKERQVYSKAVNRLFGVEASGRRIW 
TG7  ..QAQEI.LAHNTSSIGKEISTKMVGSDQRQSITSSYKYPEGSPEERAVFMKASRKMLGP.....QRA 
 
  510 
  • 
F13A.......................G..VMKSR 
TG1  .........................NRGSA 
TG2  .........................AEKEE 
TG3  ...................SSMGLETEEQE 
TG4  ..........................PVKE 
TG5  AELQPSRPTSLSQDSPRSLHTPS.LRPSDV 
TG6  I..........RRAGGRCLWRDDLLEPATK 
TG7  SL.....PF......LDLLESGG.LRD... 
 
 
2.6.2 Crystallographic Table 
 
Tab. 2.2: Data collection and refinement statistics of inhibitor ZED1301. 
Inhibitor ZED1301 
PDB Entry 4KTY 
Data collection and processing  
Wavelength [Å] 0.91841 
Beamline BESSY – 14.2 
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Space group P1 
Unit cell parameters  
a, b, c [Å] 56.8, 80.5, 102.8 
α, β, γ [°] 88.1, 76.7, 82.0 
Diffraction data  
Resolution range [Å]* 50.00 – 1.98 (2.03 – 1.98) 
Unique reflections 119138 (7864) 
R(I)sym [%] 8.4 (36.3) 
Completeness [%] 97.1 (95.8) 
Redundancy 2.2 (2.1) 
I/σ(I) 10.0 (2.0) 
Refinement  
Resolution range [Å] 20.80 – 1.98 
Reflections used in refinement (total) 119041 
Reflections used in refinement (work/free)  113061/ 5980 
Final R values for all reflections (work/free) [%] 16.9/ 20.6 
Protein residues (A/B) 695/ 698 
Atoms Inhibitor (A/B) 74/ 74 
Water molecules 920 
Other ligand atoms  
RMSDs from ideality   
Bond lengths [Å] 0.010 
Bond angles [°] 1.3 
Ramachandran plot   
Residues in most favored regions [%] 90.0 
Residues in additional allowed regions [%] 9.7 
Chapter 2 - Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-
Generation Anticoagulants 
47 
 
Residues in generously allowed regions [%] 0.1 
Residues in disallowed regions [%] 0.2 
Mean B-factor [Å2]   
Protein total (A/B) 27.3/ 27.9 
Protein main chain (A/B) 26.4/26.8 
Protein side chain (A/B) 28.2/29.1 
Inhibitor (A/B) 35.3/ 38.9 
Calcium ions 21.9 
Other ligand atoms 34.8 
Water molecules 29.7 
*Highest resolution shell is shown in parenthesis 
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3 Structure-Based Design of FXIIIa-Blockers: Addressing the 
Hydrophobic Pocket of the “α-Space” 
 
3.1 Introduction 
 
Thromboembolic events such as strokes, pulmonary embolism and acute coronary syndrome 
are among the leading causes of mortality and morbidity.[92] The administration of 
anticoagulants reduces the risk of the occurrence of a thrombus in risk patients but unfortunately 
enhance the bleeding tendency can occur as an undesired side effect. 
Thrombin represents the central enzyme of the blood coagulation cascade. Accordingly, all 
current anticoagulants lower thrombin activity, whether directly or indirectly (Fig. 3.1). 
Thrombin activates fibrinogen to fibrin that forms along with other blood cells a weak blood 
clot. Factor XIII, also activated by thrombin, finally stabilizes the clot by forming iso-peptide 
bonds between the fibrin fibers.[1, 41, 63] Accordingly, FXIII is the only enzyme in the coagulation 
cascade acting downstream of thrombin. Consequently, inhibition of FXIII would still allow 
the formation of a “soft” blood clot but would not interfere with e.g. platelet activation. These 
features rendering FXIII to a promising target for the development of anticoagulants with a 
lower bleeding risk compared to current anticoagulants. In addition to its involvement in blood 
coagulation, FXIII also decorates the clot with α2-antiplasmin, lowering fibrinolysis of the clot 
by plasmin.[93] As a result, inhibition of FXIII would lower both, half-life and weight, 
accelerating the degradation by patient’s own fibrinolytic systems.  
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Fig. 3.1: Mode-of-Action of FXIII blockers compared to current anticoagulants illustrated on a 
simplified representation of the blood coagulation cascade. Factor XIII is the last enzyme of the cascade 
and catalyzes the formation of an iso-peptide bond between a glutamine and a lysine residue. All current 
anticoagulants reduce the activity of thrombin. As a result, the coagulation and platelet activation is 
disturbed. In contrast, inhibition of FXIII would still allow the fibrin formation (that forms with blood 
cells a “soft” blood clot and does not interfere with platelet activation). Consequently, FXIII is a 
promising target for anticoagulants with an expected lower bleeding risk. 
 
The occurrence of severe bleeding events in patients with congenital FXIII deficiency should 
be kept in mind.[94, 95] However, heterozygous patients show only a mild or even none bleeding 
phenotype. Ultimately, clinical trials have to show whether there is an improved benefit-to-risk 
ratio compared to current anticoagulants or not. Looking at the unique mode-of-action it seems 
to be realistic that a direct-acting FXIIIa blocker could provide an additional treatment option 
at least for certain patients. To prove this hypothesis druggable molecules are needed to perform 
pharmacological studies first in relevant animal models and – if successful – in future clinical 
trials on humans. 
A promising strategy to obtain such druggable compounds follows the approach of structure-
based drug design. So far, all attempts to develop a FXIII blocker failed due to the lack of a 
suitable crystal structure. The crystal structure of factor XIII in the inactive state, published in 
 
Chapter 3 - Structure Based Design of FXIIIa-Blockers: Addressing the Hydrophobic Pocket of the “α-space” 
50 
 
1994, was an important academic milestone for the transglutaminase community. 
Unfortunately, the structure is not useful for structure-based design of a FXIII blocker because 
the active site is buried by the β-barrel 1 domain and the binding mode of substrates and 
inhibitors remained unclear.[17] 
In 2013, we published a high-resolution crystals structure of FXIII in the active conformation 
by co-crystallization of FXIII with a covalently-attached ligand.[60] Herein, the β-barrel 1 
domain of the protein does not covers the active site any longer but is located laterally of the 
catalytic domain. 
Despite of an excellent binding affinity of our lead structure ZED1301, the observed plasma 
half-life is short. This attributes primarily to the peptidic structure rendering the molecule prone 
to digestion by proteases. Furthermore, the molecular weight of 1,063 g/mol exceeds by far the 
Lipinski rule of five (500 g/mol) indicating properties favorable for oral application. Thus, we 
aimed to reduce the size of our inhibitors and to introduce a more non-peptidic character. We 
decided firstly to optimize the affinity in the “α-space”. As α-space the region next to the 
catalytic tunnel is defined. 
ZED1301 is an octapeptide consisting of an N-terminal acetylated aspartate followed by the 
warhead replacing in the substrate a glutamine residue. Next, three hydrophobic amino acids 
(two norleucines and a leucine) are present bridging the distance to the primary binding pocket 
which is addressed by a proline-tryptophan dipeptide. Another proline residue completes the 
peptidic lead structure (Fig. 3.2). Since the N-terminal aspartate displays most interactions 
within the active site, we decided to focus on the replacement of this amino acid by alternative 
residues. 
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Fig. 3.2: The peptidic lead structure ZED1301 possesses an acetylated aspartate at the N-terminus 
addressing the “α-space”. 
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3.2 Results & Discussion 
 
3.2.1 ZED1630 
 
The lower-affinity inhibitor ZED1630 (IC50: 139 nm) possesses a methylated thiazole 
heterocycle at the N-terminus. Additionally, ZED1630 differs from ZED1301 in that way the 
second norleucine is substituted by an isoleucine and the terminal proline was dispensed. 
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Fig. 3.3: α-Space modification (red) of ZED1630 and further modifications (blue) compared to the 
peptidic lead structure ZED1301. 
 
As shown in Fig. 3.4, the inhibitor ZED1630 is clearly defined in the electron density of both 
symmetry-related molecules (resolution: 2.10 Å). Only for the first norleucine there remain 
three and two carbon atoms in molecule 1 and 2 of the asymmetric unit undefined in the electron 
density, respectively. 
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Fig. 3.4: Fo-Fc difference electron density contoured at 3σ for the inhibitor ZED1630 (purple) in 
molecule 1 (a) and 2 (b) of the asymmetric unit. The inhibitor is covalently attached to the catalytic site 
Cys 314 (grey). 
 
Regarding the crystal structure, the thiazole is located as expected in the α-space (Fig. 3.5). 
Notably, the methyl group is exactly positioned above a hydrophobic pocket in the α-space. 
Addressing this hydrophobic pocket can result in an increase of the binding affinity. 
Furthermore, in the α-space ZED1630 binds significantly closer to the protein surface compared 
to ZED1301 (difference of the distances between Cα of the N-terminal aspartate and the 
corresponding atom of ZED1630 and the hydroxyl oxygen Tyr 372 amounts 1.3 Å), suggesting 
for an improved binding geometry. 
Finally, the indole ring of ZED1630 binds deeper into the hydrophobic pocket (1 Å) and the 
indole nitrogen forms a comparatively strong hydrogen bond to the carbonyl oxygen of Asp 367 
with a distance of 2.9 Å. It should be mentioned that Asp 367 belongs to the residues 
coordinating calcium at binding site 2 (Chapter 2.3.2) and Asp 367 adopts this position only 
after calcium has bound to the enzyme. Also the proline next to the tryptophan adopts a different 
spatial orientation in the binding modes of both inhibitors (Cα-distance: 1.4 Å). These 
conformational deviations of ZED1630 and ZED1301 may result from the lack of a terminal 
proline in ZED1630. 
a) 
b) 
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Fig. 3.5: Interaction pattern of ZED1630 (magenta, PDB ID: 5MHM) with FXIIIa° compared to 
ZED1301 (light red, PDB ID: 4KTY). The methyl group of a thiazole ring located in the α-space can 
serve as starting point for addressing the hydrophobic pocket (red arrow). The indole ring reaches 
deeper into the hydrophobic pocket due to the lacking terminal proline. 
 
Indeed, the appearance of the hydrophobic pocket in the α-space is not surprising after 
considering the fact that upon enzyme activation amino acids of the α-space remain at their 
position (Fig. 3.6). The inhibitor, described in Chapter 2.3.3, interacts with the side chain of 
Arg 223, resulting in a sealing of the hydrophobic pocket. However, the corresponding H-bond 
is according to its length, rather weak (3.6 Å) and the new conformation of Arg 223 has to 
compete with hydrogen bonds formed to the backbone oxygen of Ser 224 and Trp 292. 
Consequently, the side chain of Arg 223 adopts two conformations with a similar occupancy. 
Interestingly, in crystal structures of FXIIIa° where the hydrophobic pocket is established 
(ZED1630, ZED2360, ZED2369), Arg 223 adopts the same conformation as the higher 
populated conformation of Arg 223 in FXIIIa°-ZED1301 (not shown). 
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Fig. 3.6: The hydrophobic pocket in the α-space is already formed in the inactive state of FXIII (grey, 
PDB ID: 1F13). In the crystal structure of FXIIIa° in complex with ZED1301 (light red, PDB ID: 4KTY) 
colored in blue, a weak H-bond (3.6 Å) between the aspartate oxygen of ZED1301 and the guanidinium 
nitrogen of Arg 223 triggers a closure of the hydrophobic pocket. The side chain of Arg 223 adopts two 
conformations. One interacts with the backbone oxygen of Ser 290 and Trp 292, the other one with 
ZED1301, whereas the latter has a slightly lower occupancy of 0.45. Notably, compared to the crystal 
structure of FXIIIa°-ZED1301 in the inactive state the side chain of Arg 223 donates its hydrogen bond 
to the backbone oxygen of Ser 224 instead of Ser 290. 
 
 
3.2.2 ZED2360 
 
The inhibitor ZED2360 was synthesized to address the hydrophobic pocket in the α-space. This 
was attempted by enhancing the methylated thiazole by attaching an ethyl ester (Fig. 3.7). 
Furthermore, when compared to ZED1301, ZED2360 bears a leucine and an isoleucine instead 
of the two norleucines. Finally, the C-terminus is a carboxamide. 
R223 
0.45 
0.55 
S224 
W292 
S290 
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Fig. 3.7: α-space modification (red) of ZED2360 and further modifications (blue) compared to the 
peptidic lead structure ZED1301. 
 
The collected dataset of the crystallized complex of ZED2360 and FXIIIa° shows a moderate 
resolution of 2.48 Å. Nevertheless, the inhibitor with some exceptions is decisively shaped by 
the difference electron density (Fig. 3.8). The first inhibitor molecule in the asymmetric unit is 
almost complete visible except for the terminal carboxamide group and the leucine side chain. 
In the second molecule of the asymmetric unit, some atoms remain undefined in the difference 
density (ethyl group of the thiazole ester, methyl group of the warhead ester, terminal proline 
and some atoms of leucine and isoleucine side chain).  
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Fig. 3.8: Fo-Fc difference electron density contoured at 3σ for the inhibitor ZED2360 (light purple) in 
molecule 1 (a) and 2 (b) of the asymmetric unit. The inhibitor is covalently attached to the catalytic site 
Cys 314 (grey). 
 
As anticipated, the crystal structure shows that the ethyl group of the ester introduced at the 
thiazole moiety addresses the hydrophobic pocket in the α-space (Fig. 3.9). Moreover, the ester 
carbonyl oxygen serves as acceptor for the guanidinium NH of Arg 223 and the other ester 
oxygen accepts a hydrogen bond of the phenolic hydroxyl group of Tyr 372. The other 
hydrogen bonds are similarly established to ZED1630 (Fig. 3.5). 
Considering the geometry and the interaction pattern, the thiazole ester fits perfectly into the 
complementary binding pocket of FXIIIa° within the α-space. This is also reflected by a 
significantly improved binding affinity. The IC50 of ZED1630 exceeds with 29 nM that of 
ZED1301 by almost an order of magnitude. 
 
 
a) 
b) 
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Fig. 3.9: Interaction pattern of ZED2360 (cyan, PDB ID: 5MHN) with FXIIIa°. The ethyl group of the 
thiazole ester occupies the hydrophobic pocket. The ester oxygen atoms interact via H-bonds with 
Arg 223 and Tyr 372.  
 
 
3.2.3 ZED2369 
 
A further α-space modified inhibitor possesses a bulky and hydrophobic benzimidazole 
(IC50: 102 nM). The remaining substitution pattern corresponds to that of ZED2360 (Fig. 3.10). 
Also here, the two norleucines are replaced by leucine and isoleucine, respectively. The C-
terminus is equally amidated. 
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Fig. 3.10: α-space modification (red) of ZED2369 and further modifications (blue) compared to the 
initial ligand ZED1301. 
 
Owing to the moderate resolution of 2.92 Å, some atoms remain undefined in the density 
(Fig. 3.11) when compared to the other better resolved structures. This also affects the indole 
ring of the first molecule in the asymmetric unit that is not clearly defined in the difference 
electron density map. Furthermore, the benzimidazole adopts two different orientations 
considering the two symmetry-related molecules, although a reliable assignment of the 
conformational properties is difficult in that part of the structure due to limited resolution.  
 
 
 
Fig. 3.11: Fo-Fc difference electron density contoured at 3σ for the inhibitor ZED2369 (beige) in 
molecule 1 (a) and 2 (b) of the asymmetric unit. The inhibitor is covalently attached to the catalytic site 
Cys 314 (grey). 
a) 
b) 
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However, the crystal structure reveals that the benzimidazole moiety is located next to the α-
space (Fig. 3.12). Importantly, the carbon atom at position 4 is directly positioned above the 
hydrophobic pocket and can serve as starting point for addressing the hydrophobic pocket, with 
additional substituents, analogous to ZED1630. 
 
 
Fig. 3.12: Interaction pattern of ZED2369 (cyan, PDB ID: 5MHO) with FXIIIa°. The benzimidazole is 
located in the α-space and can also be used for occupying the hydrophobic pocket (red arrow). 
 
 
3.2.4 Indole Ring of the Hydrophobic Tunnel Affected by Calcium Binding 
 
Comparing the new crystal structures described above, an H-bond between the indole NH of 
Trp 370 and the carboxamide oxygen of Gln 400 attracts attention (because of a shorter distance 
with up to 3.1 Å). This is as compared to the first crystal structure of FXIIIa° which showed a 
rather weak interaction with 3.5 Å (Fig. 3.13). Importantly, the orientation of this indole ring is 
responsible for the formation of the hydrophobic tunnel, protecting the thioester intermediate 
from hydrolysis. 
V369 
W279 
Q313 
W315 
Y372 
Y214 
D367 
R223 
N371 
 
Chapter 3 - Structure Based Design of FXIIIa-Blockers: Addressing the Hydrophobic Pocket of the “α-space” 
61 
 
Additionally, Gln 400 also interacts with its carboxamide NH2 with the carboxyl oxygen of 
Glu 434, rendering the carboxamide oxygen a stronger hydrogen acceptor. Remarkably, both 
residues adopt this arrangement only in the active state of FXIII (Fig. 3.13), whereas the 
distance of the carboxamide of Gln 400 increases from the active and inactive state to a value 
of 4.4 Å. 
 
 
Fig. 3.13: The indole nitrogen of Trp 370 forms an H-bond with the carboxamide oxygen of Gln 400. 
The superimposed structure of the inactive state (grey sticks, PDB ID: 1F13) shows that this 
arrangement exists only in the active state (blue sticks, PDB ID: 4KTY). The distance between the 
carboxamide oxygen of Gln 400 and the indole nitrogen of Trp 370 differs between the different crystal 
structures from 3.1 to 3.5 Å. During transition from the active to the inactive state, the side chain 
carboxamide group of Gln 400 is translocated by 4.4 Å (red arrow). 
 
Closer inspection of the crystal structure of FXIIIa reveals that the calcium binding sites 2 and 
3 are involved in the formation of this tunnel simultaneously affecting the arrangement of 
Gln 400 and Glu 434 (Fig. 3.14). Coordination of Ca2+ at binding site 2 drags a loop downwards 
(red arrow), as already described for the formation of the catalytic dyad (Chapter 2.3.2), thus 
disrupting an H-bond between the backbone NH of Glu 343 and the carboxamide oxygen of 
3.1-3.5 Å 
W370 
Q400 
E434 
4.4 Å 
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Gln 400. Along with a loop rearrangement induced by the calcium coordination at site 3, the 
adjacent loop moves upwards (turquois arrow) and enables the interaction of Gln 400 and the 
indole nitrogen of Trp 370 to be formed. This newly adopted position of the side chain of 
Gln 400 also leads to a conformational rearrangement of the side chain of Glu 434 (purple 
arrow). 
 
 
Fig. 3.14: Superposition of the inactive state (grey) and the active state (blue) of FXIII reveals that Ca2+  
(purple spheres) coordination at binding sites 2 and 3 triggers the H-bond formation between Gln 400 
and the indole moiety of Trp 370. During transition from the inactive to the active state the indole ring 
rotates by around 70° (black arrow). The interaction of Glu 343 with calcium (red arrow) breaks a 
hydrogen bond (I) between Gln 400 and the backbone nitrogen of Glu 343. This in turn enables along 
with calcium coordination at site 3 (H-bond II) a loop rearrangement (turquois arrow) and brings 
Gln 400 and the indole of Trp 370 in an appropriate H-bond interaction distance (III). Finally, the side 
chain of Glu 434 adapts to the new chemical environment by a side chain flip (purple arrow) and forms 
a corresponding hydrogen bond (IV).  
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Regarding the amino acid sequences of human transglutaminases, both residues (Gln 400 and 
Glu 434) are highly conserved (Fig. 3.15). Consequently, the formation of this dyad and the 
interaction with the indole ring of the hydrophobic tunnel should have a special function with 
respect to the catalytic cycle of transglutaminases. An opening of the hydrophobic tunnel prior 
to the glutamine side chain penetration of the substrate can be excluded because in the calcium 
bound crystal structure of transglutaminase 3, where Gln 400 and Glu 434 adopts the same 
spatial arrangement as in FXIIIa°, the indole ring is identically oriented as in the inactive state 
of FXIII.[18, 75, 96] 
 
 
Fig. 3.15: Section of an alignment of human transglutaminases. The amino acids Gln 400 and Glu 434 
are conserved (highlighted in cyan) with exception of TG5. 
 
Alternatively, the formation of the hydrophobic tunnel could take place in a concerted process 
along with substrate binding, whereas the H-bond between Gln 400 and Glu 434 facilitates the 
opening of the tunnel. 
As illustrated in Fig. 3.16, a further role of the established H-bond could be anticipated to 
prevent further rotation of the indole ring leading to an extended opening of the hydrophobic 
tunnel which might result in the hydrolysis of the thioester intermediate. However, rotation of 
the indole ring by 60° would result in a shortening of the hydrogen bond distance (3.4 Å). 
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Fig. 3.16: Indole rotamers of Trp 370. a) In the inactive state of FXIII (PDB ID: 1F13), the catalytic 
site is buried by the indole ring of Trp 370 (shown: FXIIIa° with the rotamer of Trp 370 of the inactive 
state of FXIII). b)  Upon substrate binding the indole ring rotates by 68.8° and establishes formation of 
the hydrophobic tunnel (PDB ID: 4KTY). Simultaneously, an H-bond between the indole nitrogen and 
the carboxamide oxygen is formed (3.5 Å). c) Further rotation of the indole ring (here 60°) would open 
the tunnel for release of the iso-peptide cross-linked product. The hydrogen bond would become slightly 
stronger during opening of the hydrophobic tunnel (3.4 Å). Opening of the hydrophobic pocket would 
also enable water to enter the catalytic site and hydrolyzes the thioester intermediate (deamidation). 
 
Transglutaminases are known to catalyze apart from the transamidation also deamidation 
resulting in the hydrolysis of a glutamine to a glutamate.[1] Regarding the crystal structures of 
all active human transglutaminases, it has been demonstrated that calcium binding 
predominantly affects the shape of the co-substrate binding site and renders the enzyme 
prominent to catalyze the transamidation reaction (Fig. 3.17).[60] Consequently, in contrast to 
the K-substrate the Q-substrate should be able to bind to the active site of transglutaminases 
also in the absence of calcium. 
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Fig. 3.17: Calcium binding site 2 and 3 (purple spheres) affects the shape of the co-substrate binding 
site along with the formation of the catalytic dyad (His 342, Glu 401) and the H-bond between Gln 400 
with the indole nitrogen of Trp 370. 
 
Additional to the not established co-substrate binding site[60], in the absence of calcium the 
catalytic dyad is not formed as well as the H-bond between the indole of Trp 370 and Gln 400. 
Thus, the thioester intermediate should be hydrolyzed by water molecules penetrating into the 
hydrophobic tunnel. Considering all these observations, the calcium dependency could be a 
regulatory element of transglutaminases to control the preference of transamidation over 
deamidation. A preferred deamidation with respect to transamidation at a lower pH value has 
already been described by Fleckenstein et al.[97] and corroborates the assumption of a 
dependency of the transamidation-deamination-ratio on chemical environmental factors such 
as the local calcium concentration. Finally, the hypothesis with respect to a preferred 
deamidation at a lower calcium level has to be evidenced experimentally. 
 
 
 
2 3 
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Q400 
E434 
E401 
H342 
 
Chapter 3 - Structure Based Design of FXIIIa-Blockers: Addressing the Hydrophobic Pocket of the “α-space” 
66 
 
3.3 Summary & Conclusion 
 
The initial affinity of inhibitor ZED1301 could be improved by optimizing the occupancy of 
the α-space (Tab. 3.1). Substitution of the acetylated aspartate of ZED1301 by a methyl thiazole 
group (ZED1630) provides a starting point for addressing the hydrophobic pocket of the α-
space by adding an ethyl ester substituent (ZED2360) of which the ethyl group occupies the 
hydrophobic pocket. As a result, the affinity could be increased to 29 nM. Finally, the attached 
benzimidazole portion turned out to be useful for addressing the hydrophobic pocket via an 
alternative scaffold. However, it has to be considered that the inhibitors do not only modified 
the α-space. Nevertheless, the added modifications take only minor impact on the affinity with 
exception of the N-terminal proline (missing in ZED1630). 
 
Tab. 3.1: Inhibitors with their modifications in the α-space, affinity and the resolution of the 
corresponding crystal structure. 
Inhibitor α-space moiety Affinity [nM] Resolution [Å] 
ZED1301 
N
H
O OH
O
 
110 1.98 
ZED1630 S
N
 
139 2.10 
ZED2360 S
NO
O
 
29 2.48 
ZED2369 
N
N
H  
102 2.92 
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Additionally, with reference to the improvement in binding affinity, a highly conserved dyad 
consisting of Gln 400 and Glu 434 was found. The Gln 400 carboxamide oxygen involves the 
NH hydrogen of Trp 370 indole into an H-bond in the hydrophobic tunnel. Remarkably, 
calcium binding is involved in the formation of the dyad. However, the exact function of the 
hydrogen bond between the indole of Trp 370 and the carboxamide of Gln 400 remains unclear 
and requires experimental investigations. 
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3.4 Experimental Part 
 
3.4.1 Data Collection and Structure Determination 
 
Crystals of FXIIIa° in complex with the inhibitors were flash-frozen in liquid nitrogen and a 
datasets were collected at the BESSY II electron storage ring.[79] All data sets were processed 
in space group P1 using the programs HKL2000[80] (ZED1630) and XDS[98] (ZED2360, 
ZED2369). The initial phases were calculated by Fourier synthesis using the structure (PDB ID: 
4KTY) as starting model in the first refinement step with Phenix.[88] The model was manually 
improved with Coot[87] and refined with Phenix. At the beginning the structure was refined as 
rigid body, whereas both molecules of the asymmetric unit were split into the four domains. 
Subsequently, a simulated annealing was performed. All structures were refined with 
coordinates, occupancies and individual B-factors (group B-factor for ZED2369 because of the 
low resolution). Restraints of the ligands were generated by GRADE.[99]   
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3.5 Appendix 
 
3.5.1 Crystallographic Table 
 
Table 3.1: Data collection and refinement statistics of inhibitor ZED1630 and ZED2360. 
Inhibitor ZED1630 ZED2360 
PDB Entry 5MHM 5MHN 
Data collection and processing   
Wavelength [Å] 0.91841 0.91841 
Beamline BESSY 14.1 BESSY 14.1 
Space group P1 P1 
Unit cell parameters   
a, b, c [Å] 56.9, 80.7, 103.2 56.6, 80.5, 103.1 
α, β, γ [°] 88.4, 76.6, 81.8 88.0, 77.0, 82.3 
Diffraction data   
Resolution range [Å]* 25.00 – 2.12 (2.17 – 2.12) 48.12 – 2.48 (2.63 – 2.48) 
Unique reflections 97508 (6273) 60898 (9684) 
R(I)sym [%] 8.3 (40.4) 6.8 (46.9) 
Completeness [%] 97.1 (94.1) 97.4 (96.1) 
Redundancy 2.2 (2.1) 2.2 (2.2) 
I/σ(I) 10.5 (2.0) 9.83 (2.0) 
Refinement   
Resolution range [Å] 24.88 – 2.12 48.12 – 2.48 
Reflections used in refinement (total) 97449 60829 
Reflections used in refinement (work/free)  92550/ 4899 57787/ 3042 
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Final R values for all reflections (work/free) 
[%] 
16.9/ 21.3 18.0/ 23.8 
Protein residues (A/B) 684/ 683 688/ 685 
Atoms Inhibitor (A/B) 62/ 63 75/ 65 
Water molecules 841 193 
Calcium ions 6 6 
Other ligand atoms 63 43 
RMSDs from ideality    
Bond lengths[Å] 0.009 0.010 
Bond angles [°] 1.0 1.1 
Ramachandran plot    
Residues in most favored regions [%] 89.6 88.5 
Residues in additional allowed regions [%] 10.0 10.9 
Residues in generously allowed regions [%] 0.1 0.3 
Residues in disallowed regions [%] 0.3 0.2 
Mean B-factor [Å2]    
Protein total (A/B) 30.6/ 28.7 53.1/ 56.3 
Protein main chain (A/B) 29.6/ 27.3 53.1/ 55.8 
Protein side chain (A/B) 31.6/ 30.3 53.1/ 56.9 
Inhibitor (A/B) 34.9/ 35.6 64.2/ 70.4 
Calcium ions 26.0 60.2 
Other ligand atoms 36.3 57.7 
Water molecules 32.4 44.0 
*Highest resolution shell is shown in parenthesis 
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Table 3.2: Data collection and refinement statistics of inhibitor ZED2369. 
Inhibitor ZED2369 
PDB Entry 5MHO 
Data collection and processing  
Wavelength [Å] 0.91841 
Beamline BESSY 14.1 
Space group P1 
Unit cell parameters  
a, b, c [Å] 56.6, 80.5, 102.9 
α, β, γ [°] 88.2, 76.9, 82.2 
Diffraction data  
Resolution range [Å]* 48.11 – 2.92 (3.09 – 2.92) 
Unique reflections 37113 (5987) 
R(I)sym [%] 8.7 (46.0) 
Completeness [%] 97.2 (96.6) 
Redundancy 2.2 (2.2) 
I/σ(I) 10.7 (2.0) 
Refinement  
Resolution range [Å] 17.71 – 2.92 
Reflections used in refinement (total) 36458 
Reflections used in refinement (work/free)  34683/ 1775 
Final R values for all reflections (work/free) 
[%] 
21.7/ 24.8 
Protein residues 678/ 676 
Atoms Inhibitor 60/ 72 
Water molecules 107 
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Calcium ions 6 
Other ligand atoms 15 
RMSDs from ideality   
Bond lengths[Å] 0.004 
Bond angles [°] 0.7 
Ramachandran plot   
Residues in most favored regions [%] 87.6 
Residues in additional allowed regions [%] 11.7 
Residues in generously allowed regions [%] 0.7 
Residues in disallowed regions [%] 0.0 
Mean B-factor [Å2]   
Protein total (A/B) 46.5/ 47.9 
Protein main chain (A/B) 46.0/ 47.1 
Protein side chain (A/B) 47.1/ 48.8 
Inhibitor (A/B) 53.5/ 65.5 
Calcium ions 52.1 
Other ligand atoms 52.1 
Water molecules 34.6 
*Highest resolution shell is shown in parenthesis 
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4 Blood Coagulation Factor XIII – An Enzyme with a Highly 
Adaptive Binding Site 
 
4.1 Introduction 
 
Blood coagulation factor XIII (FXIII) plays an important role in the coagulation process of 
vertebrates. Blood vessel damage initiates a cascade of zymogene activations whereby a couple 
of clotting enzymes are involved. Thrombin, as the central enzyme of the cascade, converts 
fibrinogen to fibrin that forms together with blood cells like erythrocytes and platelets the initial 
blood clot. Factor XIII, concomitantly activated by thrombin, stabilizes the clot by forming iso-
peptide bonds between the fibrin fibers. Furthermore, antifibrinolytic proteins are incorporated 
rendering the clot stable against premature fibrinolysis. Inhibition of FXIII still allows clot 
formation and platelet activation highlighting this enzyme as a promising target for the 
development of safe anticoagulants with a lower bleeding risk compared to current therapeutic 
compounds.[66] 
In contrast to all other clotting enzymes, FXIII is not a serine protease but belongs to the 
transglutaminase family. In total, there are eight human iso-forms in this enzyme class. The 
characteristic reaction catalyzed by these enzymes is the formation of an isopetide bond 
between the carboxamide group of glutamine and the -amino nitrogen of lysine. First, the 
highly nucleophilic thiolate of the catalytic site residue Cys 314 attacks the carboxamide carbon 
atom of the protein-bound glutamine substrate forming a thioester. In a second step, the 
isopetide bond is formed by a nucleophilic attack of the thioester intermediate on the lysine side 
chain of the protein co-substrate.  
Human transglutaminases like FXIII are composed of a β-sandwich domain, a catalytic domain 
and two β-barrel domains (Fig. 4.1). The crystal structures of FXIII and transglutaminase 2 in 
complex with substrate-derived inhibitors confirm the early assumption that transglutaminases 
undergo a drastic conformational change during the catalytic process.[19, 60, 71] Functionally and 
structurally, the three-stranded β-sheet within the core domain appears to be a key element of 
factor XIII, and due to a high conservation of the involved amino acids, presumably also of the 
other human transglutaminases. 
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Fig. 4.1: FXIII and other human transglutaminases consist of a β-sandwich domain (purple), a catalytic 
core domain (blue), a β-barrel 1 domain (cyan) and a β-barrel 2 domain (light blue). In present of 
calcium ions and an inhibitor (here: ZED1301) the two β-barrel domains flip aside (arrow) and expose 
the active site. The homodimeric (here only one monomer is shown) inactive state (left) of FXIII 
(PDB ID: 1GGU) coordinates one calcium ion (purple sphere). In contrast, the active form (right) has 
three calcium ion binding sites (PDB ID: 4KTY). ZED1301 (red sticks) binds to the active site located 
in the upper left part of the catalytic domain. The three-stranded β-sheet represents a key structural 
element of FXIII. 
 
In our crystal structure of FXIIIa° in the active conformation published in 2013, an inhibitor 
(ZED1301) was used that possesses an ,β-unsaturated carboxylic ester as reactive head group 
to bind covalently to Cys 314.[60] This residue belongs to the catalytic center of factor XIII 
(colored in blue in Fig. 4.2). The carboxylated aspartate moiety of the ligand binds to a region 
of the active site of FXIIIa° referred to as “α-space” (purple). The indole ring of the inhibitor 
occupies a hydrophobic pocket in a second part of the active site referred to as “β-space” (light 
blue). For discussion and comparison of inhibitors and their binding mode, it is helpful to use 
a more precise nomenclature. Doiphode at al. suggested using the same nomenclature for 
proteases introduced by Schechter and Berger.[100, 101] However, we suggest designating the 
substrate glutamine as P0 and not as P1 (Fig. 4.2c). This nomenclature was already applied by 
Nikolajsen and coworkers.[53] Residues progressing towards the N-terminus are designated as 
3-Stranded β-sheet 
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P1, P2, etc. and residues progressing to the C-terminus are designated as P1’, P2’, etc. The 
corresponding interaction pockets to host the substrate side chains are labeled with an S instead 
of P and they are referred to with the same number as the corresponding substrate side chains. 
The hydrophobic tunnel of the catalytic site is occupied by the reactive glutamine (P0) or the 
inhibitor warhead respectively and is referred to as S0. 
 
  
 
Fig. 4.2: a) The inhibitor ZED1301 is covalently attached to Cys 314 (not shown) of the catalytic site 
colored in blue. The acetylated (Ac protecting group) aspartate binds to the “α-space” (purple) and the 
indole ring occupies a hydrophobic pocket in the “β-space” (light blue). b) Regarding the inactive state 
(cyan) and the active state (blue) of FXIII shows that both calcium binding sites 1 and 2 (purple spheres) 
promote a rotational movement of the three-stranded β-sheet (red arrow) being part of the substrate 
binding site. Calcium coordination at site 1 leads to a shift of an α-helix (white arrow) that brings Arg 
491 and Asp 438 in an appropriate distance to form a salt bridge and fixes the three-stranded β-sheet. 
c) Classification of the substrate and the active site of FXIII. 
D351 
a) b) 
α-Space 
β-Space 
Catalytic site 
c) 
R491 D438 
1 
2 
E490 
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Transglutaminases are calcium-depending enzymes. The exact function of calcium could be 
revealed by comparing the crystal structure of FXIII in the active versus inactive state 
(Fig. 4.2b).[17, 60, 74] Calcium binding site 1 is already occupied in the inactive state. Upon 
activation, the adjacent α-helix is translocated by about 4 Å. This enables the formation of a 
strong salt bridge between Arg 491 of the α-helix and Asp 438 fixing the three-stranded β-sheet 
at its lower part. Importantly, both amino acids are highly conserved within human 
transglutaminases.[63] Calcium binding site 3 induces conformational changes of the co-
substrate binding site. Calcium binding site 2 turns out to be the most important one for the 
activation of the protein. Full establishment of calcium coordination at this site affects the shape 
of the β-space and facilitates the formation of the catalytic dyad needed for deprotonation of 
the amino group of the lysine co-substrate. The interaction between the calcium ion at binding 
site 2 and Asp 351 promotes a rotational movement of a three-stranded β-sheet located in the 
upper part of the catalytic domain (Fig. 4.1 and Fig. 4.2) which is also part of the β-space of 
the substrate binding region. 
Here we have crystallized FXIIIa° (FXIII activated by 50 mM calcium instead of thrombin) in 
complex with a β-casein derived inhibitor Mi0621[102] that differs remarkably from our former 
inhibitors (Fig. 4.3). Interestingly, Mi0621 possesses neither the central proline (red circle) nor 
the tryptophan (blue circle). Both amino acids are crucial for the affinity of this ligand 
prototype. In case one of these amino acids is removed, affinity declines dramatically. 
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Fig. 4.3: Comparison of the inhibitors Mi0621 and ZED1301. Mi0621 lacks both the central proline 
residue (red circle) at P4’ position and the P5’ tryptophan (blue circle), essential for affinity in case of 
the ligand class ZED1301 belongs to. The inhibitors also differ in the reactive group colored in red. In 
case of ZED1301, an ,β-unsaturated carboxylic ester was utilized whereas Mi0621, comprises a 
chloromethyl ketone at the same position. 
 
The inhibitors also differ in both, the reactive group and in the way they bind to the catalytic 
residue Cys 314 (Fig. 4.4). The ,β-unsaturated carboxylic ester of ZED1301 is attacked 
nucleophilicly by the thiolate of Cys 314 at the β-position of the Michael acceptor facilitated 
by a hydrogen bond between the catalytic site His 373 and the carbonyl oxygen of the warhead. 
Subsequently, the intermediately formed methoxy enol tautomerizes to the corresponding ester 
(Fig. 4.4a). It should be mentioned that this reactive group is also used in ZED1227, a direct 
acting tissue transglutaminase inhibitor that is currently in Phase Ib clinical trials.[103]  
In contrast, Mi0621 bears a chloromethyl ketone. Here two mechanisms are discussed in 
literature.[104] Either the thiolate sulfur of Cys 314 nucleophilicly attacks the carbon atom 
between the carbonyl group and the chloro atom followed by chloride elimination (mechanism I 
in Fig. 4.4b) or the thiolate attacks initially the carbonyl carbon atom (mechanism II in 
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Fig. 4.4b). The thus formed thiohemiketal rearranges by forming a three-membered sulfonium 
alcoholate intermediate upon release of hydrogen chloride. Subsequently this complex 
rearranges in a second step to the alkylated cysteine product. Due to its high reactivity compared 
to the ,β-unsaturated carboxylic ester, the chloromethyl ketone warhead is not considered as 
part of applicable drug molecules. Furthermore, the cysteine sulfur is connected to the Cε of the 
warhead-containing amino acid. In contrast, in case of ZED1301, the catalytic site cysteine is 
covalently attached to the carbon atom at the δ-position, whereas Mi0621 reacts at the ε-
position. This offset by one C-C bond length in the latter case deviates from the situation found 
during the reaction of the natural substrate.  
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Fig. 4.4: Simplified mechanism for the covalent attachment of the ,β-unsaturated carboxylic ester and 
the chloromethyl ketone as warheads for enzyme inhibition. a) The ,β-unsaturated carboxylic ester is 
nucleophilicly attacked by the sulfur atom of Cys 314. A tautomerization of the intermediately formed 
enol generates the covalently attached thioester. b) The chloromethyl ketone is nucleophilicly attacked 
by the thiolate of Cys 314 either directly at the carbon atom at the ε-position followed by elimination of 
a chloride ion (mechanism I) or at the carbonyl carbon atom (mechanism II). Afterwards the 
thiohemiketal rearranges to a sulfonium intermediate and subsequently to the final thioether (b). 
a) 
b) 
δ 
ε 
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Interestingly, the former ,β-unsaturated carboxylic ester is linked via the δ-position, the addition of 
the chloromethyl ketone occurs more remotely in ε-position.[104] 
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4.2 Results & Discussion 
 
4.2.1 Binding Mode of the Inhibitor Mi0621 
 
The crystallization of FXIIIa° in complex with the inhibitor Mi0621 was found to be 
challenging due to its lower affinity (IC50 = 12.5 µM) when compared to inhibitor ZED1301 
from the other compound class (IC50 = 110 nM). However, a sufficiently complete dataset was 
collected with a resolution of 2.40 Å (Tab. 4.1). 
In the crystal structure, two symmetry independent molecules are found. The first inhibitor 
molecule in the asymmetric unit is well defined in the electron density contoured at a level of 
3.0 σ with the exception of the carboxy benzyl protection group, the benzyl group of the N-
terminal phenylalanine and the ε-nitrogen atom of the lysine residue (Fig. 4.5a). These side 
chains seem to be solvent exposed and consequently are not visible in the density due to 
enhanced scatter over multiple orientations. 
The second molecule in the asymmetric unit is slightly better defined in the electron density at 
a level of 3.0 σ (Fig. 4.5b). Here the benzyl group and the lysine ε-nitrogen are well defined in 
the difference electron density. However, the ε-nitrogen atom of the lysine side chain forms no 
hydrogen bond to the protein. The phenyl ring of the second molecule in the asymmetric unit 
is located in van der Waals contact distance (3.7 Å) to Glu 124 contributed by a symmetry-
related protein molecule in the crystal packing (Fig. 4.5d). A superposition of the two symmetry 
independent molecules shows that both inhibitors adopt almost identical conformational 
arrangements with an rmsd over all nonhydrogen atoms of 0.46 Å (Fig. 4.5c). 
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Fig. 4.5: a) The first molecule of inhibitor Mi0621 in the asymmetric unit is well defined by the difference 
electron density (contour level of 3.0 σ) with exception of the carboxy benzyl protection group, the benzyl 
group of the N-terminal phenylalanine and the lysine side chain. b) In case of molecule 2 in the 
asymmetric unit, the phenyl ring and the lysine nitrogen atom are additionally well defined in the 
electron density. c) A superposition of the two symmetry independent molecules shows that both 
(molecule 1, cyan and molecule 2, blue) are geometrically identical with exception of the lysine and the 
phenylalanine side chain. d) The phenyl ring of the second inhibitor molecule in the asymmetric unit is 
in van der Waals distance to Cγ of Glu 124 from a symmetry-related protein molecule. 
 
The crystal structure of FXIIIa° in complex with Mi0621 exhibits striking changes in the shape 
of the ligand binding site compared to the crystal structures of FXIIIa° with ZED1301 
(Fig. 4.6). As already described in Chapter 3.2.2, the α-space possesses a hydrophobic pocket 
that seems to remain unoccupied by the ligand. This hydrophobic pocket is opened owing to 
a) b) 
c) d) 
E124 
3.7 Å 
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the flexibility of the side chain of Arg 223. More interestingly, the hydrophobic pocket in the 
β-space is not opened upon ligand accommodation. 
 
 
 
Fig. 4.6: Comparing the surface of the active site of FXIIIa° in complex with Mi0621 (cyan, PDB ID: 
5MHL) and ZED1301 (light red, PDB ID: 4KTY). The protein surface of FXIIIa° in complex with 
Mi0621 (a) shows that the hydrophobic pocket in the β-space is not opened in contrast to the situation 
in the crystal structure of FXIIIa° in complex with ZED1301 (b), in consequence the indole ring of the 
a) 
b) 
P1‘
 
‘ 
P2‘ 
P3‘ 
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superimposed ligand ZED1301 would plunge into the surface of FXIIIa° using the coordinates of the 
complex with Mi0621. 
 
Sub-pockets of the active site of FXIIIa° have not yet been assigned. This relates to the fact that 
there is no crystal structure of FXIIIa° available in complex with a bound substrate. In the 
structure of FXIIIa° with Mi0621 a deviating interaction pattern is observed than with ZED1301 
except for the residues at the sites P1’-P3’ (Fig. 4.6). This suggests that natural substrates interact 
with FXIIIa° at these P1’-P3’ positions similarly to ZED1301 and Mi0621. To support this 
assumption, crystallization with complete substrates would be necessary. 
 
The P1’ side chain, located next to the entrance of the hydrophobic tunnel, involves the 
carboxamide group of Asn 371 as interaction partner (Fig. 4.7). However, the S1’ site can hardly 
be assigned as a visible pocket. The shallow S2’ pocket is located adjacent to the hydrophobic 
tunnel and is formed by the residues Trp 370 and Ser 368. Finally, the S3’ pocket consists of 
the side chain of Phe 339 and the methylene group and Cα atom of Asn 371. Consequently, the 
S3’ pocket possesses a more hydrophobic character. In contrast to the S2’ pocket, the P3’ side 
chain of a putative substrate occupying the S3’ pocket points in direction of the surface of the 
protein. 
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Fig. 4.7: Assignment of the S2’- S3’ sub-pockets of the active site of factor XIIIa° (PDB ID: 5MHL). The 
S3’ pocket is occupied by a valine side chain of Mi0621 (cyan) and the S2’ pocket is addressed by a 
lysine side chain (not completely defined by electron density – see Fig. 4.5a). 
 
In total, Mi0621 interacts via eight hydrogens bonds with FXIIIa° (Fig. 4.8). The hydrogen 
bonding pattern in β-space adjacent to the catalytic center is identically established in both 
complexes. Both inhibitors form two H-bonds to the oxygen of the carboxamide side chain and 
the backbone NH of Asn 371 experiences an interaction with the backbone NH of the warhead 
residue (P0) and the backbone carbonyl oxygen of the P1’ amino acid, respectively. 
Furthermore, both inhibitors establish a hydrogen bond to the backbone oxygen of Val 369 
using their peptide NH groups of the P3’ amino acid. 
Compared to ZED1301, Mi0621 forms two additional hydrogen bonds in the region bridging 
the catalytic center and the hydrophobic region in the β-space. The P4’ backbone amino group 
of Mi0621 experiences an H-bond to the carbonyl oxygen of Val 369. The corresponding P4’ 
backbone carbonyl oxygen atom of Mi0621 forms a hydrogen bond to the backbone NH of 
Val 369. This H-bonded arrangement orients the side chain of the P4’ isoleucine residue exactly 
towards the hydrophobic region of the β-space. 
Additionally, an H-bond is observed between the backbone carbonyl oxygen of the P1 amino 
acid and the backbone NH of Asn 371. Compared to ZED1301, there is no interaction of the 
S3‘ 
S2‘ 
N371 
W370 
S368 
F339 
P1‘
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peptide bond to the backbone carbonyl oxygen of Gln 313. This might result from the used 
chloromethyl ketone warhead, which elongates geometry by one methylene group. The C-
terminal glycine residue (P5’ position) of Mi0621 forms no hydrogen bond with the protein. 
This is in line with the observation that omitting the latter amino acid does not affect affinity of 
the inhibitor.  
 
  
 
Fig. 4.8: Binding mode of Mi0621 (cyan, PDB ID: 5MHL) compared to ZED1301 (light red, PDB ID: 
4KTY). In total, Mi0621 forms eight hydrogen bonds to FXIIIa°. Importantly, Mi0621 establishes two 
further hydrogen bonds with its P4’ amino acid orienting the P4’ side chain towards the hydrophobic 
region of the β-space. 
 
This is the first crystal structure of a transglutaminase inhibited by a chloromethyl ketone 
inhibitor and confirms the assumed binding mode described in the introduction (Fig. 4.4b). 
Both inhibitors interact via their carbonyl oxygens of the warhead with the indole NH of 
Trp 279 and the backbone NH of Cys 314 (Fig. 4.9). 
Moreover, Fig. 4.8 shows that Mi0621 penetrates not as deep as ZED1301 into the hydrophobic 
tunnel (distance between the Cα carbon atoms of both warheads: 1.0 Å). This is mainly 
attributed to deviating linker length of the two warheads (Fig. 4.4 and Fig. 4.9). The additional 
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carbon atom introduced into the chloromethyl warhead dislocates Mi0621 out of this area. 
Considering the fact that the glutamine of the natural substrate is also connected via the Cδ atom 
forming the thioester intermediate, the extended chloromethyl ketone deviates slightly from the 
binding geometry of a putative substrate. However, Mi0621 bears a carbonyl group at the same 
position (δ) as in the natural substrate (glutamine side chain). In case of ZED1301 the carbonyl 
oxygen of the ,β-unsaturated carboxylic ester is located in the back part of the hydrophobic 
tunnel. This slightly relocates the indole ring of Trp 279 compared to the Mi0621 complex.  
 
 
Fig. 4.9: Comparison of the warheads of Mi0621 (cyan, PDB ID: 5MHL) and ZED1301 (light red, PDB 
ID: 4KTY).  
 
Remarkably, adjacent the S3’ pocket, the inhibitor Mi0621 orients towards the co-substrate 
binding site whereas ZED1301 is directed in opposite direction, likely determined by the proline 
residue at P4’ (Fig. 4.10). Both orientations could suggest putative orientations adopted by 
natural substrates. Though ZED1301 was derived based on phage screening[68], the sequence 
QxxxP also occurs as part of natural substrates of FXIII (Chapter 4.2.3).[53] However, if a longer 
substrate would bind analogously to Mi0621, it would clash with the co-substrate. Therefore, it 
appears more likely that longer peptides orient similarly to ZED1301 in front of the three-
stranded β-sheet. Fig. 4.10 also illustrates that the protein architecture of the active site places 
substrate and co-substrate into close vicinity. Consequently, a sterically demanding protein 
occupying the substrate binding site could facilitate by chemical interaction or sterically prevent 
W279 
C314 
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the occupancy of the co-substrate binding site. This allows the assumption that the specificity 
of FXIII (and likely also other transglutaminases) concerning the co-substrate could also be 
affected by the chemical structure of the proteinogenic substrate and co-substrate remote from 
the active site. 
The orientation of the backbone of the inhibitor also differs in the α-space. Consequently, 
further sub-pockets cannot be assigned unambiguously. In this respect, crystallization with 
additional substrate-like ligands extended at the N and C-terminus could provide valuable 
information. 
 
 
Fig. 4.10: Top view of the active site of FXIIIa°. The inhibitor Mi0621 (cyan, PDB ID: 5MHL) orients 
towards the co-substrate binding site whereas ZED1301 (light red, PDB ID: 4KTY) is placed in front of 
the three-stranded β-sheet.  
Three-stranded 
β-sheet 
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4.2.2 The Three-Stranded β-Sheet Adopts Different Conformations 
 
The collapse of the hydrophobic pocket in the β-space is mainly attributed to a conformational 
transition of two amino acids in the region of the hydrophobic pocket (Fig. 4.11). The methyl 
group of Ile 352 relocates its position and mainly results in the closing of the pocket. 
Furthermore, a rotation of the isopropyl group of Val 369 also attributes to the adaptive 
behavior of this hydrophobic area. This means, the terminal tryptophan residue of ZED1301 
stabilizes the opening of the hydrophobic pocket in the β-space. 
In addition to the conformational change of individual amino acids, a significant shift of the 
adjacent amino acids to the indole ring of ZED1301 (on average 1.0 Å between the Cα atoms 
of Ile 352, Leu 439 and Tyr 441) forming the external part of the active site also occurs. 
 
 
Fig. 4.11: Spatial superposition of the crystal structures of FXIII in complex with Mi0621 (cyan, PDB 
ID: 5MHL) and ZED1301 (light red, PDB ID: 4KTY) shows that a conformational change of Ile 352 
and Val 369 along with a slight shift of Ile 352, Tyr 441 and Leu 439 are responsible for the collapse of 
the hydrophobic pocket, found in the ZED1301 complex, in the structure with Mi0621. 
 
Interestingly, the latter shifted amino acids are part of a three-stranded β-sheet. A superposition 
of FXIII in the uncomplexed inactive state, in complex with Mi0621 and in complex with 
V369 
I352 
Y441 
L439 
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ZED1301 shows that this three-stranded β-sheet adopts in the Mi0621 complex an orientation 
between the inactive state and the state induced by the inhibitors bearing a proline at P4’ position 
(Fig. 4.12).  
 
 
Fig. 4.12: Superposition of the crystal structures of FXIII in the inactive state (grey, PDB ID: 1F13), in 
complex with Mi0621 (cyan, PDB ID: 5MHL) and ZED1301 (light red, PDB ID: 4KTY). The three-
stranded β-sheet of FXIIIa° in complex with Mi0621 adopts an orientation between the inactive state 
and FXIII in complex with ZED1301. 
 
This observation can be explained by inspecting the binding site of FXIIIa° with bound Mi0621. 
The structural superposition of the crystal structure of FXIIIa° in complex with ZED1301 shows 
that the P5’ tryptophan and the C-terminal proline at P6’ position would clash with the three-
stranded β-sheet (Fig. 4.13). Comparing the backbone trace of both inhibitors, ZED1301 adopts 
a bent conformation whereas Mi0621 binds closer to the protein surface. 
 
  
 
 
Inactive 
Mi0621 
ZED1301 
 
Chapter 4 - Blood Coagulation Factor XIII – An Enzyme with a Highly Adaptive Binding Site 
91 
 
 
Fig. 4.13: View onto the binding mode of Mi0621 (cyan, PDB ID: 5MHL) compared to ZED1301 (light 
red, PDB ID: 4KTY). Mi0621 forms two further hydrogen bonds (H-bonds to Val 369) and binds closer 
to the protein surface compared to ZED1301. 
 
The crystal structure of FXIII in complex with Mi0621 can also be used to predict the binding 
mode of the factor XIII substrate K9 used in the Berichrom®-Assay[105] (Fig. 4.14). Mi0621 
and K9 are both derived from β-casein. Both ligands only differ in the α-space and at the P1’ 
position. In the α-space K9 possesses a Gly instead of a Phe at P1 position and has three further 
amino acids with Leu, Gly and Pro at P4, P3 and P2 position, respectively. At P1’ K9 bears Ser 
instead of Val. Consequently, K9 should interact in similar fashion as Mi0621 in the β-space. 
 
 
 
 
 
 
 
  
N371 
V369 
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Fig. 4.14: The substrate ”K9” used in the Berichrom®-Assay should bind in the β-space in the same 
manner like the inhibitor Mi0621. The reactive glutamine is colored red. 
 
 
4.2.3 Consensus sequence for FXIII substrates 
 
In the past decades, huge efforts were made to determine a consensus sequence for FXIII 
substrates.[53, 68, 100] In 2006 Sugimura et al. performed a phage-display screen with a random 
peptide library suggesting the consensus sequence QxxϕxWP (x and ϕ represent a non-
conserved x and hydrophobic amino acid ϕ, respectively). However, this sequence is only 
matched by about 60 % of the peptides of the phage-display screen (red letters in Tab. 4.2). The 
other peptides do not agree with this sequence.[68] The ZED inhibitors with the general sequence 
QxxxPW were derived based on this screen (highlighted in light blue in Tab. 4.2). 
 
As already discussed in Chapter 4.2.2, the inhibitor ZED1301 induces a more extensive rotation 
of the three-stranded β-sheet. This is likely because of a proline at P4’ position inducing an 
orientation of the side chain of the amino acid at P5’ position in direction of the three-stranded 
β-sheet. This calls upon the question, whether this sequence with a proline at P4’ position does 
also occur in natural substrates of FXIII? 
To answer this question, the data provided by Nikolajsen et al. in 2014 were used.[53] In this 
work the blood plasma was incubated with FXIII in presence of the amino co-substrate 5-
(biotinamido)pentylamine (PBA). After digestion with trypsin the PBA-containing peptides 
were isolated via avidin binding and detected by a mass spectrometric approach (LC-MS/MS). 
An analysis of the provided 690 sequences of peptides with a reactive glutamine shows that 36 
of the latter peptides bear proline at P4’ position (Tab. 4.3). Consequently, the trace of the 
P1 P1’ P4 P3 P2 P0 P4’ P3’ P2’ P5’ 
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backbone of ZED1301 induced by proline at P4’ position is most likely also adopted by natural 
substrates. 
 
The hydrophobic pocket of the β-space of FXIIIa° is occupied by the side chain of tryptophan 
at P5’ position of ZED1301 (Fig. 4.6). What are the preferred amino acids of natural substrates 
at P5’ of FXIII? 
Comparing the 36 peptides of Tab. 4.3 bearing proline at P4’ position with all the other substrate 
peptides shows that isoleucine is the most preferred amino acid at P5’ (Fig. 4.15). Also other 
hydrophobic amino acids like cysteine, leucine and valine occur more frequently. Interestingly, 
there is also a preference for glycine, histidine, serine and threonine. However, none of the Pro-
P4’ peptides bear tryptophan at P5’ position as the inhibitor ZED1301.  
 
 
 
 
 
Fig. 4.15: Frequency of amino acids at P5’ position of substrates with the consensus sequence QxxxPx 
(dark blue) compared to all substrates (light blue) based on a LC-MS/MS analysis published by 
Nikolajsen et all in 2014.[53] The relative frequency is shown meaning the absolute frequency number of 
an amino acid at fifth position to the reactive glutamine divided by the absolute frequency number of an 
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amino acid at the fifth position with respect to all glutamine residues (also including the non-reactive 
ones).  
 
In total, Nikolajsen et al. analyzed 690 substrate peptides in order to find a consensus sequence 
of FXIII substrates. Even if the analyzed data show a slight preference for acidic residues at P1 
and P2 position and no occurrence for proline at P1’ position, the researchers concluded that 
there is no clear consensus sequence for FXIII substrates surrounding the active glutamine (P0). 
Doiphode et al. described a decrease in affinity upon substitution of glutamate by arginine at 
P1’, glutamine by serine at P2’ and introduction of glutamine at P3’ position.[100] Furthermore, 
an increased frequency could be revealed for basic residues at surrounding the P8 and P8’ 
position.[53, 100] 
Nevertheless, FXIII and other transglutaminases, are known to be specific concerning the cross-
linking of their substrates.[1, 68] Obviously, there are areas for substrate recognition remote from 
the active site, as already suggested by Nikolajsen as well as Doiphode and co-workers.[53, 100] 
Regarding the active site of FXIIIa° (Fig. 4.10), substrate and co-substrate approach each other 
in such a close distance to interact with each other. Conceivably, the specificity of the 
transamidation can also be affected by the interaction or steric repulsion between the two 
proteins remotely from the active site and also remotely from FXIII itself. Moreover, the 
activity of plasmatic FXIII is accelerated by fibrin.[45-47] Thus, at least in the blood plasma, an 
impairment of the specificity by the B-subunit and/or fibrin cannot be excluded. 
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4.3 Summary & Conclusion 
 
Taking into account all the information provided by the crystal structures of inhibitors of the 
two compound classes it is not surprising that all attempts for finding a consensus sequence of 
FXIII substrates binding to the region of the active site must have failed. 
The α-space is adaptive due to the flexible arginine. The P1’ position can hardly contribute to 
the specificity because the side chain of the substrate at this position is oriented towards the 
solvent. The shallow pockets S2’ and S3’ provide only cavities as minor binding sites. In 
contrast, the S3’ pocket should take highest impact on substrate specificity because here the side 
chain of the corresponding amino acid points towards the surface of FXIIIa° leading to minor 
tolerance concerning the accommodation of sterically demanding side chains. Interestingly, 
proline at P4’ seems to affect the preference at P5’ especially for isoleucine. 
Moreover, the hydrophobic pocket in β-space is highly adaptive due to the ability of the three-
stranded β-sheet to adopt different orientations as well as a conformational flexibility of Ile 352 
and Val 369. Importantly, the three-stranded β-sheet is suggested as a key structural element in 
the activation of FXIIIa°. This assumption is corroborated by the interaction of highly 
conserved residues between the three-stranded β-sheet and calcium binding sites 1 and 2.[60] 
Furthermore, due to the high similarity between all members of the human transglutaminase 
family, the importance of the three-stranded β-sheet can supposedly be transferred to other 
transglutaminases as well.[63] 
Finally, the crystal structures of the two compound classes shows that the trace of the backbone 
can occur in different orientations: in direction towards the co-substrate binding site or in front 
of the three-stranded β-sheet. 
It is important to mention that we crystallized FXIIIa° in complex with covalently bound 
inhibitors. Both inhibitors are of peptidic nature and thus correspond to some degree to putative 
substrates in respect of their amino acid sequence. Considering protein-like substrates they are 
reduced in size at their N- and the C-terminus.[102, 106] In addition, the inhibitors bear a reactive 
chemical group for covalent linkage replacing the glutamine of the substrates. We therefore 
believe that our inhibitor structures provide some information with respect to possible binding 
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modes of natural substrates. However, protein-like substrates may differ in the interaction 
profile compared to our inhibitors.  
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4.4 Experimental Part 
 
4.4.1 Crystallization, Data Collection and Structure Determination 
 
The protein was crystallized utilizing the sitting drop vapor diffusion method at a concentration 
of 4.0 mg/mL and ambient temperature. 4 μL protein solutions were mixed with 5 μL 
precipitation solution (170 mM ammonium sulphate, 85 mM sodium cacodylate pH 6.5, 25.5% 
(w/v) PEG 8,000, 15% (v/v) glycerol). A suitable single crystal was obtained after removal of 
small crystallites from its surface. The extracted crystal was flash-frozen in liquid nitrogen and 
a dataset of 2000 images with 0.1 degree rotation at a wavelength of 0.9778 Å was collected at 
the ID29 beamline, European Synchrotron Radiation Facility in Grenoble, France.[107] Data 
were processed to a resolution of 2.40 Å in space group P1 using the program XDS.[98] The 
initial phases were calculated by Fourier synthesis using the structure (PDB ID: 4KTY) as 
starting model in the first refinement step with Phenix. The model was manually improved with 
Coot[108] and refined with Phenix.[88] At the beginning, a simulated annealing step was 
performed. The structure was refined with coordinates, individual B-factors, occupancies and 
TLS groups. The ligand restraints were created with eLBOW[109] implemented in Phenix. 
According to Procheck[90], 1103 residues (90 %) are found in the most favored, 119 residues 
(9.8 %) in allowed, and 3 residues (0.2 %) occur in disallowed regions (Asp 270 of molecule 1 
and 2 and Asp 139 of molecule 1). 
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4.5 Appendix 
 
4.5.1 Crystallographic Table 
 
Tab. 4.1: Data collection and refinement statistics. 
Inhibitor Mi0621 
PDB Entry 5MHL 
Data collection and processing  
Wavelength [Å] 0.97779 
Beamline ESRF – ID29 
Space group P1 
Unit cell parameters  
a, b, c [Å] 57.1, 81.0, 103,3 
α, β, γ [°] 88.1, 76.9, 81.5 
Diffraction data  
Resolution range [Å]* 48.83 – 2.40 (2.54 – 2.40) 
Unique reflections 65090 (9943) 
R(I)sym [%] 8.7 (35.2) 
Completeness [%] 92.6 (87.7) 
Redundancy 2.0 (2.0) 
I/σ(I) 7.36 (2.0) 
Refinement  
Resolution range [Å] 48.83 – 2.40 
Reflections used in refinement (total) 65031 
Reflections used in refinement (work/free)  61777/ 3254 
Final R values for all reflections (work/free) [%] 17.2/ 23.1 
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Protein residues (A/B) 692/ 692 
Atoms Inhibitor (A/B) 51/ 59 
Water molecules 368 
Other ligand atoms 54 
RMSDs from ideality   
Bond lengths[Å] 0.009 
Bond angles [°] 1.4 
Ramachandran plot   
Residues in most favored regions [%] 90.0 
Residues in additional allowed regions [%] 9.6 
Residues in generously allowed regions [%] 0.2 
Residues in disallowed regions [%] 0.2 
Mean B-factor [Å2]   
Protein total (A/B) 39.6 (41.5/ 37.8) 
Protein main chain (A/B) 39.0 (41.0/ 36.9) 
Protein side chain (A/B) 40.4 (42.0/ 38.8) 
Inhibitor (A/B) 40.8 (41.7/ 40.1) 
Calcium ions 39.5 
Other ligand atoms 47.1 
Water molecules 34.4 
*Highest resolution shell is shown in parenthesis 
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Tab. 4.2: Result of a phage-display screen performed by Sugimura et al.[68] 
Peptide ID P4 P3 P2 P1 P0 P1‘ P2‘ P3‘ P4‘ P5‘ P6‘ 
Consensus sequence     Q x x ϕ x W P 
F23   L D Q I V I P W P 
F11    D Q M M L P W P 
F18    D Q M M L P W P 
F19    D Q W M M A W P 
F9    E Q Y Q L A W P 
F14    E Q Y Q L A W P 
F2    E Q Y Q L A W P 
F16   S E Q H L L K W P 
F7    E Q Q Q L S W P 
F12    S Q H P L P W P 
F26    S Q H P L P W P 
F6    S Q I P M A W P 
F31    T Q Y T M T W P 
F20    W Q Q Q M K W P 
F13    W Q I P V D W P 
F29    W Q M Q L P W P 
F35    G Q M I L P W P 
F17    E Q F P I A F P 
F21    H Q M V L T Y P 
F32    D Q Y V L T F P 
F4    W Q M P V N L P 
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F15    W Q L K Y P W I 
F5    H Q I P I Q I H 
F28    W Q H K I D L R 
F27    W Q H K I D L R 
F22    D Q S K V W L L 
F30  W H Y Q V P Q W L Y 
F25 Y H P L Q L T P A P I 
 
 
Tab. 4.3: Peptides of FXIII substrates with proline at P4’ position based on a LC-MS/MS analysis 
published by Nikolajsen et all in 2014.[53] 
Substrate P4 P3 P2 P1 P0 P1‘ P2‘ P3‘ P4‘ P5‘ P6‘ 
Consensus sequence for 
Pro-P4’ inhibitors 
    Q x x x P x x 
Alpha-2-antiplasmin   K E Q Q D S P G N 
Apolipoprotein A-I    R Q G L L P V L 
Extracellular matrix 
protein 1 
P P L P Q E A V P L Q 
Inter-alpha-trypsin 
inhibitor heavy chain H2 
K F Y N Q V S T P L L 
Heparin cofactor 2 G E T A Q S A D P Q W 
Inter-alpha-trypsin 
inhibitor heavy chain H1 
T V S Q Q Q S C P T C 
Plasma protease C1 
inhibitor 
E D M E Q A L S P S V 
Inter-alpha-trypsin 
inhibitor heavy chain H2 
K F Y N Q V S T P L L 
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Inter-alpha-trypsin 
inhibitor heavy chain H1 
T V S Q Q Q S C P T C 
Serum albumin K K V P Q V S T P T L 
Complement C4-A  K L G Q Y A S P T A 
Hemopexin  K L L Q D E F P G I 
von Willebrand factor    K Q H S D P C A 
Carboxypeptidase N 
subunit 2 
   
K Q L V C P V T 
Complement C2 K S S G Q W Q T P G A 
Vitamin K-dependent 
protein C 
A T L S Q T I V P I C 
Fibrinogen gamma chain Q L E A Q C Q E P C K 
IgGFc-binding protein C K P G Q V C Q P S G 
Ig mu chain C region A A T S Q V L L P S K 
Complement factor B  K Y G Q T I R P I C 
Complement C3 R A E L Q C P Q P A A 
Coagulation factor XIII A 
chain 
T V E L Q G V V P R G 
Carboxypeptidase N 
subunit 2 
H L G F Q V T W P D E 
Complement C1r 
subcomponent 
R F C G Q L G S P L G 
Protein AMBP V P G E Q E P E P I L 
Plasminogen C D V P Q C A A P S F 
Plasma protease C1 
inhibitor 
E D M E Q A L S P S V 
IgGFc-binding protein  R L E Q Y E G P G F 
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Ig alpha-1 chain C region T T S S Q L T L P A T 
Inter-alpha-trypsin 
inhibitor heavy chain H2 
 
R N V Q F N Y P H T 
Apolipoprotein A-I    R Q G L L P V L 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
   
R Q L G L P G P 
Complement component 
C7 
A F E T Q S C E P T R 
Properdin H P V P Q H G G P F C 
Alpha-1B-glycoprotein G E S S Q V L H P G N 
Prolow-density 
lipoprotein receptor-
related protein 1 
P F D L Q V Y H P S R 
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5 Does TG2 Adopt Two Different Active States? 
 
5.1 Introduction 
 
Transglutaminases (TGs) represent a major protein class in humans involved in a variety of 
essential biochemical processes such as inflammation, programmed cell death, signal 
transduction and blood coagulation.[1, 63] These calcium dependent enzymes predominantly 
catalyze the cross-linking of two proteins by the formation of isopetide bonds, a process known 
as transamidation. Additionally, transglutaminases catalyze the deamidation of the reactive 
glutamine into a glutamate residue. As shown in Fig. 5.1, transamidation occurs if the thioester 
intermediate reacts with the lysine co-substrate (I) whereas water penetrating the catalytic site 
can hydrolyze the thioester intermediate to a glutamate residue (II).  
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Fig. 5.1: Transglutaminases catalyze predominantly the transamidation of a Gln-substrate (red) with a 
lysine co-substrate (cyan) resulting in a isopetide bond (I). However, transglutaminases are also 
capable to catalyze the deamidation of the Gln-substrate (II). Herein, the thioester intermediate is 
hydrolyzed by water (blue) entering the catalytic site. 
 
 
  
 
Chapter 5 - Does TG2 Adopt Two Different Active States? 
105 
 
Especially TG2 is regarded as a promising pharmacological target for many human diseases 
like celiac disease, Alzheimer’s disease and cancer.[21, 24, 26, 32] Due to the multifunctional 
features of these enzymes, especially of TG2 (transamidation, deamidation, protein disulfide 
isomerase, kinase activity, ability to act as a G-protein), it is important to understand the 
mechanism of transglutaminases on molecular level. This allows the development of specific 
inhibitors influencing these particular functions to investigate the role of the individual 
functions of TG2 in the organism and, ultimately, to develop drugs with fewer side effects.[110] 
Transglutaminases has been crystallized in different states over the past decades. The first 
crystal structure of a transglutaminase (blood coagulation factor XIII) was published in 1994[17] 
and for the first time, scientists gained insights into the molecular architecture of this enzyme 
class. However, in this crystal structure the active site is sealed by the β-barrel 1 domain. 
Chemical modification and hydrogen-deuterium exchange experiments suggested a 
conformational change during the activation process.[70, 71] 
Ahvazi et al. crystallized transglutaminase 3 in presence of calcium ions in 2002[18, 75], where 
the protein was cleaved enzymatically between the catalytic domain and the β-barrel 1 domain. 
Here, TG3 adopts an active conformation with three fully occupied calcium binding sites. 
Nevertheless, the β-barrel 1 domain remains at the same position as in the inactive state most 
likely due to the absent of a bound inhibitor. 
Five years later, the crystal structure of transglutaminase 2 was published by the lab of Chaitan 
Khosla featuring a covalent inhibitor (Fig. 5.2) attached to the cysteine residue in the active 
site[19], in the following named TG2a*. 
Finally, in 2013 we were able to crystallize for the first time a transglutaminase (FXIIIa°) in 
complex with an inhibitor and with the three fully established calcium binding sites.[60] 
Interestingly, in contrast to the crystal structure of TG2a* the enzyme adopts a globular 
geometry. 
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Fig. 5.2: Chemical structure of the TG2a*-blocker Ac-P(DON)LPF-NH2 (left) with the 6-diazo-5-oxo-
norleucine (DON) warhead (red)[19] and the FXIIIa°-blocker ZED1301 (right) with the α,β-unsaturated 
methyl ester warhead (red). 
 
In this chapter, the crystal structure of FXIIIa° is systematically compared with the crystal 
structure of TG2a*, TG3ac and a homology model of TG2a constructed on the basis of the 
crystal structure of FXIIIa° to understand why the domains in the protein-ligand complexes of 
TG2 and FXIII are arranged in a different way. The proteins will be compared concerning their 
overall structures, as well as their calcium and substrate binding sites. Overall, human 
transglutaminases are moderately conserved with respect to their primary structure (sequence 
identity amounts about 30 %) but they are highly conserved with respect to their secondary and 
tertiary structures.[17-19, 60, 63] Consequently, we therefore hypothesize that structural features 
discovered in one of the crystal structure of an iso-enzyme can be transferred to the other 
members of this enzyme class, at least with respect to the highly conserved catalytic site and 
the calcium binding sites.  
 
 
 
  
ZED1301 Ac-P(DON)LPF-NH2 
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5.2 Comparison of FXIIIa° and TG2a* 
 
5.2.1 Overall Structure 
 
A superposition of FXIIIa° in the most likely active conformation (three calcium sites fully 
populated; inhibitor: ZED1301) and TG2a* in the assumed active conformation (none of the 
calcium sites populated; inhibitor: Ac-P(DON)LPF-NH2) shows significant differences in the 
overall domain orientation (Fig. 5.3a). As illustrated in Chapter 2.3.1, the two β-barrel domains 
of FXIII swing aside (red arrow), whereas the four domains of transglutaminase 2 adopt a linear 
arrangement (purple arrow).[19, 60] Notably, the β-barrel 1 domain of TG2a* is partially located 
at the position where the three-stranded β-sheet of FXIIIa° is located (red box in Fig. 5.3b). 
Consequently, in FXIIIa° the domains cannot be arranged in a linear geometry.  
 
  
Fig. 5.3: Structural superposition of FXIII, FXIIIa° and TG2a*. TG2a* (beige, PDB ID: 2Q3Z) adopts 
in contrast to FXIIIa° (blue, PDB ID: 4KTY) a linear array of its domains. The inactive state of FXIII 
(PDB ID: 1F13) is colored in gray (only shown one monomer of the dimer). The movement of the two 
TG2a* 
FXIII 
(TG2) 
FXIIIa° 
TG2a* 
FXIIIa° 
β-barrel 1  
domain 
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β-barrel domains of FXIII and TG2 are indicated by a red and a purple arrow, respectively. A similar 
linear arrangement of FXIIIa° cannot be adopted as the three-stranded β-sheet in the upper part of the 
catalytic domain prevents this geometry (red box). 
 
Obviously, the three-stranded β-sheet experiences a conformational change during the 
transition from TG2 to TG2a*. This becomes evident by superimposing the structures in both 
states. Strand I and II (green, blue) are translocated during the transition process. In contrast, 
strand III (red) reorganizes and forms an α-helix (red arrow in Fig. 5.4).[111] In the active state, 
the position of the reorganized strand III is taken by strand 4 of the β-barrel 1 domain, forming 
a five-stranded β-sheet, whereas four strands (1-4) originate from the β-barrel 1 domain and 
strand 5 has its origin in the three-stranded β-sheet (strand II). 
 
  
Fig. 5.4: Structural rearrangement of the three-stranded β-sheet of TG2 during transition from the 
inactive (grey, PDB ID: 1KV3)[112] to the active state (beige, PDB ID: 2Q3Z).[19] Strand I (green) and 
II (blue) of the inactive state are only shifted in space, whereas strand III and an adjacent loop region 
(red) adopts an α-helical structure in the active state. Exactly at the previous position of strand III of 
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the inactive state, strand 4 of the β-barrel 1 domain in the active state is located and forms a five-
stranded β-sheet, whereas strand 1-4 originates from the β-barrel 1 domain and strand 5 was originally 
strand II of the three-stranded β-sheet. 
 
 
5.2.2 Calcium Binding Sites 
 
Even though, TG2a* adopts an active conformation with respect to the arrangement of the β-
barrel domains, the calcium binding sites are not established.[19] 
As shown in Fig. 5.5b, in the crystal structure of TG2a* the side chains of Arg 491 and Asp 438 
(FXIII nomenclature) do not interact owing to the missing calcium ion at site 1 (Chapter 2.3.2). 
Notably, both residues are highly conserved among human transglutaminases (Chapter 2.6.1). 
The amino acids which are according to the crystal structure determined for FXIIIa° in the 
assumed active state involved in calcium binding site 2, are found with large distance from the 
location of calcium binding site 2 (Fig. 5.5c). Importantly, two amino acids (Glu 314 and 
Leu 312) of calcium binding site 2 are even part of the α-helix. Consequently, calcium 
coordination at site 2 is not compatible with the presence of the α-helix and would even prevent 
the reorganization of strand III to the α-helix. Remarkably, in TG2a* the α-helix contributes to 
the active site and if the binding pose of ZED1301 is hypothetically transferred to TG2a* the 
tryptophan moiety of ZED1301 in FXIIIa° would clash with the α-helix. Most likely, the lack 
of the established calcium binding site 2 prevents the formation of the active site in the crystal 
structure of TG2a* as observed in the crystal structure of FXIIIa°. Moreover, the coordination 
of calcium ions at site 2 triggers the formation of the catalytic dyad (Chapter 2.3.2)[60], which, 
confirmed by mutational studies, is essential for the enzyme function to catalyze the 
transamidation reaction.[76]  
Finally, calcium binding site 3, also involved in the formation of the co-substrate binding site 
in the crystal structure of FXIIIa°, is not established in TG2a*. In particular, the TG2 residues 
of Tyr 407 and Lys 269 (FXIII nomenclature) do not adopt the corresponding positions, as 
observed in the assumed active state of FXIII (Fig. 5.5d). Furthermore, TG2a* possesses a 
disulfide bond (black arrow in Fig. 5.5d) that is formed under oxidative conditions and has been 
discussed to inactivate TG2.[15, 16] Notably, this disulfide bond is part of the loop, which 
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reorganizes during the activation process of FXIIIa° and is responsible for shaping of the co-
substrate binding site and the formation of the catalytic dyad. 
 
  
  
Fig. 5.5: In contrast to the most likely active state of FXIIIa° (blue, PDB ID:  4KTY), in the 
superimposed structure of TG2a* (beige, PDB ID: 2Q3Z) the three calcium (magenta spheres) binding 
sites are not established (red arrows indicate significant differences between both structures). a) Overall 
representation with the inhibitor ZED1301 of FXIIIa° (light red) and the inhibitor Ac-P(DON)LPF-NH2 
of TG2a* (green). b) In the crystal structure of FXIIIa°, the residues Arg 491 and Asp 438 forms a 
strong salt bridge. Due to the lack of calcium at binding site 1 the corresponding residues of TG2a* 
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Arg 453 and Asp 400 are found remote from each other in very different locations. c) Two amino acids 
of calcium binding site 2 (Glu 314 and Leu 312) are involved in the formation of the α-helix (black 
arrow) which had reorganized from strand III of the three-stranded β-sheet. Due to lacking calcium 
coordination at site 2 in the crystal structure of TG2a*, the catalytic dyad (His 305 and Glu 363) is not 
formed. d) The missing calcium ion at site 3 results in a different positioning of the co-substrate 
containing amino acids like Asn 231 (Lys 269 of FXIII) and Tyr 369 (Tyr 407 of FXIII). The formation 
of a disulfide bond (black arrow) in TG2 restricts the conformational flexibility of the corresponding 
loop. Notably, this loop region belongs to the co-substrate binding site. 
 
 
5.2.3 Active Site 
 
How do the active sites differ between FXIIIa° and TG2a*? As expected, due to the fact that 
the activation process does not affect the α-space, this region is structurally similar concerning 
the backbone arrangement structure. However, four amino acids disagree in the chemical 
composition of their side chains (Fig. 5.6a). Notably, instead of the flexible arginine residue 
(Arg 223) TG2 exhibits an isoleucine at this position.  
The β-space of the crystal structure of TG2a* in complex with the inhibitor Ac-P(DON)LPF-
NH2 (Fig. 5.2) is reduced in its size compared to FXIIIa° in complex with ZED1301. 
Remarkably, this is attributed to the reorganized α-helix that prevents access to the rear part of 
the β-space as established in the FXIIIa° structure (Fig. 5.6b). The superposition of both crystal 
structures (TG2a* and FXIIIa°) shows that the inhibitor ZED1301 would clash with its C-
terminal part (Pro-Trp-Pro) into the α-helix (black arrow in Fig. 5.6b) present in TG2a*. 
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Fig. 5.6: Substrate binding sites of the superimposed crystal structures of FXIIIa° (blue, PDB ID: 4KTY) 
and TG2a* (beige, PDB ID: 2Q3Z). a) Surface is shown for FXIIIa°. In the α-space four amino acids 
differ in their side chain composition compared to FXIIIa° (Ser 290 → Met, Arg 223 → Ile, Tyr 214 → 
Gln, Tyr 372 → Phe). The shorter inhibitor Ac-P(DON)LPF-NH2 (green) of TG2a* compared to the 
inhibitor ZED1301 of FXIIIa° (light red) would clash via its phenyl ring with Val 369 of FXIIIa° if 
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transferred using the adopted conformation in the TG2a* complex. However, the clash can be avoided 
by minor conformational rearrangements of Val 369 or the phenyl ring of the inhibitor. b) Instead, the 
extended FXIII inhibitor ZED1301 would clash using the observed binding pose in FXIIIa° with the α-
helix in TG2a* indicated by a black arrow (shown: surface and cartoon representation of TG2a*). With 
other words, the α-helix diminishes the size of the substrate binding site, particularly of the β-space of 
TG2a* and does not allow the binding of the bulkier FXIII-inhibitors of the α(wh)xxxPW-type to TG2 
in the linear state (TG2a*). 
 
Based on the knowledge of the crystal structure of FXIIIa°, the co-substrate binding site as well 
as the catalytic dyad (His 342, Glu 401; FXIII nomenclature) cannot be established in TG2a* 
because of the missing calcium coordination. A superposition of both crystal structures (FXIIIa° 
and TG2a*) provides strong evidence for this assumption (Fig. 5.7). Also the H-bond described 
in Chapter 3.2.4 between the indole ring of Trp 370 and the carboxamide group of Gln 400 
(FXIII nomenclature) is not formed in the crystal structure of TG2a*.  
 
 
Fig. 5.7: A superposition of the crystal structures of FXIIIa° (blue, PDB ID: 4KTY) and TG2a* (beige, 
PDB ID: 2Q3Z) shows that a co-substrate binding site is not established in TG2a* (no structural 
agreement with FXIIIa° can be found). Also the catalytic dyad that is necessary for the deamidation 
reaction (His 342 and Glu 401, FXIII nomenclature) and the two amino acids Gln 400 and Glu 434 
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(FXIII nomenclature) of which Gln 400 accepts a hydrogen bond of the indole moiety of Trp 370 are 
not formed. 
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5.3 Comparison of FXIIIa° and TG3ac 
 
5.3.1 Overall Structure 
 
Transglutaminase 3 was crystallized in the presence of calcium ions, whereas the protein was 
enzymatically truncated between the catalytic domain and the β-barrel 1 domain (in this chapter 
named as TG3ac; c: cleaved).[18, 75] Interestingly, as shown in Fig. 5.8, the enzyme adopts the 
same domain arrangement as FXIII in the inactive state. This is likely due to the fact that TG3 
was crystallized in the absence of an active site ligand, hence, the domain rearrangement and 
substrate binding seems to be most likely, a concerted process.  
 
 
Fig. 5.8: Superposition of the inactive state of FXIII (grey, PDB ID: 1GGU), the active state of FXIII 
(blue, PDB ID: 4KTY) and the crystal structure of TG3ac (green, PDB ID: 1L9N) enzymatically 
truncated between the catalytic domain and the β-barrel 1 domain (black arrow). Herein, TG3ac adopts 
the same domain arrangement as FXIII in the inactive state. 
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5.3.2 Calcium Binding Sites 
 
In the crystal structure of TG3ac, the three calcium binding sites are populated and the catalytic 
dyad is established (Fig. 5.9).[17, 75] With respect to the coordination spheres of the calcium ions 
the active form of FXIII (FXIIIa°) and the structure of TG3ac show remarkable similarity. 
Nevertheless, there is an important difference at site 2. In the case of FXIIIa°, the side chain of 
Asp 351 interacts with the calcium ion at this site, whereas in the TG3ac structure a water 
molecule occupies this coordination site. As a consequence, in TG3ac the adjacent three-
stranded β-sheet is only shifted and not rotated. In FXIIIa°, complete rotation is essential to 
fully establish the substrate binding pocket, especially the hydrophobic pocket of the β-space. 
Therefore, it can be assumed that the TG3ac structure does not represent the fully active state. 
Remarkably, an Asp residue at this pivotal position is highly conserved across all 
transglutaminases except TG2, which contains a Glu residue at this position. 
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Fig. 5.9: Comparison of the three Ca2+ binding sites in FXIIIa° (blue, PDB ID: 4KTY, Ca2+ magenta) 
and TG3ac (green, PDB ID: 1L9N, Ca2+ cyan). a) The superimposed catalytic domains of FXIIIa° and 
TG3ac only differ in the orientation of the three-stranded β-sheet. b) At site 1 virtually the same 
coordination geometry as well as the salt bridge between the arginine and glutamate are found in both 
structures. c) Compared to the active state of FXIII (FXIIIa°), the coordination polyhedron around the 
calcium ion is not yet fully established as comparable interactions to Gln 349 are lacking and the 
coordination site of Asp 351 is not occupied by a functional group of the protein but by a water molecule 
in the TG3ac structure. As a consequence, the three-stranded β-sheet is not shifted (red arrow) and 
rotated and the substrate binding site which accommodates the ligand’s indole moiety (ZED1301) in 
a) 
c) 
b) 
d) 
H2O 
A457 
E485 
E490 
R491 
D438 
N436 
1 
H2O D351 
D345 
N347 
D434 
D367 
Q349 
2 
H2O 
A264 
D271 
N267 
K269 
3 
TG3a FXIIIa° 
H342 
E401 
E401 
H342 
 
Chapter 5 - Does TG2 Adopt Two Different Active States? 
118 
 
active FXIIIa° is not formed. d) The third calcium ion binding site shows similar geometry as at the site 
in active FXIIIa°. 
 
 
5.3.3 Active Site 
 
Comparable to TG2a*, the arrangement of the amino acids of TG3ac in the α-space corresponds 
to that found in FXIIIa° (Fig. 5.10). As in case of TG2a* (Fig. 5.6a), only exchanges of amino 
acid side chains of the same four residues are observed. However, the variations of these amino 
acids can be used for the design of selective inhibitors of the corresponding transglutaminases. 
The β-space of TG3ac is also geometrically reduced compared to FXIIIa° due to the three-
stranded β-sheet (black arrow) that remains, despite of the incomplete calcium coordination at 
site 2, in an orientation found for the inactive state of FXIIIa°. 
 
 
Fig. 5.10: Substrate binding sites of the superimposed crystal structures of FXIIIa° (blue, PDB ID: 
4KTY) and TG3ac (green, PDB ID: 1L9N). The surface is shown of FXIIIa°. In the α-space four amino 
acids differ in their side chains compared to FXIIIa° (Ser 290 → Arg, Arg 223 → Ile, Tyr 214 → Val, 
R223 Y372 Y214 
S290 
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Tyr 372 → Phe). The size of the β-space of TG3ac is slightly reduced because of the non-rotated three-
stranded β-sheet (black arrow). 
 
In contrast to TG2a*, in TG3ac the co-substrate binding site is fully established as in the crystal 
structure of FXIIIa°. The catalytic dyad and the H-bond to the indole ring of Trp 370 (FXIII 
nomenclature) are also formed. Even though, the arrangement of the β-barrel domains of TG3ac 
corresponds to the inactive state of a transglutaminase, TG3ac adopts a geometry obvious 
approaching closer the active state when compared to the TG2a* structure in terms of 
transamidation activity. FXIIIa° and TG3ac differ only in the orientation of the three-stranded 
β-sheet and the orientation of the indole ring of Trp 370. The three-stranded β-sheet adopts an 
arrangement as observed in the inactive state of FXIII possibly due to the lack of a bound 
inhibitor. Interestingly, the indole ring of Trp 370 also adopts an orientation found for the 
inactive state, and not for the active one (red arrow in Fig. 5.11). Though, as already discussed 
in Chapter 4.2.5, the H-bond is formed between the indole NH and the carboxamide oxygen of 
Gln 400 (FXIII nomenclature). 
 
 
Fig. 5.11: The co-substrate binding site is completely established as suggested by the superimposed 
crystal structures of TG3ac (green, PDB ID: 1L9N) and FXIIIa° (blue, PDB ID: 4KTY). This transition 
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also comprises the catalytic dyad (His 342 and Glu 401, FXIII nomenclature) and the two amino acids 
Gln 400 and Glu 434 (FXIII nomenclature) of which Gln 400 accepts a hydrogen bond of the indole NH 
of Trp 370. In contrast to FXIIIa°, the indole ring of TG3ac adopts a conformation resembling the 
inactive state (red arrow), this observation might also result from the fact that the TG3ac structure does 
not host any active site ligand. 
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5.4 Comparison of FXIIIa° and a Homology Model of TG2a Based on the 
Structure of FXIIIa° 
 
5.4.1 Overall Structure 
 
A homology model of TG2a based on the crystal structure of FXIIIa° was generated (Fig. 5.12) 
to investigate whether active TG2 can in principle adopt the same conformation as FXIIIa° 
resulting from the fully established calcium coordination sites as well as the substrate and co-
substrate binding sites (Chapter 5.4.2 and 5.4.3). 
The generated homology model of TG2a* has 0.8 % outliers and 80.2 % residues in most 
favored regions in the Ramachandran plot, whereas the template structure has 0.3 % outliers 
and 89.6 % residues in most favored regions (see Chapter 5.7). Thus, the quality of the model 
appears sufficient in terms of the backbone geometry. As constrained, in the homology model 
TG2a adopts the same arrangement of its domains as in the active state of FXIII (Fig. 5.12). 
 
 
Fig. 5.12: Superposition of the inactive state of FXIII (grey, PDB ID: 1F13), the active state of FXIII 
(blue, PDB ID: 4KTY) and the homology model of TG2a (magenta) generated based on the crystal 
structure of FXIIIa°.  
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5.4.2 Calcium Binding Sites 
 
As expected, the three calcium binding sites of the homology model can be equally formed with 
respect to the orientation of corresponding secondary structural elements like β-sheets, α-
helices and loop regions (Fig. 5.13). Much more importantly, those amino acids serving as 
coordination partners for the calcium ions, bear negatively charged side chains and are localized 
at the same positions as in the active state of FXIIIa°. Finally, the catalytic dyad is also 
established in the homology model of TG2a (Fig. 5.13c,d). 
As previously stated in Chapter 2.3.2, the calcium coordinating amino acid Asp 351, that 
belongs to the three-stranded β-sheet, is a glutamate in TG2. Due to the longer side chain, the 
orientation of the three-stranded β-sheet is not affected to the same extent as in FXIIIa°. 
Additionally, Asp 367 of FXIII is in case of TG2 a glutamate. Thus, the corresponding loop 
might also not to be shifted downwards to the same amount as suggested by the homology 
model. Importantly, this loop affects the shape of the co-substrate binding site. 
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Fig. 5.13: Comparison between the three Ca2+ binding sites in FXIIIa° (blue) and in a homology model 
of TG2a based on FXIIIa° (magenta). a) The superimposed catalytic domains of FXIIIa° and the 
homology model are identical in the arrangement of secondary structure elements. b) At site 1 virtually 
the same coordination geometry as well as the salt bridge between the highly conserved arginine and 
glutamate are found in both structures. c) Calcium binding site 2 is established similarly to FXIIIa°, 
whereas Asp 351 and Asp 367 (FXIII nomenclature) are glutamates in TG2 resulting in a possibly less 
extensive rotation of the three-stranded β-sheet and minor loop reorientation. d) Also calcium binding 
site 3 can be perfectly established as in FXIIIa°. 
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5.4.3 Active Site 
 
In Fig. 5.14 a superposition of the substrate binding sites of the homology model of TG2a and 
FXIIIa° is shown. The highly conserved amino acids Trp 279 and Trp 370 (FXIII 
nomenclature) which form the hydrophobic tunnel, are located in virtually identical positions. 
The same applies to the catalytic triad (not shown). Furthermore, the α-space possesses the 
same amino acid arrangement as was the case in the crystal structure of TG2a* in complex with 
the inhibitor Ac-P(DON)LPF-NH2 (Fig. 5.6a). 
Importantly, in contrast to the crystal structure of TG2a* (Fig. 5.6), the inhibitor ZED1301 of 
the general α(wh)xxxPW-type fits into the active site of the homology model (Fig. 5.14). The 
inhibitor only clashes at the rear end of the β-space with the amino acids Tyr 315, Lys 327 and 
Leu 424. However, all these side chains appear flexible enough to move out of the space thus 
avoiding further clashes with an inhibitor of the general α(wh)xxxPW-type. This also confirms 
the quality of the homology model. 
It should be mentioned that the affinity of ZED1301 towards TG2 (IC50: 2.9 μM) is 20-fold 
lower compared to FXIII (IC50: 110 nM). However, ZED1630 (Chapter 3.2.1) belongs also to 
the α(wh)xxxPW-type and binds to both enzymes with similar affinity (IC50,FXIII: 139 nM, 
IC50,TG2: 262 nM). The same observation was made for an inhibitor (not shown) that only differs 
in the α-space and at P2’ position (IC50,FXIII: 56 nM, IC50,TG2: 102 nM). Thus, the preferred 
binding of ZED1301 to FXIII should be predominantly affected by the α-space. Considering 
the homology model (Fig. 5.14), TG2 bears a phenylalanine instead of a tyrosine residue 
(Tyr 372; FXIII nomenclature). Consequently, the negatively charged carboxylate residue of 
ZED1301 would be located in a more apolar environment. Additionally, the H-bond between 
the carboxylate oxygen atom of ZED1301 and the hydroxyl group of Tyr 372 cannot be 
established if ZED1301 would bind to TG2a, according to the homology model. 
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Fig. 5.14: Substrate binding site of the superimposed crystal structure of FXIIIa° (blue) and the 
homology model of TG2a based on FXIIIa° (magenta). The surface is shown of FXIIIa°. Conserved 
functional amino acids (like Trp 279 and Trp 370) are located at the corresponding positions to FXIIIa°, 
corroborating the relevance of the homology model. The inhibitor ZED1301 (light red) fits into the 
active site of the homology model. Clashes with the amino acids Tyr 315, Lys 327 and Leu 424 can 
potentially be avoided by side chain reorientation of the latter residues. 
 
Finally, the co-substrate binding site of the homology model is also identically shaped to 
FXIIIa°. All conserved residues are at the right positions in contrast to the crystal structure of 
TG2a* (Fig. 5.7). The catalytic dyad (His 342, Glu 401; FXIII nomenclature) is established as 
well as the corresponding residues forming the H-bond to the indole of Trp 370 (Gln 400, 
Glu 434; FXIII nomenclature). 
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Fig. 5.15: The co-substrate binding site of the superimposed homology model of TG2a (magenta) onto 
the crystal structure of FXIIIa° (blue) suggested that it is fully established, comprises the catalytic dyad 
(His 342 and Glu 401, FXIII nomenclature) and the two amino acids Gln 400 and Glu 434 (FXIII 
nomenclature) of which Gln 400 accepts a hydrogen of the indole moiety of Trp 370. 
 
It can be concluded that all functional and major structural elements of the homology model of 
TG2a are located at correct positions. The catalytic site comprising the catalytic triad, catalytic 
dyad and hydrophobic tunnel match well with the crystal structure of FXIIIa°. The calcium 
binding sites of the homology model correlate with those in FXIIIa° concerning the 
arrangement of negatively charged side chains around the calcium ions. Additionally, in 
contrast to the crystal structure of TG2a*, the active site of the homology model provides 
sufficient space to accommodate the bulky α(wh)xxxPW inhibitors.  
As elucidated in Chapter 5.2.2, in contrast to FXIIIa* and TG3ac, in TG2a* the catalytic dyad 
is not established and mutational studies reveal that the highly conserved catalytic dyad is 
essential for transamidation activity.[76] Consequently, the linear state found in the crystal 
structure of TG2a* most likely does not represent the active state of TG2 with respect to the 
transamidation activity. The fact that TG2 can act as a transglutaminase suggests that TG2 can 
adopt the same conformation as FXIIIa°. This assumption is reinforced by the homology model 
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of TG2a generated based on the crystal structure of FXIIIa°. Herein, the catalytic dyad is located 
at the same position as of FXIIIa° and TG3ac. 
 
The hypothesis that active TG2 can also exists in the same conformation as FXIIIa° is supported 
by FRET measurements with the irreversible inhibitor NC9 and the competitive, reversible 
inhibitor CP4d (Fig. 5.16b) performed by Caron and co-workers.[113] For this experiment, FRET 
donor and acceptor were located at N- and C-terminus of TG2. NC9 behaves as expected, 
meaning the FRET signal decreases owing to a larger distance between the N- and C-terminus 
in TG2a* with its linear domain arrangement. Remarkably, CP4d leads to an increase of the 
FRET signal, indicating that TG2 adopts a conformation where the distance is shorter between 
N and C-terminus. This observation is in agreement with the homology model of TG2a based 
on FXIIIa° (see distances in Fig. 5.16a). In the globular active state, the distance between the 
β-sandwich domain and the β-barrel 2 domain is 45 Å, in contrast to the inactive state where 
the distance is 61 Å (red arrows).  A distortion of the flexible β-barrel 2 domain reinforced by 
the crystal packing can be excluded by calculating the distances between the β-sandwich 
domain and the β-barrel 1 domain (blue arrows). Here the ratio of the distances is similar to the 
β-barrel 2 domain (61:45 vs 83:61). 
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Fig. 5.16: a) Superposition of the inactive state of TG2 (cyan), the crystal structure of TG2a* (beige) 
and the homology model of TG2a (magenta). The distances between the N-terminus (Met 1of TG2a*) 
and the respective β-barrel 2 domain are indicated by red arrows. Since in the template (crystal 
structure of FXIIIa°) the β-barrel 2 domain does not interact with the protein and the arrangement can 
be a result of the crystal packing, the distances between the N-terminus and the respective β-barrel 1 
domain were measured as well (blue arrows). b) Inhibitors used in the FRET experiment. CP4d inhibits 
the linear active state TG2a*[113], whereas NC9 inhibits most likely the globular active state TG2a.  
 
Notably, some inhibitors synthesized by Zedira for FXIIIa° with the general α(wh)xxxPW-type 
(α: α-space addressing moiety, wh: warhead, x: any amino acid) have despite of their size 
similar affinity in the two to three-digit nanomolar range to FXIII and TG2 (see Chapter 5.4), 
also indicating that TG2 can adopt a very similar conformation in its active state as observed 
for FXIIIa° (Fig. 5.17). 
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Fig. 5.17: As suggested by the comparison of the different crystal structures, the homology model of 
TG2a based on the crystal structure of FXIIIa° and the FRET experiment[19, 60, 113], TG2 appears to adopt 
depending on the inhibitor two different active states. Inhibitors of the α(wh)xPϕ-type and CP4d 
stabilize TG2 in the linear active state (TG2a*) whereas inhibitors of the α(wh)xxxPW-type and NC9 
force the enzyme into globular active state (TG2a). Since calcium ions already induces in the absence 
of an inhibitor or substrate a conformational change of TG2[19, 113], TG2a adopts possibly a calcium-
dependent pre-activated transition state (TG2‡). Herein, the location of the β-barrel domains cannot be 
defined. Departing from this transition state, TG2 can transform into its linear or calcium-dependent in 
its globular active state. 
 
Why does TG2 adopt two different states distinguishing from the inactive state? The 
conformation adopted by FXIIIa° appears to represent the active state of a transglutaminase in 
terms of catalyzing the transamidation reaction due to the existence of the catalytic dyad.  
Even though, in the linear state (TG2a*) TG2 cannot act as a transglutaminase (catalyzing of 
transamidation) due to the lacking catalytic dyad, the catalytic site is accessible for the 
glutamine side chain of a putative substrate. Consequently, TG2a* could still be able in the 
given conformation to hydrolyze the glutamine to a glutamate side chain. Thus, with some care 
the hypothesis can be put forward that TG2a* could correspond to the deamidation state. 
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The following question arises: Which influencing factors decide whether TG2 adopts the linear 
or the globular active state? Judging by the crystal structures, the homology model and the 
FRET experiments[113], it seems that the local calcium concentration, the inhibitor and, most 
likely, also the macromolecular substrate represents the crucial determinants. Chemical 
complementary inhibitors to the active site of TG2a* keep the enzyme in the linear state, 
whereas chemical complementary inhibitors to the active site of TG2a force the enzyme into 
the globular active state. This would means, possibly the shape and composition of the substrate 
determines whether the corresponding glutamine placed into the active site tunnel is trans- or 
deamidated. Exactly this assumption is in agreement with various experiments showing that 
TG2 specifically deamidates particular glutamine residues whereas other glutamine residues of 
the same protein are specifically transamidated.[7, 114, 115] Originally, it was assumed that only 
the presence or absence of the lysine-containing co-substrate and the local calcium 
concentration as well as the pH determines whether a substrate is deamidated or 
transamidated.[7, 97]  
Regarding the crystal structure of TG2a*, calcium coordination at site 2 possibly prevents 
formation of the α-helix that in turn seems to trigger the linear arrangement of the domains. 
Overall with increased local calcium concentration, the linear active state (TG2a*) is 
supposedly less preferred as the globular active state (TG2a). Conclusively, both the shape of 
the substrate and the local calcium concentration appears to determine which state (linear or 
globular active state) is preferably adopted by the enzyme. 
 
In Chapter 3.2.4, it has been speculated about the role of the function of the highly-conserved 
H-bond between the indole ring of Trp 370 and Gln 400 (FXIII nomenclature). If TG2a* would 
still exhibit deamidation activity without forming this H-bond, then this provides evidence that 
the H-bond functions as a required stabilizing element to keep the indole ring in the tunnel 
position and thus preventing water penetration into the catalytic site of transglutaminases. If 
TG2a* represents the deamidation state of a transglutaminase, water penetration is even 
necessary to hydrolyze the thioester intermediate to the corresponding glutamate residue. 
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5.5 Summary & Conclusion 
 
Detailed structural analysis of the crystal structure of FXIIIa°, TG2a*, TG3ac and a homology 
model of TG2a based on FXIIIa° suggests that TG2 can adopt two calcium-induced active 
states, a linear (TG2a*) and a globular active state (TG2a). 
The linear domain arrangement of TG2a* seems to be attributed to a rearrangement of strand III 
of the three-stranded β-sheet to an α-helix. Importantly, amino acids of the α-helix contributing 
to calcium binding site 2. Thus, in the linear state, the enzyme should not be able to establish 
transamidation activity, because the catalytic dyad cannot be formed (triggered by calcium 
binding site 2). Therefore, it is hypothesized that another state of the enzyme must exist, capable 
to catalyze the transamidation reaction (transamidation state). This state is most likely a 
globular active form similar to the one adopted by FXIIIa° in complex with ZED1301. This 
hypothesis is also corroborated by the homology model of TG2a generated based on the crystal 
structure of FXIIIa°, the FRET experiments performed by Caron and co-workers[113] and the 
fact that the FXIIIa° inhibitors of the α(wh)xxxPW-type also inhibit TG2. 
 
Even if TG2 cannot possesses transamidation activity in the linear state (TG2a*), the catalytic 
site is accessible for putative Q-substrates. Thus, it is assumed that the linear active form 
(TG2a*) is competent to catalyze deamidation (deamidation state of TG2), whereas the globular 
active state (TG2a) represents the enzyme as catalyst for transamidation (transamidation state 
of TG2). 
The FRET experiments[113] and the ability of FXIIIa° inhibitors of the α(wh)xxxPW-type also 
to bind TG2 suggests that the complementarity of a substrate to the active site of TG2a or 
TG2a* decides whether a substrate will be transamidated or deamidated. Remarkably, this is in 
line with experimental investigations revealing that TG2 is capable to specifically transamidate 
and deamidate glutamine side chains of the same protein.[7, 114, 115]  
 
The fact that several amino acids are reorganized in an α-helix and belong to calcium binding 
site 2 has to also be taken into account with respect to the development of drugs inhibiting TG2. 
The local calcium concentration can be important for the transition of the β-strand to the α-
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helix, an important structural feature to generate TG2a*. Consequently, an increasing local 
calcium concentration could shift the equilibrium between TG2a* and TG2a towards the latter. 
Possibly, even the affinity of different TG2 inhibitors could depend on the local calcium 
concentration and correlate to the state stabilized by these inhibitors. Finally, it can be 
hypothesized that the shape of TG2 blockers can possibly be designed in a way to inhibit more 
strongly the linear or the globular active state of TG2 which might give the option to develop 
ligands either inhibiting TG2 in diseases where the deamidation activity plays a crucial role. In 
contrast, a globular active state inhibitor could be more suitable where the transamidation 
activity is involved in pathogenesis.  
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5.6 Experimental Part 
 
5.6.1 Homology Model Building of TG2a 
 
The homology model of TG2a was generated based on the crystal structure of FXIIIa° in 
complex with ZED1301 (PDB ID: 4KTY) by using the Molecular Operating Environment 
(MOE).[116-118] After sequence alignment of TG2 and FXIII (using the UniProt entries P21980 
for TG2 and P00488 for FXIII), five main chain models were generated. For each main chain 
model one side chain sample was generated. Subsequently, each model was submitted to an 
electrostatics-enabled minimization run, which terminated when the gradient fell below the 
specified RMS gradient of 1. The temperature was set to 300 K and the Merck Molecular Force 
Field 94x (MMFF94x) was chosen. After protonation, the models were minimized as described 
above with an RMS gradient of 0.5. The five models were visually inspected and validated by 
comparing conserved regions of human transglutaminases comprising calcium binding sites, 
catalytic triad, catalytic dyad and hydrophobic tunnel. A Ramachandran plot of the homology 
model and the template structure was generated with Procheck.[90] 
The distances between the β-sandwich domain and the β-barrel 2 domain of TG2 (PDB ID: 
1KV3), TG2a* (PDB ID: 2Q3Z) and the homology model of TG2a were measured with 
Pymol.[119] The crystal structures were structural superimposed on the basis of the Cα atoms of 
the β-sandwich and catalytic domain. Since in the crystal structure of TG2, TG2a* and FXIIIa° 
the C- and the N-terminus are not completely defined in the electron density, the distance was 
measured between the Cα atom of Met 1 of TG2a* and the Cα atom of Ile 683 of the respective 
structures. The distance between the β-sandwich domain and the β-barrel 1 domain was 
measured between the Cα atom of Met 1 of TG2a* and the Cα atom of Tyr 583 of the respective 
structures. 
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5.7 Appendix 
 
 
 
 
Fig. 5.18: Ramachandran-Plot (generated with Procheck[90]) of the homology model of TG2 based on 
the crystal structure of FXIIIa° (PDB ID: 4KTY). In contrast to the template structure (see next page), 
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the homology model has three further residues in disallowed regions und 80.2 % instead of 89.6 % in 
most favored regions. 
 
 
 
Fig. 5.19: Ramachandran-Plot (generated with Procheck[90]) of the crystal structure of FXIIIa° (PDB 
ID: 4KTY). 
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6 Crystallographic Fragment Screening Using the Example of the 
Surrogate Protease Endothiapepsin 
 
6.1 Introduction 
 
The development of FXIIIa blockers demonstrate the disadvantage of the popular approach in 
drug design, which starts with the search for initial hits with sufficient binding affinity to allow 
a structural characterization and to subsequently improve ligand’s binding efficiency by tailored 
chemical modification. High molecular weight hits yielded by high-throughput screening 
usually possess reasonable starting affinity. However, the lead compound already adopts a 
certain binding geometry (Fig. 6.1a) restricting the subsequent optimization process. Moreover, 
the improvement of binding affinity by replacement of functional groups and interaction 
partners can turn out to be enormously time consuming as for example the search of a non-
peptidic shortcut between the catalytic site and the hydrophobic pocket in case of FXIII. 
Furthermore, upon binding of a high molecular weight hit, the enzyme may be forced into a 
tensed geometry reducing binding affinity and therefore rendering the subsequent optimization 
more difficult. 
A powerful alternative strategy to the above described classical approach is to start with much 
smaller ligands showing a molecular weight of up to 250 Da (fragments) and binding into 
different regions of the active site of the protein (Fig. 6.1b).[120, 121] Subsequently, fragments 
can be used as starting points to grow a ligand into further subpockets (Fig. 6.1c) or to 
chemically connect two fragments resulting in high affinity inhibitors of still rather low 
molecular weight.  
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Fig. 6.1: Hits from high-throughput screening of high molecular weight molecules do not fill the active 
site of an enzyme in an optimal way (a). In contrast, fragments occupy commonly only one subpocket 
with optimal interaction geometry (b) that can serve as a starting point for addressing further 
subpockets (c). Image taken from Rees et al.(slightly modified).[121] 
 
The main issue of this method named in the literature as fragment-based lead discovery (FBLD) 
is to find fragments binding to the enzyme. The reason for this difficulty arises from the fact 
that small molecules generally represent weak binders. Usually putative binders are detected 
by applying a broad range of biophysically diverse assays like native mass spectrometry (MS), 
thermal-shift assay (TSA), saturation-transfer difference NMR, surface plasmon resonance 
(SPR) or micro thermophoresis (MST).[122-125] These methods are associated with a non-
negligible amount of time but do provide only limited insights on how the molecule interacts 
with the target protein. Hence, it appears obvious to start immediately with a screening method 
that provides structural information directly like protein crystallography. Of course, 
crystallography is still rather time-consuming as well but this fact can be overcome by 
automatization of the entire process from crystallization via data collection to structure 
refinement. 
FBLD would also be a powerful approach for the development of transglutaminase inhibitors, 
especially, concerning non-covalent transglutaminase blockers but also for the optimization 
within the α-space and β-space. Unfortunately, the active site of transglutaminases is not 
accessible for the fragments because it is covered by the β-barrel 1 domain and the affinity of 
fragments is most likely not sufficient to successfully displacing this domain. Thus, removing 
the two β-barrel domains by molecular biology would provide a promising strategy to make a 
molecular species available for crystallization of weak binders like fragments and the 
development of alternative transglutaminase inhibitors possibly of non-peptidic character. 
a) b) c) 
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However, the obstacle producing such a truncated variant and then of finding new 
crystallization conditions would have to be resolved. 
To investigate the above outlined strategy and start directly with a crystallographic screening, 
a library comprising 361 fragments were soaked into endothiapepsin crystals and for each 
fragment exposure a dataset was collected.[126-129] Due to the time-consuming process including 
data collection, processing of the corresponding datasets, visual inspection of the electron 
density, structure refinement and deposition, the fragment project has been split and transferred 
to several members of our research group. The range studied by the author of the present thesis 
covered the fragments 211 to 256. Here, eight binders were discovered and the corresponding 
structures were deposited in the protein data bank (see Chapter 6.5.2). 
To classify the hits found in this project, fragments are related to the areas to which they bind 
namely the S1’-S3’ pockets and in remote areas beyond the active site (remote binders).[126] 
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6.2 Results & Discussion 
 
6.2.1 Overview  
 
Four fragments (F31, F131, F261, F268) of the crystallographic screen bind to the S1’, S2’ and 
S3’ pocket and four fragments (F56, F114, F171, F227) bind remotely from the catalytic site of 
endothiapepsin (Tab. 6.1, Fig. 6.2). It should be mentioned that F114, F171 and F261 represent 
multiple binders. A further copy of F114 and F171 interact with the catalytic dyad, F114 
directly and F171 via the catalytic water. Two additional copies of F261 occupies the S3/S5 
pockets.  
 
Tab. 6.1: Fragments binding to the S1’, S2’ and S3’ pocket and remotely from the active site of 
endothiapepsin. 
S1’, S2’ and S3’ pocket Remote binder 
F31 
H2N
O
O
 
F56 
OH
OH
O
Cl
 
F131 N
H
O
F3C
N O  
F114 
HN N
N
NH2N
 
F261 
N
NH
N
O
 
F171 
N
N
S
N
NH2  
F268 
N
H
O
O
 
F227 
HO
O Br
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Fig. 6.2: Four fragments (F31, F131, F261, F268) bind to the S1’-S3’ pockets and four fragments (F56, 
F114, F171, F227) bind remotely from the active site of endothiapepsin. The subpockets of the active 
site are indicated by cyan (S1-S6) and magenta (S1’-S3’) spheres. The surface is shown of the apo 
structure (PDB ID: 4Y5L). Additional copies of multiple binders (F114, F171, F261) are not shown. 
 
In the following, the exact interaction pattern of those fragments binding to the S1’-S3’ pockets 
and the remote binders will be described. 
 
 
 
  
F56 
F171 
F227 
F114 
F268 
F131 
F261 
S1‘ 
S2‘ S3‘ 
S1 
S6 
S5 
S4 S3 
S2 
F31 
Catalytic dyad 
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6.2.2 Fragments Addressing the S1’-S3’ Subpockets 
 
 
F31 
 
Fragment 31 binds to the S1’ pocket, whereas the exocyclic nitrogen atom forms a weak 
hydrogen bond (3.4 Å) with the hydroxyl group of Thr 222 (Fig. 6.3). Much more interesting, 
the fragment induces a water network involving the catalytic water 501. In detail, the exocyclic 
amino nitrogen atom interacts with water 515 that in turn establishes a hydrogen bond with 
water 503. Finally, water 503 interacts with the catalytic water (W501). With other words, 
fragment 31 interacts water-mediated both with the flap region and the catalytic dyad. The 
exocyclic nitrogen atom also forms a direct H-bond with the carboxylate oxygen of Asp 219 of 
the catalytic dyad. The weak binding character (3.5 Å) can be presumably attributed to the 
methyl group. Considering that the ethyl ester of F31 is not defined in the electron density, an 
aniline molecule could represent an interesting fragment to address the catalytic dyad and the 
S1’ pocket. 
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Fig. 6.3: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 5DPZ) in complex 
with fragment 31 (green). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules of 
the complex structure are colored in red and of the apo structure in cyan. To simplify the representation, 
hydrogen bonds between the catalytic water (W501) and the catalytic dyad (Asp 35 and Asp 219) are 
not shown. 
 
 
F131 
 
Fragment 131 occupies the S1’ pocket with its trifluoromethyl group and the S3’ pocket hosts 
its oxazole (Fig. 6.4). The methyl group of the oxazole is not resolved in the electron density 
map. The central carboxamide interacts with the flap by accepting a hydrogen bond of Gly 80 
NH with the carboxamide oxygen, whereas the adjacent carboxamide NH forms a hydrogen 
bond to the opposite oxygen of Gly 37 that is additionally addressed by the isoxazole NH of 
F131. However, the pKa of the isoxazole nitrogen falls into a range making protonation unlikely 
even though the pH of the crystallization buffer was 4.6. Thus, the nitrogen predominantly 
exists in the deprotonated state. Accordingly, replacement of the oxazole against e.g. a 
pyrrolidine heterocycle might be an obvious option to improve fragment binding. Furthermore, 
T222 
3.4 Å 
2.8 Å 
W515 
W501 
W503 
G80 
2.7 Å 
2.7 Å 
3.5 Å 
3.5 Å 
2.8 Å 
D35 
D219 
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the hydrogen bond has only a moderate strength with 3.2 Å. Replacement by a six-membered 
ring (piperidine) could show whether the different angle relationships in the larger ring allows 
for better interactions with the binding site. 
 
  
Fig. 6.4: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4Y4E) in complex 
with fragment 131 (brown). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules 
of the complex structure are colored in red and of the apo structure in cyan. 
 
 
F261 
 
Compound F261 binds with its quinazolinone in the area of the S1’ pocket (Fig. 6.5), whereas 
the cyclopropyl moiety points towards the solvent and thus it is not completely defined in 
electron density (see Chapter 6.5.1). Interestingly, the fragment does not form any polar 
interactions with the protein. The occupancy of the fragment was refined to 0.86 suggesting a 
weak affinity of the fragment towards the target enzyme endothiapepsin in this binding pose. 
However, ITC measurements reveal F261 as a potent binder with a Kd of 0.6 mM.
[129] But F261 
represents a multiple binder and consequently there is no direct correlation between one of the 
G37 
G80 
2.9 Å 
3.2 Å 2.7 Å 
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three binding poses and binding affinity because the binding affinity distributes on the three 
different binding poses.  
 
 
Fig. 6.5: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4Y5B) in complex 
with fragment 261 (light purple). The apo structure is shown in cyan (PDB ID: 4Y5L). The water 
molecules of the complex structure are colored in red and of the apo structure in cyan. 
 
 
F268 
 
This fragment interacts with its carboxamide similar to F131 (Fig. 6.6). The carbonyl oxygen 
accepts the hydrogen atom of the backbone NH of Gly 80 and the carboxamide nitrogen 
interacts via a hydrogen bond with the backbone oxygen of Gly 37. However, the carboxamide 
is reversely oriented compared to the latter meaning the tetrahydrofuran portion occupies the 
S1’ pocket and the methyl cyclohexyl part is located in the S2’ pocket whereas the methyl 
cyclohexyl ring displaces two water molecules (water 677 and 645) in the S2’ pocket. 
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Fig. 6.6: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 5Y5E) in complex 
with fragment 268 (green). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules 
of the complex structure are colored in red and of the apo structure in cyan. 
 
 
6.2.3 Fragments Bind Remotely from the Active Site 
 
F56 
 
Fragment 56 belongs to the group of remote binders (Fig. 6.7). One carboxylate oxygen of 
fragment 56 acts as a hydrogen acceptor for the hydroxyl group of Ser 288 and interacts water-
mediated (water 2330) with the hydroxyl group of Ser 289.  The hydroxyl group of F56 donates 
a hydrogen bond to the carbonyl oxygen of Ser 288 and interacts via water 2540 with the 
hydroxyl group of Ser 256. Comparison of the crystal structure of endothiapepsin in complex 
with F56 with the apo structure shows that the fragment displaces three water molecules. The 
hydroxyl group of F56 is exactly located at the position where water 2483 is located in the apo 
structure.  
 
G37 
G80 
2.9 Å 
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W677 
W645 
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Fig. 6.7: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4Y54) in complex 
with fragment 56 (pink). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules of 
the complex structure are colored in red and of the apo structure in cyan. 
 
 
F114 
 
This fragment interacts directly with the protein via one hydrogen bond (Fig. 6.8). Here, the 
endocyclic pyrazole nitrogen forms a hydrogen bond with the hydroxyl group of Tyr 251. 
Additionally, the nitrogen interacts water-mediated (W1739) with the hydroxyl group of 
Ser 233. The second endocyclic nitrogen forms a hydrogen bond with water 1398. Finally, the 
exocyclic nitrogen of F114 interacts with the hydroxyl group of Ser 4 of a symmetry-related 
molecule via a hydrogen bond. The fragment displaces five water molecules, and the 
pyrrolidine portion is located at the position where an acetate ion is found in the apo structure. 
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Fig. 6.8: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4Y4T) in complex 
with fragment 114 (dark grey). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules 
of the complex structure are colored in red and of the apo structure in cyan. 
 
 
F171 
 
Fragment 171 forms two direct hydrogen bonds to the protein (Fig. 6.9). One is formed by the 
endocyclic nitrogen of the thiazole moiety and the backbone nitrogen of Leu 259. The other 
one is formed between the exocyclic nitrogen of the thiazole moiety and the backbone carbonyl 
oxygen of Leu 259. The exocyclic nitrogen interacts furthermore water-mediated with Asp 276. 
The imidazole nitrogen interacts with the backbone oxygen of Ala 257 and Cys 255 via 
water 2212. Moreover, the π-electron system of the imidazolium ring interacts with the 
carboxyl oxygen of Asp 279. Notably, due to the interaction profile between F171 and the 
protein and for steric reasons, the thiazole and imidazole ring are twisted against each other by 
an angle of 63.0 degrees. In close vicinity to the fragment, a glycerol molecule is bound (lower 
left part of Fig. 6.9) which does not interact with F171. 
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Fig. 6.9: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4Y3X) in complex 
with fragment 171 (beige). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules of 
the complex structure are colored in red and of the apo structure in cyan.  
 
 
F227 
 
Probably, the most interesting fragment of the entire screen represents F227, which binds 
covalently to the carboxyl group of Asp 279 of endothiapepsin (Fig. 6.10). The fragment is a 
benzyl bromide in its unbound state, and the bromine has been substituted by one of the 
aspartate oxygen atoms of Asp 279 in the bound state.  
 
 
D276 
D279 
C255 
A257 
L259 
W1962 
W2212 
2.7 Å 
2.9 Å 
2.8 Å 
3.0 Å 
2.8 Å 
2.5 Å 
2.9 Å 
3.2 Å 
Acetate 
Glycerol 
 
Chapter 6 - Crystallographic Fragment Screening Using the Example of the Surrogate Protease Endothiapepsin 
149 
 
  
Fig. 6.10: Crystal structure of endothiapepsin (grey sticks, white surface, PDB ID: 4YD4) in complex 
with fragment 227 (light red). The apo structure is shown in cyan (PDB ID: 4Y5L). The water molecules 
of the complex structure are colored in red and of the apo structure in cyan. 
 
Remarkably, as shown in Fig. 6.11, the fragment only binds to Asp 279, although in total there 
are 21 aspartate and glutamate side chains located at the surface of endothiapepsin and therefore 
in principle accessible for F227. Thus, the covalent attachment seems to be highly selective. 
Regarding the binding site in terms of polar interaction partners available to the fragment which 
could facilitate the binding to Asp 279, gives no indication for the specific binding of F227. 
Also the influence of symmetry-related molecules can be excluded after inspection of the 
crystal packing. Nevertheless, it is interesting to notice that an acetate ion is found close to the 
binding site of F227 in the apo structure which is replaced upon fragment accommodation. 
 
 
D279 
C255 
C290 
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Fig. 6.11: Endothiapepsin possesses 21 solvent-exposed aspartate (red, PDB ID: 4YD4) and glutamate 
residues but the fragment 227 (cyan) binds selectively to Asp 279. 
 
Interestingly, regarding the binding site of F227 (Fig. 6.10), a disulfide bond is present, formed 
between Cys 255 and Cys 290 in close vicinity (3.8 Å) to the bound fragment. Since disulfides 
can act as electrophiles, as for instance in thiol-disulfide exchange reactions[130], possibly, an 
interaction of the bromine of F227 with the disulfide facilitates the nucleophilic attack of the 
carboxyl oxygen of Asp 279 (Fig. 6.12).  
 
 
Fig. 6.12: Proposed mechanism of the covalent attachment of F227 to Asp 279. 
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Regarding the apo structure of endothiapepsin, the displaced acetate ion binds next to the 
disulfide bond in close proximity at the position where F227 is found. This is even more 
surprising by taken into account that there are no positively charged residues in this area. Why 
does the acetate ion exactly binds to this site of the enzyme? It can be speculated whether the 
disulfide bridge serves with its electrophilic character as an interaction partner for the 
negatively charged acetate ion. 
 
The above assumed influence of the disulfide bond on carboxylate groups has to be investigated 
by evaluating other proteins. Transglutaminase 2 could serve as an appropriate candidate since 
also its disulfide bond is found in the neighborhood of an aspartate (4.0 Å) with similar 
geometry as in endothiapepsin (Fig. 6.13). Notably, this disulfide bond is assumed to be 
responsible for the disulfide isomerase activity of TG2.[15, 16] Thus, it can be speculated whether 
a corresponding modification of the benzyl bromide could even work as a low molecular 
inhibitor that affects the disulfide isomerase activity. 
 
 
Fig. 6.13: Disulfide bond with an adjacent aspartate of Transglutaminase 2 (PDB ID: 2Q3Z). 
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6.3 Summary & Conclusion 
 
Four fragments (F31, F131, F261, F268) out of the crystallographic screen comprising 361 
molecules were observed to bind to the S1’-S3’ pockets. Four fragments (F56, F114, F171, 
F227) bind remotely from the active site of endothiapepsin. Both fragment 131 and 268 
interacts with the flap by forming a hydrogen bond to the backbone nitrogen of Gly 80 and 
serves as potent interaction partner for fragments binding to adjacent subpockets of the active 
site. The remote binders show impressively that certain fragments bind to the surface of a 
protein without the presence of deep pockets. Thus, the FBLD approach could possibly be 
applied to generate ideas how to address the β-space by appropriate moieties in the development 
of transglutaminase inhibitors. 
Fragment 227, that binds covalently and highly selective to Asp 279, turned out as exceedingly 
interesting. Possibly an adjacent disulfide bond facilitates the formation of covalent attachment 
with the benzyl bromide by nucleophilic substitution reaction.  
In academic and industrial research, it is highly desired to selectively modify proteins in 
mixtures with other proteins with labels that enable specific detection (fluorescence 
microscopy), protein purification (His-tag), protein labeling (SPR spectroscopy, investigation 
of conformational changes with ESR spectroscopy) and therapeutic conjugation (PEGylation 
for improvement of the plasma half-life of therapeutic proteins).[131-135] 
Usually, proteins are modified at the C- or N-terminus.[132, 133] Unfortunately, the C- and N-
terminus are not always accessible or such additionally modifications affect the activity of the 
protein in an undesired way. An alternative approach is the selective mutation of particular 
amino acids at the surface of the protein by lysine or cysteine residues which can be 
subsequently modified by covalent linkage. In case of lysine mutation the remaining lysine 
residues have to be mutated to guarantee selective modifications. However, these mutations 
may affect the isoelectric point and enhance the immunogenicity which is problematic 
especially for therapeutic proteins. The introduction of cysteine mutations can result in 
undesired cross-linking of the modified protein by formation of disulfide bonds with other thiol 
groups. 
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The benzyl bromide discovered in the present example could give a unique possibility to modify 
a protein at special position. Notably, transglutaminases also represent a promising tool for 
specific modification of proteins (PEGylation of therapeutic proteins).[136]  
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6.4 Experimental Part 
 
6.4.1 Processing and Refinement 
 
Datasets of each fragment in the range of F211-F256 were collected at the BESSY II electron 
storage ring[79] and reprocessed using XDS[98]. Datasets with insufficient statistical power 
(resolution > 2.0 Å, R-merge > 10 %) were recollected and processed again. 
Afterwards the 45 datasets were subjected to Fourier synthesis using Phenix[88], and the crystal 
structure of endothiapepsin with the PDB ID 3PCW (P21) or 4Y3M (P212121) served as starting 
model depending on the space group. As first two refinement steps, rigid body refinement (at 
4.0 Å) und simulated annealing were applied. Subsequently, the difference maps (> 3.0 σ) of 
the whole enzyme of all datasets were visually inspected. Those datasets where the difference 
map indicated a bound fragment were further refined anisotropic and water molecules were 
assigned manually. Finally, the structures with clearly defined difference electron density for 
the fragment were completely refined and deposited in the protein data bank. Model building 
was performed with Coot.[87, 108] Every dataset of bound fragments was refined anisotropic in 
respect to the B factors with and without water, with TLS groups and with hydrogen atoms. 
Restraints of the fragments were generated using the GRADE server.[99]  
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6.5 Appendix 
 
6.5.1 Difference Electron Density Map (2.5 sigma) 
 
F31 F56 
  
 
 
F114 F131 
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F171 F227 
  
 
 
F261 F268 
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6.5.2 Crystallographic Table 
 
Tab. 6.2: Data collection and refinement statistics of fragment 211 and 216. 
Fragment 211 216 
PDB Entry 4YCK 4YCT 
Data collection and processing   
Wavelength [Å] 0.91841 0.91841 
Beamline 14.1 14.2 
Space group P21 P21 
Unit cell parameters   
a, b, c [Å] 45.3, 73.0, 52.8 45.2, 73.0, 52.6 
α, β, γ [°] 90.0, 109.7, 90.0 90.0, 109.5, 90.0 
Diffraction data   
Resolution range [Å]* 42.7 - 1.07 (1.13 - 1.07) 42.6 - 1.13 (1.20 - 1.13) 
Unique reflections 137772 (21639) 114817 (17169) 
R(I)sym [%] 4.8 (54.5) 4.8 (45.1) 
Completeness [%] 96.7 (94.0) 95.4 (88.5) 
Redundancy 3.8 (3.7) 4.1 (3.8) 
I/σ(I) 14.2 (2.2) 17.4 (3.0) 
Refinement   
Resolution range [Å] 36.5 - 1.07 34.7 - 1.13 
Reflections used in refinement (total) 137767 114806 
Reflections used in refinement (work/free)  130879/ 6888 109066/ 5740 
Final R values for all reflections (work/free) 
[%] 11.9/ 13.6 13.8/ 15.7 
Protein residues  330 328 
Atoms Fragment 12 13 
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Water molecules 302 267 
Other ligand atoms 32 27 
RMSDs from ideality    
Bond lengths[Å] 0.006 0.006 
Bond angles [°] 1.2 1.2 
Ramachandran plot    
Residues in most favored regions [%] 93.9 93.5 
Residues in additional allowed regions [%] 6.1 6.5 
Residues in generously allowed regions [%] 0 0 
Residues in disallowed regions [%] 0 0 
Mean B-factor [Å2]    
Protein total 10.7 11.1 
Protein main chain 9.84 10.3 
Protein side chain 11.5 11.8 
Fragment 12.2 16.3 
Other ligand atoms 19.3 27.2 
Water molecules 25.6 24.6 
*Highest resolution shell is shown in parenthesis 
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Tab. 6.3: Data collection and refinement statistics of fragment 218 and 224. 
Fragment 218 224 
PDB Entry 4YCY 4YD3 
Data collection and processing   
Wavelength [Å] 0.91841 0.91841 
Beamline 14.2 14.1 
Space group P21 P21 
Unit cell parameters   
a, b, c [Å] 45.6, 72.9, 52.7 45.3, 73.2, 52.7 
α, β, γ [°] 90.0, 108.9, 90.0 90.0, 109.7, 90.0 
Diffraction data   
Resolution range [Å]* 19.2 - 1.70 (1.80 - 1.70) 42.7 - 1.25 (1.32 - 1.25) 
Unique reflections 35814 (5648) 86779 (13216) 
R(I)sym [%] 5.8 (49.1) 3.9 (33.1) 
Completeness [%] 99.4 (98.5) 96.5 (91.0) 
Redundancy 4.2 (4.2) 3.4 (3.3) 
I/σ(I) 19.5 (3.3) 18.9 (3.3) 
Refinement   
Resolution range [Å] 19.3 - 1.70 42.7 - 1.37 
Reflections used in refinement (total) 35813  86776 
Reflections used in refinement (work/free)  34022/ 1791 82437/ 4339 
Final R values for all reflections (work/free) 
[%] 16.6/ 19.8 11.1/ 13.2 
Protein residues  323 330 
Atoms Fragment 16 34 
Water molecules 164 293 
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Other ligand atoms 19 59 
RMSDs from ideality    
Bond lengths[Å] 0.006 0.006 
Bond angles [°] 1.0 1.2 
Ramachandran plot    
Residues in most favored regions [%] 93.0 94.2 
Residues in additional allowed regions [%] 7.0 5.8 
Residues in generously allowed regions [%] 0 0 
Residues in disallowed regions [%] 0 0 
Mean B-factor [Å2]    
Protein total 20.4 11.4 
Protein main chain 19.7 10.4 
Protein side chain 21.4 12.3 
Fragment 38.5 15.6 
Other ligand atoms 35.8 23.6 
Water molecules 27.8 27.0 
*Highest resolution shell is shown in parenthesis 
  
 
Chapter 6 - Crystallographic Fragment Screening Using the Example of the Surrogate Protease Endothiapepsin 
161 
 
Tab. 6.4: Data collection and refinement statistics of fragment 227 and 236. 
Fragment 227 236 
PDB Entry 4YD4 4YD5 
Data collection and processing   
Wavelength [Å] 0.89440 0.91841 
Beamline 14.3 14.1 
Space group P21 P21 
Unit cell parameters   
a, b, c [Å] 45.3, 73.2, 52.7 45.3, 73.0, 52.7 
α, β, γ [°] 90.0, 109.7, 90.0 90.0, 109.3, 90.0 
Diffraction data   
Resolution range [Å]* 42.7 - 1.27 (1.35 - 1.27) 42.8 - 1.21 (1.28 - 1.21) 
Unique reflections 84492 (13403) 96832 (14290) 
R(I)sym [%] 4.8 (48.3) 5.2 (22.4) 
Completeness [%] 97.8 (96.5) 98.1 (89.8) 
Redundancy 4.2 (4.2) 3.6 (2.8) 
I/σ(I) 18.8 (3.2) 13.7 (3.6) 
Refinement   
Resolution range [Å] 29.6 - 1.27 42.8 - 1.21 
Reflections used in refinement (total) 84482  96831  
Reflections used in refinement (work/free)  80260/ 4222 91989/ 4842 
Final R values for all reflections (work/free) 
[%] 12.2/ 14.7 11.9/ 13.6 
Protein residues  330 330 
Atoms Fragment 10 13 
Water molecules 237 226 
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Other ligand atoms 34 34 
RMSDs from ideality    
Bond lengths[Å] 0.007 0.006 
Bond angles [°] 1.2 1.2 
Ramachandran plot    
Residues in most favored regions [%] 94.2 94.2 
Residues in additional allowed regions [%] 5.8 5.8 
Residues in generously allowed regions [%] 0 0 
Residues in disallowed regions [%] 0 0 
Mean B-factor [Å2]    
Protein total 11.9 11.6 
Protein main chain 11.0 10.6 
Protein side chain 12.8 12.5 
Fragment 29.0 18.6 
Other ligand atoms 36.7 23.6 
Water molecules 27.3 25.5 
*Highest resolution shell is shown in parenthesis 
 
 
 
 
 
 
Chapter 7 - Summary and Outlook (Transglutaminases) 
163 
 
7 Summary and Outlook (Transglutaminases) 
 
To treat and prevent thromboembolic events like strokes, lung embolism and heart attacks, 
anticoagulants such as heparin, vitamin K-antagonists (i.e. Markumar and Warfarin, 
respectively) and the new oral direct thrombin and factor Xa blockers are administered.[61] 
These substances, commonly called blood thinners, reduce the tendency for blood coagulation 
and thus the thrombotic risk as well. However, such substances also significantly increase the 
risk of experiencing a life-threating bleeding event. Moreover, the administration of vitamin K-
antagonists requires time-consuming monitoring and results in an extra restriction of quality of 
life of patients. 
An agent blocking the enzyme factor XIII (FXIII) of the blood coagulation cascade could prove 
to be a superior anticoagulant with a lower bleeding tendency. The advantage of inhibiting 
FXIII, in contrast to all the other enzymes of the coagulation cascade, is that it does not affect 
the plasma level of thrombin (FII). Thrombin represents the central enzyme of the blood 
coagulation catalyzing the activation of fibrinogen to fibrin (Fig. 3.1). Subsequently, fibrin 
polymerizes and forms a blood clot along with other blood components (i.e. erythrocytes and 
thrombocytes). Apart from the activation of fibrinogen, thrombin is also involved in the 
activation of the primary hemostasis (aggregation of red blood cells) and even exhibits an 
antithrombotic impact.[62] 
FXIII belongs to the family of transglutaminases, mainly catalyzing the cross-linking of 
proteins by formation of an isopetide bond between a glutamine and a lysine side chain.[1] FXIII 
represents the last enzyme of the blood coagulation cascade providing final stability to the blood 
clot by cross-linking of fibrin fibers (Fig. 3.1).[52] Consequently, inhibition of FXIII would still 
allow the formation of a weak blood clot, most likely resulting in a lower bleeding risk by using 
a FXIII blocker compared to other anticoagulants. 
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The primary goal of the thesis was to obtain a crystal structure of factor XIII in its active 
conformation (FXIIIa) and subsequently to use the gained information about the chemical 
composition of the active site for the development of FXIIIa blockers. 
In collaboration with the biotech company Zedira GmbH FXIIIa° could be crystallized in 
complex with the covalently-attached inhibitor ZED1301 (Fig. 2.3).[60] The crystal structure 
shows that an enormous conformational change occurs during the transition from the inactive 
to the active state, whereby two β-barrel domains move out of space exposing the active site 
for inhibitors or substrates (Fig. 2.8). The inhibitor ZED1301 binds covalently by its warhead 
(α,β-unsaturated carboxylic ester) to Cys 314 of the active site. The binding of the ligand 
induces the formation of a hydrophobic tunnel by rotation of the indole ring of Trp 370 
(Fig. 2.11). The natural function of this tunnel is most likely the shielding of the intermediately 
formed thioester from hydrolytic cleavage. The substrate binding site can be subdivided into 
three areas: The catalytic site, an area located N-terminal named α-space as well as an area 
located C-terminal named β-space (Fig. 2.7). In the β-space a hydrophobic pocket is formed, 
presumably induced by the tryptophan indole ring of the inhibitor. 
In close collaboration with Zedira the lead compound was optimized in α-space. A thiazole 
proved as a promising building block. Starting with the thiazole (Fig. 3.5), the hydrophobic 
pocket in the α-space could be addressed by the introduction of an ethyl ester (Fig. 3.9). This 
leads to an improvement of the affinity by about one order of magnitude. 
The inhibitors developed in the present thesis exhibit a short plasma half-life due to the peptidic 
chemical structure. Moreover, owing to their high molecular weight the inhibitors are not orally 
available. Thus, in the future, it should be intended to substitute the part of the inhibitor bridging 
between the catalytic center and the hydrophobic pocket in the β-space by non-peptidic moiety, 
in order to prevent degradation by proteases and to reduce molecular weight. 
 
Apart from the usage for the structure-based development of FXIIIa-blockers, the crystal 
structure of FXIIIa° provides mechanistic insights at atomic level that in turn are of fundamental 
importance for the development of inhibitors for FXIIIa and other human transglutaminases. 
By means of the crystal structure of FXIIIa° it could be understood for the first time how 
calcium ions are involved in the activation process (Fig. 2.10). The coordination of calcium 
ions induces the rearrangement of loop-regions being parts of the co-substrate binding site 
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(Fig. 2.12, Fig. 3.17). Moreover, the coordination of the calcium ions triggers the formation of 
a catalytic dyad possessing the function to deprotonate the nitrogen atom of the side chain of 
the lysine co-substrate (Fig. 2.2). In contrast to the inactive conformation, the indole ring of 
Trp 370 of the hydrophobic tunnel forms a hydrogen bond with the carboxylate oxygen of 
Gln 400 (Fig. 3.13). The carboxamide NH of Gln 400 in turn interacts with the carboxylate 
oxygen of Glu 434. Also, the conformational reorientation of these amino acids is induced by 
complexation to the calcium ions (Fig. 3.14). Interestingly, both amino acids, the catalytic dyad 
and the calcium binding sites are highly conserved within the human transglutaminase family 
(Chapter 2.6.1, Fig. 3.15). Moreover, a rotational movement of a three-stranded β-sheet during 
the transition from the inactive to active state is observed which is assisted by calcium 
coordination of Asp 351 (Fig. 2.10c). The three-stranded β-sheet is part of the β-space. Thus, 
the extent of the rotation determines the accessible space for ligand binding to the β-space. 
Furthermore, FXIIIa° could be crystallized with the inhibitor Mi0621 in a collaboration with 
the academic partner of the laboratory of Prof. Steinmetzer, and this inhibitor differs 
significantly from the inhibitors of the ZED1301-type (Fig. 4.3). Mi0621 contains neither the 
rigid amino acid proline nor a tryptophan necessary for the occupation of the hydrophobic 
pocket in the β-space. Instead, Mi0621 possesses an isoleucine residue with an apolar side 
chain. However, the latter residue is located at the same position as the proline in the other type 
of inhibitors. The crystal structure of FXIIIa° in complex with Mi0621 shows that the 
hydrophobic pocket in β-space is not shaped and is most likely only induced by the indole ring 
of the Zedira inhibitors (Fig. 4.6). However, the hydrophobic region of the β-space is addressed 
by the isoleucine side chain. Interestingly, in the crystal structure of FXIIIa° in complex with 
Mi0621 the three-stranded β-sheet adopts an orientation between the inactive state and the 
crystal structure of FXIIIa° in complex with ZED1301 (Fig. 4.12).  
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Including FXIII there are eight human catalytically active transglutaminases (FXIII, TG12-
TG7).[1] Apart from FXIII, transglutaminase 2 is of particular pharmacological interest and 
represents a promising target protein for treatment of celiac disease, Alzheimer’s disease and 
diabetic nephropathy (Fig. 1.3).[21] 
In the crystal structure of transglutaminase 2 in complex with a covalent inhibitor (named 
TG2a*) published in 2007, the enzyme adopts an active state, as in case of FXIIIa°, however 
not with a globular but linear conformation (Fig. 5.3).[19] Based on the new structural and 
mechanistic insights obtained by the crystal structure of FXIIIa° and further experimental data 
from the literature, it has been attempted to explain the occurrence of two different active 
conformations adopted by FXIII and TG2. 
First, at closer inspection of the crystal structure of TG2a*, strand III of the three-stranded β-
sheet of the β-barrel 1 domain is displaced, forming a five-stranded β-sheet out of the four-
stranded β-sheet of the β-barrel 1 domain and strand II of the original three-stranded β-sheet 
(Fig. 5.4). The displaced strand III now adopts an α-helical structural element in the region of 
the β-space which thus is enormously reduced in size. Remarkably, amino acids forming the α-
helix belong to calcium binding site 2 (Fig. 5.5c). Consequently, occupancy of calcium binding 
site 2 does not allow a linear domain arrangement because the β-barrel 1 domain would clash 
with the three-stranded β-sheet (Fig. 5.3). Since only the occupancy of calcium binding site 2 
enables the formation of the catalytic dyad (Fig. 2.10c), the linear state should not exhibit 
transamidase activity. 
By use of a homology model based on the crystal structure of FXIIIa° (Fig. 5.12 - Fig. 5.15), 
it could be shown that TG2 can adopt a conformation equivalent to FXIII in the active state 
(FXIIIa°). This is in accordance with the observation that some FXIII inhibitors of the 
α(wh)xxxPW-type have the same affinity against FXIII and TG2. However, due to their size 
these inhibitors should not be able to bind to the active site of the linear state of TG2 (TG2a*) 
since they would clash with the α-helix in β-space (Fig. 5.6). Inhibitors of the α(wh)xxxPW-
type bind most likely only to the globular active conformation of TG2 as suggested in the 
present thesis. 
Consequently, the inhibitor seems to determine if TG2 adopts the linear or globular active state 
(Fig. 5.17). This is also indicated by FRET measurements performed by the Keillor lab in 
 
Chapter 7 - Summary and Outlook (Transglutaminases) 
167 
 
Canada showing that, depending on the inhibitor, the enzyme adapts to different conformational 
states (Fig. 5.16).[113] One state corresponds to the linear conformation, the other state to a more 
compact conformation. The measurement of the distances between the N- and the C-terminus 
of the inactive and the active globular state shows that the distances between the N- and the C-
terminus decrease during the transformation to the active conformation. Thus, the compact state 
found by the FRET experiment corresponds most likely the globular active state. 
Transferring these findings to the endogenous biochemical function of transglutaminase 2, the 
complementarity of substrates binding to the linear or the globular active state determines 
whether the linear active state is formed and the glutamine residue is hydrolyzed in the catalytic 
center (deamidation) or the globular active state is formed and the glutamine residue is cross-
linked with the lysine residue of a co-substrate by formation of an iso-peptide bond. The 
hypothesis of the substrate-induced chemoselectivity could give an explanation that 
simultaneously particular glutamine residues of a protein become deamidated whereas other 
glutamine residues of the same protein become transamidated.[7, 114, 115] 
Whether a substrate is deamidated or transamidated can also be affected by the chemical 
environment (i.e. pH value).[97] Analysis of the crystal structures also shows that the calcium 
concentration might impair the ratio of the linear (TG2a*) to the globular (TG2a) state, since 
the occupancy of calcium binding sites presumably does not allow the formation of the linear 
state. Consequently, with increasing calcium concentration the adoption of the globular state 
should be preferred. However, at this point it cannot be determined which influencing factor 
(substrate complementary or calcium concentration) plays the prominent role concerning the 
chemoselectivity.  
Nevertheless, an investigation of the transamidation of FXIII substrates of different sizes by 
Siebenlist and co-workers shows that the higher the molecular weight the lower the calcium 
concentration which is required for substrate turnover.[137] It appears that the calcium 
concentration is less mandatory in case of binding of macromolecular substrates to FXIII. This 
indicates that calcium shifts the equilibrium from the inactive state to a pre-active species where 
the catalytic center becomes exposed subsequently to a conformational change of the two β-
barrel domains. Thus, at high calcium concentrations even low molecular weight substrates 
with minor affinity might bind to FXIII. At this point it should be mentioned that FXIII exists 
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in the inactive state as a dimer and calcium might also shift the equilibrium between the dimeric 
and the monomeric state. 
 
As already described, the substrate induces depending on its structural and chemical 
constitution the formation of the linear or globular active state. Reversely, also the present 
conformation of the active TG2 (TG2a* or TG2a) might determine which inhibitors are potently 
bound. If the hypothesis that the enzyme adopts the globular active state depending on certain 
influencing factors turns true, a potential inhibitor of the linear active state could exhibit a 
strikingly lower affinity in the organism under certain conditions as the in-vitro experiment 
suggested. Therefore, it might be useful to develop both, TG2-blockers active on the linear and 
the globular state. Consequently, drugs might result for diseases where the deamidase or the 
transamidase activity is disease relevant. 
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Ultimately, further experimental investigations are necessary to corroborate the hypothesis that 
TG2 can adopt a linear deamidation or a globular transamidation state depending on the 
complementarity of the substrates and the local calcium concentration. In the following, a short 
outlook is provided in terms of further investigations to confirm the hypothesis made in the 
present thesis.  
 
Clear evidence for the hypothesis that TG2 can also adopt an active globular state would be 
provided by a crystal structure of TG2 in complex with an inhibitor of the ZED1301 type. 
However, for this purpose new crystallization condition will be needed. Also, the FRET 
experiment with TG2 in complex with TG2-potent inhibitors of the ZED1301 type could 
provide a valuable insight. In this experiment, the FRET signal should have a similar intensity 
as in case of inhibitor binding that induce the distance to decrease between the β-sandwich and 
the β-barrel 2 domain. Also, native gel electrophoresis could give some insights concerning the 
induced conformation of TG2 depending on the inhibitor.[19] In case of a globular state blocker 
of the ZED1301 type a band at similar position as the inactive state should be observed. 
 
Affinity measurements of TG2 inhibitors concerning a variant of TG2 that does not contain 
both β-barrel domains could provide an important clue concerning the involvement of the β-
barrel 1 domain in terms of the formation of the α-helix. In contrast to the wildtype, the affinity 
of a TG2a* inhibitor should be lower with respect to the β-barrel domain deletion variant. This 
would mean that the formation of the five-stranded β-sheet out of the four-stranded β-sheet of 
the β-barrel 1 domain represents a precondition for the formation of the α-helix out of strand 
III of the three-stranded β-sheet. A decreased affinity to the β-barrel domain deletion variant 
should not be observed by an TG2a-potent inhibitor of the ZED1301-type. 
 
The preferred formation of the globular active state during increase of the calcium concentration 
could be investigated by affinity measurements of a linear state blocker depending on the 
calcium concentration. The affinity should decrease with increasing calcium concentration. 
This observation should not be observed with a globular state blocker. 
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Also, the hypothesis that the linear active state possesses mainly deamidation activity whereas 
the globular active state exhibits predominantly transamidation activity needs to be 
investigated.  
For this purpose, the ratio of deamidation and transamidation could be analyzed. With 
increasing calcium concentration, the substrate should increasingly exhibit transamidation 
activity, as far as the assumption is correct that a preferred formation of the globular active state 
correlates with enhanced calcium concentration. 
Furthermore, the ratio of deamidation and transamidation could be investigated for a TG2 
variant that is only composed by the β-sandwich and the catalytic domain. The β-barrel-reduced 
TG2 variant should have a higher tendency towards transamidation compared to the wildtype, 
since the four-stranded β-sheet of the β-barrel 1 domain cannot displace strand III of the three-
stranded β-sheet. Therefore, the tendency to form a α-helix would be reduced. Thus, calcium 
binding site 2 could be occupied more easily and thus the catalytic dyad can be formed. 
It would be also interesting to investigate if also other transglutaminases are able to adopt the 
linear active state in addition to the globular active state or if the linear state is unique for TG2. 
 
Also, the function of the lacking hydrogen bond between the indole ring of Trp 370 (forming 
the hydrophobic pocket) and the highly conserved amino acid Gln 400 should be investigated. 
The crystal structure of FXIIIa° shows that occupancy of calcium binding site 2 orients Gln 400 
in a way to enable formation of a hydrogen bond with the indole ring. Since the analysis of the 
crystal structures indicate that calcium coordination mainly prepares transglutaminases for 
transamidation, it can be assumed that the hydrogen bond fixes the indole ring in its “tunnel” 
position to prevent a premature opening of the hydrophobic tunnel resulting in the hydrolysis 
of the thioester. This assumption could be investigated by mutating the involving amino acids 
Gln 400 and Glu 434. Expectably, a mutation should result in a preferred deamidation. 
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8 Zusammenfassung und Ausblick (Transglutaminasen) 
 
Thromboembolischen Ereignisse wie Schlaganfälle, Lungenembolien und Herzinfarkte 
begegnet man präventiv mit der Verabreichung antikoagulativ wirkender Substanzen wie 
Heparin, Vitamin-K-Antagonisten (z.B. Markumar) und den neuen oralen direkten Thrombin- 
und Faktor Xa-Blockern.[61] Diese im Volksmund als Blutverdünner bezeichneten Substanzen 
verringern die Gerinnung (Koagulation) des Blutes und somit auch das Thromboserisiko. 
Allerdings wird bei der Verabreichung solcher Substanzen auch das Risiko, eine 
lebensbedrohliche Blutung zu erleiden, beträchtlich erhöht. Zudem ist im Falle der Vitamin-K-
Antagonisten eine zeitaufwendige Überwachung und Kontrolle notwendig, was die 
Lebensqualität der Patienten zusätzlich einschränkt.  
Als ein überlegenes Antikoagulants mit einer geringeren Blutungsneigung könnte sich ein 
Wirkstoff erweisen, der das Enzym Faktor XIII (FXIII) der Blutgerinnungskaskade blockiert. 
FXIII hat den entscheidenden Vorteil, dass dessen Inhibierung im Gegensatz zu allen anderen 
Enzymen der Blutgerinnungskaskade den Plasmapegel von Thrombin (FII) nicht beeinträchtigt. 
Thrombin ist das zentrale Enzym der Blutgerinnung, das die Aktivierung von Fibrinogen zu 
Fibrin katalysiert, das dann polymerisiert und mit weiteren Bestandteilen des Blutes (wie 
Erythrozyten und Thrombozyten) das Blutgerinnsels bildet (Abb. 3.1). Neben der Aktivierung 
von Fibrinogen ist Thrombin zudem an der Aktivierung der primären Hämostase (Aggregation 
der roten Blutkörperchen) beteiligt und weist sogar eine antithrombotische Wirkung auf.[62] 
FXIII gehört zur Proteinklasse der Transglutaminasen, deren Hauptfunktion die 
Quervernetzung von Proteinen durch die Ausbildung einer Isopeptidbindung zwischen 
Glutamin- und Lysinseitenketten darstellt.[1] FXIII ist das letzte Enzym der 
Blutgerinnungskaskade und verleiht durch Quervernetzung der Fibrinfasern dem Blutgerinnsel 
seine finale Stabilität (Abb. 3.1).[52] Dies bedeutet letztendlich, dass sich bei der Inhibierung 
von FXIII noch ein schwaches Blutgerinnsel ausbilden könnte, wodurch das Blutungsrisiko bei 
einem FXIII-Blocker geringer im Vergleich zu allen anderen Antikoagulantien sein sollte. 
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Primäres Ziel der vorliegenden Arbeit war es, die Kristallstruktur des Faktors XIII in der 
aktiven Konformation (FXIIIa) zu erhalten, um anschließend die Information bezüglich der 
chemischen Beschaffenheit des aktiven Zentrums für die Entwicklung von FXIIIa-Blockern 
nutzen zu können. 
In Kooperation mit dem Biotech-Unternehmen Zedira GmbH konnte FXIIIa° im Komplex mit 
dem kovalent-gebundenen Inhibitor ZED1301 kristallisiert werden (Abb. 2.3).[60] Die 
Kristallstruktur zeigt, dass es beim Übergang vom inaktiven in den aktiven Zustand zu einer 
enormen konformativen Änderung kommt, wobei die beiden β-Barrel-Domänen zur Seite 
wegdrehen und so das aktive Zentrum für Inhibitoren bzw. Substrate zugänglich gemacht wird 
(Abb. 2.8). Der Inhibitor ZED1301 bindet kovalent über seine Kopfgruppe, einem α,β-
ungesättigter Carbonsäureester, an Cys 314 des aktiven Zentrums. Die Bindung des Liganden 
induziert durch Rotation des Indolrings von Trp 370 die Bildung eines hydrophoben Tunnels 
(Abb. 2.11), dessen natürliche Funktion vermutlich die Abschirmung einer hydrolytischen 
Spaltung des intermediär gebildeten Thioesters ist. Die Substrat-Bindungsstelle kann in drei 
Bereiche eingeteilt werden: Dem katalytischen Zentrum, einem Bereich, der sich N-terminal 
vom katalytischen Zentrum befindet und als α-Raum bezeichnet wird sowie einem Bereich, der 
sich C-terminal vom katalytischen Zentrum befindet und als β-Raum bezeichnet wird 
(Abb. 2.7). Im β-Raum kommt es zur Bildung einer hydrophoben Tasche, die vermutlich durch 
den Tryptophan-Indolring des Inhibitors induziert wird.   
In enger Zusammenarbeit mit Zedira wurde die Leitstruktur im α-Raum optimiert. Als 
vielversprechend erwies sich ein Thiazol-Baustein (Abb. 3.5). Von dem ausgehend es gelungen 
ist, durch die Einführung eines Ethylesters die hydrophobe Tasche im α-Raum zu adressieren 
(Abb. 3.9). Hierdurch konnte die Affinität um etwa eine Größenordnung gesteigert werden.  
Die bisherigen Inhibitoren weisen aufgrund der peptischen chemischen Struktur eine geringe 
Plasmahalbwertszeit auf. Zudem sind die bis jetzt zur Verfügung stehenden Inhibitoren 
aufgrund ihres hohen Molekulargewichts nicht oral applizierbar. Daher sollte in Zukunft 
versucht werden, den Bereich zwischen katalytischem Zentrum und hydrophober Tasche im β-
Raum durch einen nicht-peptidischen Baustein zu ersetzen, um so den Abbau durch Proteasen 
verhindern und das Molekulargewicht reduzieren zu können. 
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Neben der Verwendung für die Struktur-basierte Entwicklung eines FXIIIa-Blockers gewährt 
die Kristallstruktur von FXIIIa° mechanistische Einblicke auf molekularer Ebene, die 
wiederrum von fundamentaler Bedeutung für die Entwicklung weiterer Inhibitor von FXIIIa 
und anderer Transglutaminasen sind. Mit Hilfe der Kristallstruktur von FXIIIa° konnte erstmals 
verstanden werden, wie Kalziumionen in den Aktivierungsprozess involviert sind (Abb. 2.10). 
Durch Koordination an Kalziumionen kommt es zur Neuanordnung von Schleifen-Regionen, 
die Teile der Cosubstrat-Bindungsstelle sind (Abb. 2.12, Abb. 3.17). Zudem löst die 
Koordination der Kalziumionen die Bildung einer katalytischen Diade aus, deren Funktion die 
Deprotonierung des Stickstoffatoms der Seitenkette des Lysin-Cosubstrats ist (Abb. 2.2). Im 
Vergleich zur inaktiven Konformation bildet der Indolring von Trp 370 des hydrophoben 
Tunnels eine Wasserstoffbrücke mit dem Carboxamid-Sauerstoff von Gln 400, dessen 
Carboxamid-NH wiederrum mit dem Carboxylat-Sauerstoff von Glu 434 wechselwirkt 
(Abb. 3.13). Auch die konformative Umorientierung dieser beiden Aminosäuren wird durch die 
Komplexierung an Kalziumionen induziert (Abb. 3.14). Interessanterweise sind diese beiden 
Aminosäuren, sowie die Aminosäuren der katalytische Diade und der Kalziumbindungsstellen 
hoch konserviert innerhalb der Klasse der menschlichen Transglutaminasen 
(Kapitel 2.6.1, Abb. 3.15). Des Weiteren ist beim Übergang vom inaktiven in den aktiven 
Zustand eine rotierende Bewegung eines dreisträngigen β-Faltblatts zu beobachten, die durch 
die Kalzium-Koordination von Asp 351 unterstützt wird (Abb. 2.10c). Das dreisträngige β-
Faltblatt ist Teil des β-Raums, so dass das Ausmaß der Rotation den für die Bindung eines 
Liganden zur Verfügung stehenden Platz des β-Raums bestimmt (Abb. 4.12). 
FXIIIa° konnte zudem mit dem Inhibitor Mi0621 des akademischen Kooperationspartners der 
Arbeitsgruppe von Prof. Steinmetzer kristallisiert werden, der sich signifikant von den 
Inhibitoren vom ZED1301-Typ unterscheidet (Abb. 4.3). Mi0621 enthält weder die rigide 
Aminosäure Prolin noch ein Tryptophan zur Besetzung der hydrophoben Tasche im β-Raum. 
Stattdessen besitzt Mi0621 Isoleucin als Aminosäure mit einer unpolaren Seitenkette, die sich 
allerdings an der Position des Prolins befindet. Bei Betrachtung der Kristallstruktur von FXIIIa° 
im Komplex mit Mi0621 zeigt sich, dass die hydrophobe Tasche im β-Raum nicht ausgebildet 
ist und vermutlich durch den Indolring der Zedira-Inhibitoren erst induziert wird (Abb. 4.6). 
Jedoch wird der hydrophobe Bereich im β-Raum von der Isoleucin-Seitenkette adressiert. 
Interessanterweise nimmt das dreisträngige β-Faltblatt von FXIIIa° im Komplex mit Mi0621 
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eine Orientierung zwischen der des inaktiven Zustands und der in der Kristallstruktur von 
FXIIIa° im Komplex mit ZED1301 an.  
 
Einschließlich FXIII gibt es acht menschliche katalytisch-aktive Transglutaminasen (FXIII, 
TG1-TG7).[1] Neben FXIII ist Transglutaminase 2 von erheblichem pharmakologischem 
Interesse und stellt ein vielversprechendes Zielprotein zur Behandlung von Zöliakie, Alzheimer 
und Diabetischer Nephropathie dar (Abb. 1.3).[21]  
In der in 2007 publizierten Kristallstruktur der Transglutaminase 2 im Komplex mit einem 
kovalenten Inhibitor (als TG2a* bezeichnet) nimmt das Enzym im aktiven Zustand keine, wie 
im Fall von FXIIIa°, globuläre, sondern eine lineare Konformation an (Abb. 5.3).[19] Auf 
Grundlage der neuen strukturellen und mechanistischen Erkenntnisse, die aus der 
Kristallstruktur von FXIIIa° gewonnen werden konnten und weiteren experimentellen Daten 
aus der Literatur, wurde versucht, das Auftreten zweier unterschiedlicher aktiver 
Konformationen bei FXIII und TG2 zu erklären. 
Zunächst zeigt sich bei genauerer Betrachtung der Kristallstruktur von TG2a*, dass Strang III 
des dreisträngigen β-Faltblatts von der ersten β-Barrel-Domäne verdrängt wird und ein 
viersträngiges β-Faltblatt der β-Barrel-1-Domäne mit Strang II des ursprünglichen 
dreisträngigen β-Faltblatts ein fünfsträngiges β-Faltblatt bildet (Abb. 5.4). Der verdrängte 
Strang III bildet ein α-helikales Strukturelement im Bereich des β-Raums, wodurch dieser 
enorm verkleinert wird. Bemerkenswerterweise sind Aminosäuren, aus denen sich die α-Helix 
bildet, Teil der Kalzium-Bindungsstelle 2 (Abb. 5.5c). Bei Besetzung der Kalzium-
Bindungsstelle 2 ist demnach eine lineare Anordnung der Domänen nicht möglich, da die β-
Barrel-1-Domäne mit dem dreisträngigen β-Faltblatt zusammenstoßen würde (Abb. 5.3). Da 
erst die Besetzung der Kalzium-Bindungsstelle 2 die Ausbildung der katalytischen Diade 
ermöglicht (Abb. 2.10c), sollte der lineare aktive Zustand der TG2 keine 
Transamidierungsaktivität besitzen. 
Mit einem Homologiemodell von TG2a basierend auf der Kristallstruktur von FXIIIa° 
(Abb. 5.12 - Abb. 5.15), konnte gezeigt werden, das TG2 eine zu FXIII in der aktiven 
Konformation äquivalente Konformation einnehmen kann. Hierfür spricht auch die 
Beobachtung, dass einige FXIII-Inhibitoren vom α(wh)xxxPW-Typ die gleiche Affinität zu 
FXIII und TG2 besitzen. Diese Inhibitoren sollten jedoch aufgrund ihrer Größe nicht in der 
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Lage sein, im aktiven Zentrum von TG2 im linearen Zustand (TG2a*) zu binden, da sie mit der 
α-Helix im β-Raum zusammenstoßen würden (Abb. 5.6). Inhibitoren vom α(wh)xxxPW-Typ 
binden vermutlich nur an die hier vorgeschlagene globuläre aktive Konformation der TG2. 
Dementsprechend scheint der Inhibitor zu bestimmen, ob TG2 den linearen oder globulären 
aktiven Zustand annimmt (Abb. 5.17). Hierauf deuten auch FRET-Messungen der 
Arbeitsgruppe Keillor aus Kanada hin, die zeigen, dass je nach gebundenem Inhibitor das 
Enzym zwei Zustände annehmen kann (Abb. 5.16).[113] Der eine Zustand entspricht der linearen 
Konformation, bei dem zweiten Zustand nimmt das Enzym nach den Autoren einen 
kompakteren Zustand an. Die Messung der Abstände zwischen N- und C-Terminus der 
inaktiven Konformation sowie der globulären aktiven Konformation zeigt, dass die Distanz 
zwischen N- und C-Terminus beim Übergang in die globuläre aktive Konformation abnimmt 
und der kompaktere Zustand vermutlich der globulären aktiven Konformation entspricht. 
Überträgt man diese Erkenntnisse auf die natürliche biochemische Funktion der 
Transglutaminase 2, so könnte die Komplementarität des Substrates zur linearen oder 
globulären aktiven Konformation darüber entscheiden, ob der lineare aktive Zustand gebildet 
und der Glutamin-Rest im katalytischem Zentrum somit hydrolisiert wird (Deamidierung) oder 
ob der globuläre aktive Zustand gebildet und der entsprechende Glutamin-Rest mit einem Lys-
Rest eines Cosubstrats durch Ausbildung einer Isopeptidbindung quervernetzt wird 
(Transamidierung). Die Hypothese der Substrat-induzierten Chemoselektivität könnte eine 
Erklärung dafür liefern, dass simultan (also unter gleichen Bedingungen) bestimmte Glutamine 
eines Proteins zu Glutamat deamidiert werden, wohingegen andere Glutamine desselben 
Proteins transamidiert werden.[7, 114, 115]  
Ob ein Substrat deamidiert oder transamidiert wird, kann zudem auch von der chemischen 
Umgebung (wie dem pH-Wert) beeinträchtigt werden.[97] Nach Analyse der Kristallstrukturen 
könnte auch die Kalziumkonzentration das Verhältnis von linearer (TG2a*) und globulärer 
(TG2a) Form beeinträchtigen, da bei Besetzung der Kalzium-Bindungsstelle 2 die Bildung des 
linearen Zustands vermutlich nicht möglich wäre. Somit müsste es mit steigender Kalzium-
Konzentration zu einer zunehmend bevorzugten Bildung des globulären aktiven Zustands 
kommen. Eine Aussage darüber, welcher der beiden Einflussfaktoren (Substrat-
Komplementarität oder Kalziumkonzentration) entscheidend für die Chemoselektivität ist, lässt 
sich jedoch nicht treffen.  
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Eine Untersuchung der Transamidierung von FXIII-Substraten unterschiedlicher Größe von 
Siebenlist und Mitarbeitern zeigt jedoch, dass mit zunehmenden Molekulargewicht, eine 
geringere Kalziumkonzentration für den Substratumsatz nötig ist.[137] Demnach scheint bei 
makromolekularen Substraten die Kalziumkonzentration für die Bindung an FXIII von 
geringerer Bedeutung zu sein. Dies ist ein Indiz dafür, dass Kalzium das Gleichgewicht vom 
inaktiven Zustand zu einer prä-aktiven Spezies, bei der durch konformative Änderung der 
beiden β-Barrel-Domänen das aktive Zentrum exponiert wird, verschiebt. Bei hoher 
Kalziumkonzentration könnten somit auch niedermolekulare Substrate mit geringerer Affinität 
an FXIII binden. An dieser Stelle sei bemerkt, dass FXIII im inaktiven Zustand als Dimer 
vorliegt und somit Kalzium möglicherweise auch das Dimer-Monomer-Gleichgewicht 
verschieben könnte. 
Wie bereits erwähnt wurde, könnte das Substrat je nach struktureller und chemischer 
Beschaffenheit die Bildung des linearen oder globulären aktiven Zustands induzieren. 
Umgekehrt, könnte somit auch die vorliegende Konformation der aktiven TG2 (TG2a* oder 
TG2a) festlegen, welche Inhibitoren affin gebunden werden. Sollte das Enzym in Abhängigkeit 
bestimmter Einflussfaktoren bevorzugt den globulären Zustand annehmen, so könnte ein 
potentieller Inhibitor des linearen aktiven Zustands im Organismus unter bestimmten 
Bedingungen eine deutlich geringere Affinität besitzen als es das in-vitro Experiment suggeriert 
hat. Demnach wäre es sinnvoll, sowohl TG2-Blocker des linearen als auch des globulären 
Zustands zu entwickeln. Somit hätte man Wirkstoffe an der Hand, die bei Krankheiten 
eingesetzt werden können, bei denen entweder die Deamidaseaktivität oder 
Transamidaseaktivität von pathogener Relevanz ist, wodurch letztendlich die Nebenwirkungen 
minimiert werden könnten. 
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Letztendlich sind weitere experimentelle Untersuchungen notwendig, um die Hypothese zu 
bekräftigen, dass TG2 in Abhängigkeit von der Komplementarität des Substrats und der lokalen 
Kalziumkonzentration eine linearen Deamidierungszustand oder einen globulären  
Transamidierungszustand annehmen kann. Im Folgenden soll ein kurzer Ausblick bezüglich 
weiterer Untersuchungen gegeben werden, die die in der vorliegenden Arbeit aufgestellte 
Hypothese bestätigen könnte. 
 
Die Annahme, dass TG2 neben der linearen auch in der globulären Form vorliegen kann, muss 
durch weitere Experimente bestätigt werden. 
Ein klarer Beweis wäre die Kristallisation von TG2 im Komplex mit einem Inhibitor vom 
ZED1301-Typ. In der entsprechenden Kristallstruktur sollte TG2 die globuläre Konformation 
annehmen. Hierzu müsste jedoch eine neue Kristallisationsbedingung gefunden werden. 
Allerdings könnte die Durchführung des FRET-Experiments mit TG2-affinen Inhibitoren vom 
ZED1301-Typ ebenfalls einen Hinweis auf die Existenz des globulären aktiven Zustands 
liefern. Bei diesem Experiment sollte das FRET-Signal die gleiche Intensität haben, wie bei 
den Inhibitoren, bei denen nach dem FRET-Experiment der Abstand zwischen β-Sandwich und 
β-Barrel-2-Domäne abgenommen hat. 
Auch die native Gelelektrophorese könnte Aufschluss über die induzierte Konformation von 
TG2 im Abhängigkeit vom Inhibitor geben.[19] Bei einem Globular-State Blocker vom 
ZED1301-Typ sollte, im Gegensatz zu einem linear-State Blocker, eine Bande auf Höhe der 
inaktiven Form zu sehen sein. 
 
Die Messung der Affinität der TG2-Inhibitoren bezüglich einer Variante der TG2, die nicht die 
beiden β-Barreldomänen enthält, könnte ein wichtiges Indiz für die Beteiligung der β-Barrel-
1-Domäne an der Bildung der α-Helix im aktiven Zentrum liefern. Die Affinität eines TG2a*-
Inhibitors sollte bezüglich der um die β-Barreldomänen-verkürzten TG2-Variante geringer im 
Vergleich zum Wildtyp sein. Dies würde bedeuten, dass die Ausbildung des fünfsträngigen β-
Faltblattes aus dem viersträngigen β-Faltblatt der β-Barrel-1-Domäne eine Voraussetzung für 
die Bildung der α-Helix aus Strang III des dreisträngigen β-Faltblattes wäre. Eine verringerte 
Affinität gegenüber der β-Barreldomänen-verkürzten TG2-Vaiante sollte hingegen bei einem 
TG2-affinen Inhibitor vom ZED1301-Typ nicht zu beobachten sein. 
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Die bevorzugte Bildung der globulären aktiven Konformation bei Zunahme der 
Kalziumkonzentration könnte mit Hilfe von Affinitätsmessungen eines Linear-State Blockers 
in Abhängigkeit von der Kalzium-Konzentration untersucht werden. Mit steigender Kalzium-
Konzentration sollte die Affinität abnehmen. Diese Beobachtung sollte man bei einem 
Globular-State Blocker nicht machen.  
 
Auch muss die Hypothese, dass der lineare aktive Zustand überwiegend Deamidierungsaktivität 
und der globuläre aktive Zustand vermehrt Transamidierungsaktivität besitzt, experimentell 
untersucht werden. 
Hierzu könnte man das Deamidierungs-/Transamidierungsverhältnis in Abhängigkeit von der 
Kalzium-Konzentration untersuchen. Mit zunehmender Kalzium-Konzentration sollte es 
vermehrt zur Transamidierung kommen, sofern sich eine bevorzugte Bildung des globulären 
Zustands ab einer bestimmten Kalzium-Konzentration bewahrheitet. 
Des Weiteren könnte man das Deamidierungs-/Transamidierungsverhalten der TG2-Variante 
untersuchen, die nur aus der β-Sandwich-Domäne und der katalytischen Domäne besteht. Die 
β-Barreldomänen-verkürzten TG2-Variante sollte im Vergleich zum Wildtyp eine höhere 
Tendenz zur Transamidierung aufweisen, da das viersträngige β-Faltblatt der β-Barrel-1-
Domäne den Strang III des dreisträngigen β-Faltblattes nicht verdrängen kann. 
Dementsprechend ist die Tendenz zur Bildung der daraus resultierenden α-Helix geringer. Als 
Konsequenz kann Kalzium-Bindungsstelle 2 leichter besetzt werden und sich somit die 
katalytische Diade ausbilden. 
Es wäre des Weiteren interessant zu untersuchen, ob auch andere Transglutaminasen in der 
Lage sind, neben dem globulären Zustand den linearen Zustand einzunehmen oder ob der 
lineare Zustand einzigartig für TG2 ist.  
 
Auch die Funktion der in der Kristallstruktur von TG2a* nicht ausgebildeten Wasserstoffbrücke 
zwischen dem Indolring von Trp 370, der den hydrophoben Tunnel bildet, und der 
hochkonservierten Aminosäure Gln 400 sollte experimentell untersucht werden.  
Nach der Kristallstruktur von FXIIIa° wird durch die Besetzung der Kalzium-Bindungsstelle 2 
Gln 400 derart orientiert, dass die Wasserstoffbrücke zu dem Indolring ausgebildet werden 
kann. Da die Analyse der Kristallstrukturen zeigen, dass die Kalzium-Koordination 
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Transglutaminasen bezüglich der Transamidierung vorbereiten, liegt die Vermutung nahe, dass 
die Wasserstoffbrücke den Indolring in seiner „Tunnel“-Position fixiert, um eine verfrühte 
Öffnung des hydrophoben Tunnels und die damit verbundene Hydrolyse des Thioesters zu 
verhindern. Diese Annahme könnte durch Mutationsstudien der beiden involvierten 
Aminosäuren Gln 400 und Glu 434 untersucht werden. Erwartungsgemäß sollte es bei einer 
Mutation bevorzugt zur Deamidierung kommen. 
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Abbreviations 
 
Å Angstrom (1Å = 10-10 m) 
Ac Acetate 
Ala Alanine 
Arg Arginine 
Asn Asparagine 
Asp Aspartic acid 
B-factor Debye-Waller factor 
c cellular 
Ca Calcium 
Cys Cysteine 
Da Dalton 
DIPEA Diisopropylethylamine 
DMF Dimethylformamide 
DON 6-Diazo-5-oxo-L-norleucine 
ESR Electron spin resonance 
F Fragment 
FBLD Fragment-based lead discovery 
Fc Calculated structure amplitudes 
FII Factor II 
Fmoc Fluorenylmetyloxycarbonyl 
Fo Observed structure amplitudes 
FRET Förster resonance energy transfer 
FX Factor X 
FXIII Factor XIII 
FXIII-A A subunit of FXIII 
FXIIIa° Active FXIII-A with uncleaved activation peptide 
FXIII-B B subunit of FXIII 
GDP Guanosine diphosphate 
Gln Glutamine 
 
Abbreviations 
188 
 
Glu Glutamic acid 
Gly Glycine 
G-protein Guanine nucleotide-binding protein 
GTP Guanosine triphosphate 
HATU 
 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate 
H-bond Hydrogen bond 
His Histidine 
HOBt Hydroxybenzotriazole 
HTS High-throughput screening 
IC50 Half maximal inhibitory concentration 
Ile Isoleucine 
ITC Isothermal microcalorimetry 
k Kilo 
K Kelvin 
LC Liquid chromatography 
Leu Leucin 
Lys Lysine 
MA Michael acceptor 
Met Methionine 
MS Mass spectrometry 
MST Micro thermophoresis 
MW Molecular weight 
Nle Norleucine 
NMR Nuclear magnetic resonance 
p Plasmatic 
PDB Protein data bank 
PDB ID Protein data bank identifier 
PEG Polyethylene glycol 
pH  Potentialis hydrogenii 
Phe Phenylalanine 
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pKa Logarithmic acid dissociation constant 
PKC Protein kinase C  
Pro Proline 
R-factor Reliability factor 
RMSD Root mean square deviation 
Ser Serine 
SPR Surface plasmon resonance  
TBTU N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
tBu Tert-butyl 
TG(s) Transglutaminase(s) 
TG2a* Transglutaminase 2 in the active linear state 
TG3ac Transglutaminase 3 with enzymatically cleaved β-barrel domains 
Thr Threonine 
TLS Translation/libration/screw-motion 
Tris Tris(hydroxymethyl)aminomethane 
Trp Tryptophan 
TSA Thermal-shift assay 
Tyr Tyrosine 
V0 Void volume 
Val Valine 
Ve Elution volume 
X-ray Röntgen radiation 
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One- and three-letter code of proteinogenic amino acids 
 
 
The one-letter code for amino acids was used in the figures of the present thesis. The following 
table contains the one-/three-letter code and the name of the corresponding amino acid. 
 
 
One-letter code Three-letter code Amino acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartate 
E Glu Glutamate 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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